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ABSTRACT 
 
 Producing safe and wholesome food is a priority of animal agriculture in order to 
maintain consumer confidence in the products produced by the animal agriculture industries.  
Antimicrobial residues and antimicrobial resistant organisms are two of the most important 
concerns of consumers regarding food safety. Withholding periods are in place to minimize 
the risk of antimicrobial residues being present in food.  However, these withholding periods 
are established on healthy animals, not clinically ill animals. Additionally, there is no such 
withholding period in place to minimize the risk of transporting antimicrobial resistant 
organisms through food following treatment, although it has been proposed.   The first 
objective of this dissertation was to investigate the impact of clinical disease on the 
pharmacokinetics of ceftiofur. The second objective was to investigate changes in the fecal 
microbiota following drug therapy. The results of this work demonstrate the volume of 
distribution is increased in diseased animals and area under the concentration curve is 
decreased. Additionally, the mean elimination half-life can be significantly different. In both 
studies involving clinical disease, at least one animal in each group had an elimination half-
life that was nearly twice as long as the mean of the control group. No animals were found to 
have violative drug residues present in tissues following observation of the labeled withholding 
time. Fecal Escherichia coli populations transiently decreased following therapy with ceftiofur 
and ceftiofur resistant populations were significantly different than untreated controls. There 
was a tendency towards a significantly higher ceftiofur resistant E. coli population in diseased 
animals treated with ceftiofur versus healthy animals treated controls.  By 14 days following 
therapy, total and resistant E. coli populations returned to pre-treatment levels. E. coli isolates 
xii 
 
 
that were resistant to ceftiofur were also cross-resistant to ampicillin and ceftriaxone. 
Additionally, 64.3% of the resistant isolates were also resistant to tetracycline. The ß-lactamase 
gene blaCTX-M was most commonly found in ceftiofur resistant isolates but mechanism for 
ceftiofur resistance was not identified in 55.8% of the ceftiofur resistant isolates. Isolates that 
were determined to be phenotypically ceftiofur cross-resistant were resistant to 4.72 while 
isolates that were ceftiofur sensitive were cross-resistant to 1.1 antimicrobials. The current 
study suggests that changes in bacterial populations following clinical disease are not different 
from those of healthy cows treated with ceftiofur. Observation of the established drug 
withholding period following treatment with ceftiofur crystalline free acid minimizes the risk 
of transferring fecal isolates harboring antimicrobial resistance to the public. 
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CHAPTER 1.  LITERATURE REVIEW  
 
Cephalosporin Residues in Dairy Cattle 
 
Pharmacology of ceftiofur 
Ceftiofur (CEF) is a 3rd generation cephalosporin approved by the Food and Drug 
Administration (FDA) in the United States (US) for cattle, swine, horses, sheep, goats, dogs, day-
old chickens, and day-old turkey poults, depending upon the formulation. In the US, there are 
currently 5 veterinary formulations of CEF that could be utilized in dairy cattle, all of which were 
developed and are now marketed by Zoetis, Inc (Florham Park, NJ) or their predecessor 
companies. These include three parenteral formulations, CEF sodium (Naxcel®), CEF 
hydrochloride (Excenel® RTU EZ), and CEF crystalline free acid (CFA) (Excede®). There are also 
two intramammary (IMM) preparations, both of which contain different concentrations of CEF 
hydrochloride (Spectramast® LC and Spectramast® DC). In addition, there is now a generic 
formulation of CEF sodium (CeftiFlex®; Cephazone Pharma LLC, Pomona, CA). In the US, CEF 
is the only cephalosporin approved for parenteral use in the bovine. 
As it is a 3rd generation cephalosporin, CEF is considered a broad-spectrum antimicrobial. 
In the US cattle industry, parenteral CEF products are labeled for bovine respiratory diseases 
(shipping fever and pneumonia) associated with Mannheimia haemolytica, Pasteurella multocida, 
and Histophilus somni; bovine interdigital necrobacillosis (foot rot, pododermatitis) associated 
with Fusobacterium necrophorum and Bacteroides melaninogenicus; and acute metritis associated 
with organisms susceptible to CEF in cows 1-14 days postpartum. It should be noted that not all 
formulations are labeled for all of these listed indications. For example, CEF sodium is not labeled 
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for the treatment of acute metritis. Usage of CEF sodium for the treatment of acute metritis would 
be considered a violation of the Animal Medicinal Drug Use Clarification Act (AMDUCA), as 
there is already a labeled formulation of CEF approved for acute metritis in CEF hydrochloride 
and CEF CFA (US FDA, 1996). 
The lactating IMM product (Spectramast® LC) is labeled for clinical mastitis caused by 
coagulase negative staphylococci, Streptococcus dysgalactiae, and Escherichia coli. In addition, 
it is labeled for diagnosed subclinical infections associated with coagulase negative staphylococci 
and Streptococcus dysgalactiae. Finally, the dry cow IMM formulation (Spectramast® DC) is 
labeled for subclinical infections caused by Staphylococcus aureus, Streptococcus uberis, and 
Streptococcus dysgalactiae (Zoetis Services LLC, 2017). 
Cephalosporins exert their activity by binding to penicillin-binding proteins and disrupting 
the developing bacterial cell wall. Like other ß-lactams, they are considered to be bactericidal, 
although not as bactericidal as carbapenems and penicillins. Cephalosporins are time above 
minimum inhibitory concentration (MIC) dependent killers, so maintaining an effective plasma 
concentration for a sufficient duration is more important than creating a high peak concentration. 
Being broad spectrum antimicrobials, cephalosporins generally have good activity against 
Staphylococcus, including ß-lactamase producing strains; streptococci; gram-negative organisms, 
with the exception of Pseudomonas; and anaerobic bacteria, except Bacteroides fragilis. 
Cephalosporins also do not have activity against Enterococcus spp. Third generation 
cephalosporins generally have less activity against gram-positive organisms, although there is 
much variability in the group. Cefotaxime is considered to have the best activity against 
streptococci amongst the 3rd generation drugs (Papich and Riviere, 2009).  
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Following systemic absorption for the administration site, CEF is rapidly metabolized to 
its active metabolite, desfuroylceftiofur (DFC) and small concentrations of other non-polar and 
polar metabolites (Jaglan et al., 1989; S. A. Brown et al., 1991). Desfuroylceftiofur has an exposed 
sulfhydryl group that forms reversible disulfide bonds with other sulfurous compounds, such as 
sulfhydryl-containing proteins and glutathione. Cephalosporins are relatively polar compounds 
and generally have a low volume of distribution (VD), usually 0.2-0.3 L/kg (Papich and Riviere, 
2009). In cattle, protein binding is age-dependent, with calves often having <50% of the CEF 
metabolites being protein-bound while healthy adult cows have CEF metabolites that are >90% 
protein-bound (S. A. Brown et al., 1991). This increases the excretion half-life (T1/2) compared to 
most other cephalosporins, which are generally considered to have a short T1/2. Ceftiofur CFA is a 
slow release compound due its ability to form a depot at the site of injection, thus giving it 
prolonged periods of activity compared to CEF sodium or CEF hydrochloride (Papich and Riviere, 
2009).  
Repeated dosing with CEF may result in saturation of protein binding sites, resulting in the 
presence of more unbound, active metabolites over time without increasing T1/2 (Halstead et al, 
1992). More than 95% of administered CEF sodium is excreted within 24 hours; with 61-77% of 
the total drug excreted through urine and the balance excreted in feces (S. A. Brown et al., 1991).  
Drug approval studies show that metabolism and excretion of CEF hydrochloride by cattle 
is similar to that of CEF sodium (US FDA, 1998). Tissue distribution of CEF is similar regardless 
of the CEF salt administered (US FDA, 1998; KuKanich et al., 2005). Desfuroylceftiofur has 
clinical efficacy similar to cefotaxime (Papich and Riviere, 2009). However, DFC does not have 
good clinical activity against Staphylococcus in comparison to parent CEF (Cortinhas, 2013).   
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Cephalosporin use in the dairy industry 
Antimicrobial use in the US dairy industry, or the US livestock industry, is not well 
documented (Landers et al., 2012). This is a source of controversy regarding the impact on public 
health (Mellen et al., 2001; Pew Commission, 2008). According to the US FDA, 34.34 million 
pounds of antimicrobials were sold for veterinary use in 2015. This is a 24% increase over 2009 
data. Of the total, 13.05 million pounds of ionophores and other antimicrobial that are not 
medically important were sold, representing 38% of the total sales (US FDA, 2016a). The 
remaining sales represented medically important antimicrobial drugs, as dictated by the US FDA 
(US FDA, 2003). Tetracyclines represented the largest share of the 21.29 million pounds of 
medically important antimicrobials sold at 71% of the total, while fluoroquinolones and 
cephalosporins each represented <1%. Feed grade antimicrobial sales accounted for 70% of the 
sales, water-soluble medications were 24%, injectable medications were 5%, and other routes were 
1%. Intramammary antimicrobials are included in the “Other” category (US FDA, 2016a). Sales 
figures for 2016 are not yet available, but it is expected that sales will be increased again in 2016 
with the implementation of the Veterinary Feed Directive on January 1, 2017 (US FDA, 2013), as 
many entities stockpiled feed grade antimicrobials prior to the implementation date.  
Based on the 2015 sales, the dairy industry utilizes a share of the 1.06 million pounds of 
injectable medications and 0.21 million pounds from the other routes category. Since sales are 
tracked through drug distribution networks that supply all facets of the livestock industry, more 
precise data is not available. The US FDA recently proposed a biomass calculator to more precisely 
estimate drug use by each of the major livestock species (US FDA, 2017).  
Every 5-7 years, the US Department of Agriculture (USDA) conducts a National Animal 
Health Monitoring Survey (NAHMS) of the dairy industry. The most recent dairy survey was 
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undertaken in 2014. According to one of the reports that specifically looked at milk quality, 24.8% 
of all lactating animals have been affected with mastitis during the 12 months prior to the survey, 
with 87.3% of all clinical cases treated with an IMM antimicrobial. In total, 89.4% of operations 
treated mastitis with antimicrobials. In addition, 48.4% of participating operations reported using 
systemic antimicrobials to treat mastitis. In all total, 96.9% of operations used an antimicrobial via 
any route to treat mastitis. ß-lactam antimicrobials were utilized by 85.6% of operations, with 
cephalosporin antimicrobials representing the majority of the total ß-lactam use. Intramammary 
tubes containing CEF were used as the primary IMM antimicrobial on 38.6% of operations, while 
IMM tubes containing cephapirin were utilized on 34.4% of all operations. When the survey was 
broken down by treatments to the cow level, 50.4% of cows were treated with CEF, while 15.2% 
were treated with cephapirin. This indicates that large herds (≥500 cows) in this study used CEF 
as their primary IMM antimicrobial. Regarding antimicrobial selection, only 22.2% of operations 
utilized bacterial culture prior to deciding which antimicrobial to utilize (USDA, 2016a). 
Other disease maladies in adult dairy cattle investigated by the 2007 NAHMS dairy survey 
included respiratory disease, diarrhea/digestive problems, reproductive diseases, lameness, and 
other. Respiratory disease affected 2.9% of cows, with 96.4% of those cases treated with an 
antimicrobial. Thirty-three percent of respiratory cases were treated with cephalosporins. Diarrhea 
affected 6% of cows on US dairies, with 32.3% of those cases treated with an antimicrobial. The 
majority of these cases were not treated with an antimicrobial; however, when they were, 11.3% 
were treated with a cephalosporin. Reproductive disease affected 10% of the cows, with 74.7% 
treated with an antimicrobial. Cephalosporins were used 17.2% of the time for these cases. 
Lameness affected 12.5% of cows, with 56.5% treated with antimicrobials; while “other” diseases 
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affected 0.7% of cows, with 66.2% of those treated with antimicrobials. Cephalosporins were used 
for 23% and 1.8% of the lameness and other categories, respectively (USDA, 2008a). 
In a more recent survey of Midwest dairy farm treatment practices, our research group 
investigated drug use on 85 dairy farms. As with the NAHMS study, mastitis represented the most 
common reason for antimicrobial use in lactating cows. In our study, 100% of farms were using 
antimicrobials to treat mastitis, with 85% of farms indicating that cephalosporins were the primary 
drug class utilized. Sixty percent of farms indicated that CEF was their primary IMM choice for 
mastitis therapy, followed by cephapirin (25%). This finding was similar to that reported in a 
survey of large Wisconsin dairy farms, in which 71.6% of cases were treated with IMM CEF as 
the primary treatment (Oliveira and Ruegg, 2014). Older studies have found that cephapirin was 
the most commonly used IMM antimicrobial (Sawant et al., 2005; Raymond et al., 2006); however, 
these studies were conducted prior to the approval of the IMM formulation of CEF (US FDA, 
2005). Fifteen farms in this survey indicated that they used bacterial culture to dictate therapy. 
Only three farms chose to not treat some cases of mastitis based on culture results (Schuler et al., 
2017). 
In the previously mentioned survey of Midwest farms (Schuler et al., 2017), treatment 
practices in lactating dairy cows were recorded for systemic mastitis, metritis, respiratory disease, 
and lameness; in addition to IMM mastitis therapy. Ceftiofur was indicated as the primary 
antimicrobial choice on 22%, 88%, 74%, and 90% of the farms for systemic mastitis, metritis, 
respiratory diseases, and lameness therapy, respectively. Reasons for selection of CEF as the 
primary antimicrobial for these diseases were the short milk withdrawal; broad spectrum of 
activity; and maintaining on-label therapy for metritis, respiratory diseases, and foot rot (Schuler 
et al., 2017). These findings are consistent with previous studies (Zwald et al., 2004; Sawant et al., 
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2005; Raymond et al., 2006), confirming that CEF is the most commonly used antimicrobial on 
dairy farms in the US.  
Dry cow IMM therapy represents the most common preventative use of antimicrobials in 
adult dairy cattle, although there is also therapeutic benefit to dry cow therapy (Arruda et al., 
2013a,b; Johnson et al., 2016). The 2014 NAHMS study determined that 90.8% of operations dry 
treat at least some of the cows on their operations and 80.3% of the farms treat all cattle that 
concluded a lactation with IMM antimicrobials. In total, 93% of all cows in the survey received 
dry cow therapy at the end of their lactation (USDA, 2016a). Cephapirin was the most commonly 
utilized dry cow therapy in the NAHMS survey, with 58.1% of operations utilizing this product, 
followed by CEF on 27.9% of operations. However, like with lactating IMM products, larger farms 
in this dataset utilized CEF as their dry cow therapy (USDA, 2016a). In the survey of Midwest 
dairy farms, CEF and cephapirin were each used on 41% of the farms surveyed (Schuler et al., 
2017).  
Based on this information, it is readily apparent that the US dairy industry has a heavy 
reliance on the use of CEF. Surveys that have investigated the reasons why dairymen select one 
antimicrobial over another indicate that past history is the most common determinant, with a 
veterinarian being consulted in <50% of cases (Sawant et al., 2005; USDA, 2016a). Additionally, 
short withdrawal intervals for meat and milk make CEF an attractive antimicrobial choice, as the 
cost of discarded milk is often the most expensive component of drug therapy in lactating dairy 
cattle. Finally, marketing strategies promoting broad spectrum therapy and flexible labeling to 
maintain on-label therapies for the IMM product, have made CEF an attractive choice for  
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veterinarians and dairy producers. However, with increasing levels of antimicrobial residues 
associated with CEF use and concerns about antimicrobial resistant bacteria being transmitted to 
humans, there are fears that application of drug stewardship and prudent drug use practices are not 
being followed (US FDA, 2012b). Ceftiofur is closely related to the human drug ceftriaxone and 
resistance mechanisms can be mediated by similar mechanisms between the two antimicrobials 
(see below).   
 
Antimicrobial residues in milk and dairy beef from cull dairy cows   
Milk and meat offered for sale by dairy producers are routinely screened for violative 
antimicrobial residues. For Grade “A” milk, which represents >99% of all the milk produced in 
the US, every tanker truck load of milk is screened for ß-lactam antimicrobials using ELISA 
technology prior to being offloaded for processing. These test kits have sensitivity levels that detect 
drug residues at or below US residue tolerances. These tests are not quantitative nor do they 
identify the individual ß-lactam antimicrobial that is present in the milk (US FDA, 2015). Using 
this approach, the US dairy industry has achieved historically low levels of tanker truck loads with 
violative ß-lactam residues (Figure 1). The most recent data indicated that only 0.011% of tankers 
contained violative levels of ß-lactams (GLH Inc., 2016). Beginning July 1, 2017, a residue testing 
program was implemented for screening tanker trucks for tetracycline family drugs (US FDA, 
2015). Currently, there is no data available regarding violative tetracycline residues. 
Violative meat residues are monitored by a combination of sampling approaches conducted 
by the USDA. Tier 1 sampling is random in nature and is used to determine the baseline level for 
chemical residue exposure to consumers from meat products. The number of samples collected in 
each production class is based on the probability of finding at least one positive sample. The  
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Figure 1. Percentage of tanker truck loads of Grade “A” found to have violative antimicrobial 
residues for ß-lactam antimicrobials and total volume of milk disposed (2000-2016). Source: 
National Milk Drug Residue Data Base (GLH Inc., 2016). 
 
analyses performed on the samples is dependent upon the production class and laboratory capacity. 
The samples may be tested with one or more of the following methods: the Multiple-Residue 
Method (MRM), aminoglycoside method, pesticide method, metal method, ß-agonist method, 
hormones method, avermectins method, or arsenic method. The MRM methodology can determine 
the presence and quantify residues of approximately 90 analytes simultaneously, not just 
antimicrobials, using liquid chromatography coupled with mass spectrometry (USDA, 2016b). 
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In FY2016, there were 739 Tier 1 samples collected in cull dairy cattle, with three violative 
samples found. Two of these violative samples were caused by sulfadimethoxine and one was 
caused by a permethrin insecticide. Compared to the beef cull cow production class, these numbers 
are comparable (USDA, 2017b). 
The second sampling approach is Inspector-Generated Sampling. Inspector-generated 
samples are initiated by in-plant veterinary inspectors, when they detect evidence of disease that 
they suspect has been treated with a drug or just suspect a drug has been administered. In these 
circumstances, the Kidney Inhibition Swab (KISTM) test (Charm Sciences Inc., Lawrence, MA) is 
utilized in-plant. If the KISTM test is positive, samples from the suspect animal are submitted to a 
USDA laboratory, where the MRM methodology is utilized to determine the presence of and 
quantify residues (USDA, 2016b).  
In addition to the testing described above, USDA implements targeted testing in response 
to data obtained in the above testing programs or from information received by the FDA or 
Environmental Protection Agency regarding misuse of animal drugs and/or exposure to 
environmental contaminants. The nature and degree of testing is dependent upon each situation 
(USDA, 2016b). 
During the FY2016, USDA conducted 99,660 Inspector-Generated KISTM tests on cull 
dairy cattle and found 2276 positive results. In cattle, there were 129,522 total KISTM tests 
conducted in FY2016 (USDA, 2017b). In CY2016, there were 30.1144 million cattle processed in 
US, of which, there were 2.8857 million dairy cattle processed. Despite cull dairy cows only 
accounting for 9.6% of the total US marketed cattle (USDA, 2017c), they account for nearly 77% 
of the KISTM tests run in 2016 (USDA, 2017b).  The rate of inspector-generated samples is 
triggered: 1) by the incidence of previous residue positive samples; and 2) by the presence of 
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carcass defects. Observations of animals that are marketed with mastitis, metritis, pneumonia, 
peritonitis, surgical incisions, or active injection site lesions may generate a screening test for 
antimicrobial residues (USDA, 2016b). 
As a result of MRM testing from inspector-generated samples, there were 480 dairy cull 
cows with confirmed residue violations and 574 total residues detected in FY2016. In all cattle, 
there were 591 animal carcasses and 740 total violative residues detected. This means that during 
FY2016, cull dairy cattle accounted for 81.2% and 77.6% of the total cattle with confirmed residue 
violations and total residues confirmed, respectively (USDA, 2017b).  
Desfuroylceftiofur, the official marker residue for CEF, was the most commonly found 
residue with 192 violative residues present in FY2016, followed by penicillin with 153 confirmed 
violative residues. There were also violative residues present for: sulfadimethoxine (67), flunixin 
meglumine (49), ampicillin (28), sulfamethazine (27), florfenicol (11), oxytetracycline (8), 
tilmicosin (8), lincomycin (5), gentamycin (4), sulfadoxine (4), meloxicam (3), 
dihydrostreptomycin (3), ketoprofen (2), neomycin (2), tylosin (2), and one violative residue each 
for amikacin, cefazolin, ciprofloxacin, sulfmethoxazole, sulfamethoxypyridazine, and tetracycline 
(USDA, 2017b). The presence of sulfamethazine, ciprofloxacin, sulfadoxine, sulfmethoxazole, 
and sulfamethoxypyridazine indicate that illegal drug use took place, as these are all prohibited 
drugs in dairy cattle. In addition, the presence of florfenicol, tilmicosin, lincomycin, gentamycin, 
meloxicam, ketoprofen, neomycin, tylosin, amikacin, and cefazolin would be violations of 
AMDUCA, as these would have to be used in an extra-label manner in dairy cattle. The stipulations 
within AMDUCA state that if a veterinarian is going to prescribe a drug in an extra-label manner, 
they must prescribe a withdrawal time that is sufficiently long to prevent a violative residue from 
being present in meat or milk when offered for sale for human consumption (US FDA, 1996). 
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Figure 2 displays the residue violation data for the last ten years in cull dairy cattle. In 
2007, no violative residues for CEF were detected in cull dairy cattle. From 2008 to 2012, the 
number of violative CEF residues ranged from a low of 53 in 2011 to a high of 124 in 2009. 
Beginning in 2012, there was an increasing trend of CEF violative residues in cull dairy cows, 
with 130 in 2012, 238 in 2013, and 283 in 2014, which was the highest number recorded over the 
last 10 years. It should be noted that in 2013, the FDA changed the time frame for reporting residue 
data from a calendar year to a fiscal year. As a result, 2013 data only represents 9 months of time 
(USDA, 2015a). In 2013, CEF surpassed penicillin as the most common residue violation found 
in cull dairy cattle and has remained the highest violative residue analyte through FY2016 (USDA, 
2008b, 2009, 2011b, 2012a, 2013, 2014, 2015a, 2015b, 2017a, 2017b).  
Potential reasons for the increase in CEF violative residues include a short slaughter 
withdrawal, changes in tolerances for CEF in processed tissues, and changes in testing 
methodology implemented by the USDA. When used according to label, the parenteral products 
have a zero-hour milk withdrawal. Ceftiofur sodium and CEF hydrochloride formulations 
currently have a 4-day slaughter withdrawal, while CEF CFA has a 13-day slaughter withdrawal. 
When CEF sodium was first approved in 1988, it had a zero-day slaughter withdrawal, as there 
was no need to establish a tolerance as the residue levels in tissues were below the safe 
concentration with a zero-day withdrawal because the drug is rapidly cleared from the body (US 
FDA, 1988). However, with the approval of the first CEF hydrochloride parenteral formulation in 
1998, tissue residues did not clear as readily as with CEF sodium and subsequently a tolerance of 
8 parts per million (ppm) was established by the FDA. Desfuroylceftiofur, was designated as the 
marker residue with kidney being the marker tissue (US FDA, 1998). This change resulted in 
implementation of a 2-day slaughter withdrawal for CEF sodium and parenteral CEF 
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Figure 2. Summary of residue sampling and results for cull dairy cattle (2007-2016). The 
number of Inspector-Generated Kidney Inhibition Swab (KISTM) tests conducted each year is 
displayed on the left axis. Total violative residue detected, number of carcasses with violative 
residues, number of violative ceftiofur residues, and number of violative penicillin residues are 
displayed on the right axis. The years 2007-2012 were based on calendar years. In 2013, the 
reporting was switched to fiscal year, so CY2013 only represents 9 months of data. Source: US 
Department of Agriculture - Red Books 2007-2016 (USDA, 2008b, 2009, 2011b, 2012a, 2013, 
2014, 2015a, 2015b, 2017a, 2017b). 
 
 
hydrochloride. With the subsequent approval of CEF CFA, the FDA again changed the tolerance 
for DFC to 0.4 ppm, which is the current tolerance level (US FDA, 2006a). These changes have 
resulted in the current meat withdrawals for CEF parenteral products.  
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Another change that occurred in residue monitoring programs was the implementation of 
MRM for verifying and quantifying residues in meat, replacing the 7-plate bio-assay (USDA, 
2012b). However, due to the sophisticated extraction process required for CEF residues, CEF 
detection using an MRM process was not done prior to 2016. CEF was instead analyzed separately 
using the 7-plate bioassay for screening, a high-pressure liquid chromatography-ultraviolet 
detection (HPLC–UV) method to quantify the residue, and liquid chromatography coupled with 
tandem mass spectrometry (LC–MS/MS) for confirmation (Feng et al., 2014). Additionally, the 
KISTM test replaced an older in-plant screening test. Subsequently, it has been suggested that these 
new testing methodologies are more sensitive to CEF residues. However, published data suggests 
that the KISTM test has a sensitivity for CEF in kidney tissue of 4 ppm, nearly 10x higher than the 
tolerance (Jones et al., 2014). Therefore, the KISTM test is not very sensitive to CEF compared to 
the bovine tolerance. Published information on the 7-plate bioassay indicates that it’s sensitivity 
for quantifying residues was well below the tolerance of 0.4 ppm (USDA, 2008b). Furthermore, 
the new testing methodology has improved precision in quantifying residues (USDA, 2012b). 
Based on this information, changes in test sensitivity likely have little impact on increased CEF 
residue violations, but instead should have reduced the number of violative residues.  
One of the major contributors to the increased number of violative CEF residues is 
marketing cull cattle earlier than their withdrawal date, which should be easily remedied by 
producer education programs. However, it is plausible that disease could be affecting drug 
pharmacokinetics (PK) in treated animals, thus increasing the time necessary for drug 
concentrations to reach tolerance levels. 
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Altered drug pharmacokinetics in diseased animals 
Under the current drug approval process, drug manufacturers are required to undertake 
efficacy determination, toxicological safety testing, and residue depletion studies to determine 
withdrawal periods. In addition, microbiological safety testing is required for antimicrobials. 
Residue depletion studies are completed on healthy animals (US FDA, 2006b), which potentially 
have different drug PK than the diseased animals that veterinarians and their clients normally treat 
with these drugs. This may lengthen the depletion times needed for drug residues to fall below 
tolerance levels.  
The primary PK parameters that impact the time it takes drugs to reach their tolerance 
levels in a given species are the dose administered, the rate of absorption, and the rate of excretion 
(Riviere	et	al.,	1998). For most drugs, the rate of absorption is rapid, therefore elimination rate is 
dictated by the drug’s VD and clearance (CL). These two parameters are utilized to determine the 
drugs T1/2. If either of these two parameters are altered significantly, depletion of the drug from 
the plasma can be substantially altered (Riviere, 2009a,b). For example, if T1/2 is doubled, then it 
will take twice as long for the drug to be removed from the plasma. Depending on the physiologic 
ability to remove the drug at an organ of elimination (e.g., liver or kidneys), this may or may not 
closely resemble changes in clearance from the body and the resulting withdrawal intervals in food 
animals (Riviere et al., 1998). 
There are several well characterized physiological factors that affect the PK of certain 
drugs, including age, gender, genetic variation, obesity, pregnancy in females, and circadian 
rhythms (Modric and Martinez, 2010). Furthermore, renal, hepatic, and cardiovascular disease are 
often associated with alterations in PK (Martinez and Modric, 2010). What is less understood is 
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the impact of inflammation or endotoxemia on PK of drugs, and the impact this may have on drug 
efficacy and withdrawal intervals.   
 
Studies involving ceftiofur usage in the diseased bovine 
Ceftiofur usage is widespread in dairy cattle (Zwald et al., 2004; Sawant et al., 2005; 
Schuler et al., 2017), yet there is minimal data comparing PK parameters of CEF between healthy 
and diseased cattle. In a summary article, Martinez and Modric (2010) conducted PubMed searches 
using the variables “pharmacokinetics” and “inflammation” from which they acquired 12 relevant 
hits for cattle. They received 14 relevant hits using the variables “pharmacokinetics” and 
“infection”. Of these 26, only 3 dealt with ceftiofur.  
Erskine et al. (1995) compared drug concentrations in healthy cows versus cows 
experimentally challenged with IMM E. coli, using a non-conventional dosing strategy (3 mg/kg 
IV every 12 hours for 3 treatments). This resulted in all drug administration occurring within 24 
hours. They reported no difference in peak concentrations (Cmax) of CEF in the serum of treated 
vs. healthy control cows. The assay used in this trial was a modified agar gel diffusion assay to 
determine bioactivity. They found higher serum concentrations of active CEF metabolites in the 
control group, suggesting that diseased cattle had increased distribution out of the plasma pool 
(Erskine et al., 1995).  
Others have compared CEF concentrations using both HPLC and microbiological assay in 
feedlot cattle implanted with tissue chambers. Later, half of the chambers were inoculated with 
Mannheimia haemolytica. Both methodologies indicated that total CEF was significantly higher 
in infected than uninfected tissue chambers, even within a single animal. It should be noted that 
the described analytical procedure for determining CEF levels in plasma and other analytes, is to 
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convert all parent compound and metabolites to desfuroylceftiofur acetamide (DCA), and report 
these as CEF equivalents (Jaglan et al., 1990). Interestingly, the ratio of active CEF, determined 
with the microbiological assay, to total DCA was higher in the infected chamber than uninfected 
chamber. In this work, CEF was administered via the IV route and tissue chamber concentrations 
of CEF persisted longer than in plasma (Clarke et al., 1996). Later, a similar experiment was 
conducted using CEF CFA, which showed similar results, except that tissue chamber 
concentrations declined in parallel to those of plasma (Washburn et al., 2005). The investigators 
suggested that a higher concentration of total CEF (both protein bound and active) accumulates at 
the site of infection by passively moving through disrupted endothelial cell barriers and from the 
binding of CEF to acute phase proteins, such as a1-anti-trypsin, which rapidly move to sites of 
infection (Walker et al., 1994; Clarke et al., 1996; Washburn et al., 2005).  
The work cited previously (Clarke et al., 1996; Washburn et al., 2005) should be interpreted 
cautiously, as tissue cages create an artificial, fluid-filled space surrounded by granulation tissue 
with porous vascular tissue (Davis et al., 2005). ß-lactam antimicrobials have a low VD, so they 
move into interstitial fluid from plasma but do not readily cross cell membranes (Papich and 
Riviere, 2009). Tissue cage environments creates physiological spaces that mimics interstitial 
fluid, for which water-soluble drugs like CEF can concentrate in higher concentrations than that 
of infected or inflamed tissues. These inflamed tissues normally are more cellular in nature with 
large amounts of fibrin, which will limit drug diffusion. Much of the drug in this area is protein-
bound and would be biologically ineffective against infectious agents. However, the authors state 
that bound fractions of CEF will dissociate quickly in chemically reduced environments found in 
areas of inflammation (Clarke et al., 1996). Based on deficiencies in clinical relevance of tissue 
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chambers to interstitial fluid drug dynamics, investigational approaches that measure non-protein 
bound drug will provide data that is more clinically relevant (Davis et al., 2005).    
North Carolina State researchers published a manuscript demonstrating altered PK and the 
need for increased milk withdrawal times for flunixin meglumine in cows affected with naturally 
occurring mastitis. In this trial, mastitic cows received both systemic FLU and CEF simultaneously 
(Kissell, et al., 2015). In plasma, FLU (Anderson, et al., 1990; Odensvik and Johansson, 1995) and 
metabolites of CEF (S. A. Brown, et al., 1991) are both reported to be >90% protein-bound in adult 
cattle, leading to a question as to whether co-administration of two highly protein-bound drugs 
may result in an interaction affecting protein binding of one or both drugs. Ceftiofur and flunixin 
are both weak acids, which primarily bind to albumin (Riviere, 2009a). In disease, albumin 
concentrations typically decrease to compensate for the body’s need to increase production of 
acute phase proteins (Ceciliani et al., 2012), which should lead to a higher unbound fraction of the 
two drugs. As both CEF and flunixin are low extraction ratio drugs, an increase in the unbound 
fraction should reduce the total concentration of the drug in the circulation but not the free 
concentration (Toutain and Bousquet-Melou, 2002). Therefore, the prolonged milk withdrawal 
times for flunixin seen in this trial are likely due to changes in drug clearance due to decreased 
milk production or changes in drug metabolism associated with liver dysfunction due to disease 
(Kissell et al., 2015).  
 
Studies involving ceftiofur usage in diseased animals in other species 
Comparisons of CEF PK in diseased versus healthy animals have been completed in swine 
(Tantituvanont et al., 2009; Day et al., 2015; Sparks et al., 2016) and chickens (Amer et al., 1998). 
The swine trials included pigs experimentally infected with porcine reproductive and respiratory 
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syndrome virus (PRRSv) (Tantituvanont et al., 2009); pigs co-infected with PRRSv and 
Streptococcus suis (Day et al., 2015); and pigs infected with PRRSv and vaccinated (Sparks et al., 
2017), all of which were compared to healthy control animals. In these trials, volume of 
distribution per fraction of the dose absorbed (VD/F) and clearance per fraction of the dose 
absorbed (CL/F) were higher and DCA plasma concentrations were lower in diseased than healthy 
animals (Tantituvanont et al., 2009; Day et al., 2015; Sparks et al., 2017). In all three of the 
previously mentioned studies, changes in the VD and CL are potentially confounded by differences 
in absolute bioavailability (F). None of the studies included an IV study to directly determine F, 
but Sparks et al. (2017) determined a relative F of 0.8, which decreased the differences in these 
two parameters in their group challenged with PRRSv. In the Sparks et al. (2017) study, the 
investigators demonstrated previous vaccination with a commercial PRRSv vaccine prior to viral 
challenge preserved PK parameters similar to that of the control animals.  
In the poultry trial, one group of healthy chickens was exposed to aflatoxin in their diet 
while the control group was fed a diet devoid of aflatoxin. Both groups were treated with CEF via 
the IV, IM, or oral route. In chickens treated via the oral and IV route, serum concentrations of 
CEF were significantly lower and CEF was eliminated more quickly in birds exposed to aflatoxin 
(Amer et al., 1998).  
 
Other studies investigating disease and altered pharmacokinetics 
In a summary article evaluating the acute phase response to febrile disease, van Miert 
(1990) described the impacts on drug absorption, metabolism, and excretion. Diseases in which 
endotoxin is the inciting cause, gastric secretion and hunger sensations are absent in monogastric 
animals, which may change gastric pH and motility. Even though drugs are not directly absorbed 
20 
 
from the stomach, delayed gastric emptying may decrease intestinal absorption and drug solubility 
may be changed alterations in gastric pH.  
In a trial by this research group, pigs were challenged with Actinobacillus 
pleuropneumonia and the effects on PK were evaluated. During the febrile state, orally 
administered oxytetracycline (OTC) took 4 times longer than control animals to achieve time to 
maximum concentration (Tmax) and Cmax was 50% of the concentration acquired in the control 
animals. Additionally, T1/2 and AUC were increased in febrile animals, indicating that withdrawal 
times should be prolonged (van Miert, 1990). 
In comparisons of absorption of ampicillin administered via the IM route, Groothuis et al. 
(1980) found absorption to be greater in febrile goats while shivering compared to non-febrile 
control goats. In contrast, less absorption and lower serum ampicillin concentration was noted in 
non-shivering, febrile calves compared to non-febrile controls (Groothuis et al., 1978). 
Infection and inflammation potentially results in down regulation of drug transporters and 
hepatic and extra-hepatic cytochrome P450 metabolizing enzymes in the liver or intestinal 
epithelium. These alterations in cytochrome P450 activity usually decrease CL, but may increase 
CL. These changes are most important from a toxicology standpoint with low therapeutic index 
drugs, but also would be important from a drug residue standpoint in food-producing animals 
(Morgan, 2009). 
Several studies suggest that inflammation of membranes surrounding joints or the 
membrane representing the blood milk barrier in the mammary gland are more porous when 
inflamed. As a result, this will allow more drug to penetrate the membrane (van Miert, 1990). 
However, three separate studies investigating drug diffusion across inflamed joint membranes 
have outcomes that are contrary to this suggestion. The first study investigated cephapirin diffusion 
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into suppurative synovial joints compared to normal joints on the same animal. Following 
cephapirin administration, drug concentrations were not significantly different between normal 
and infected joints (M. P. Brown et al., 1991). In a second contrary study, Cornell researchers 
described the effect of IV sodium penicillin G or IV OTC in calves following induced joint 
inflammation. After treatment, synovial fluid drug concentrations were not different in inflamed 
joints compared to healthy joints (Guard et al., 1989). Lastly, Shoaf et al. (1986) failed to show a 
difference in trimethoprim/sulfadiazine synovial fluid concentrations or plasma PK in neonatal 
calves. This demonstrates the need to characterize each drug and disease condition individually is 
it relates to drug PK.    
Gips and Soback (1999) compared IV norfloxacin PK in milk and serum of cows with 
naturally occurring sub-clinical Staph aureus infections and cows with induced E. coli clinical 
mastitis. In both trials, norfloxacin concentrations and PK were compared to healthy, control cows. 
As a result, mean residence time (MRT) and T1/2 were significantly lower in mastitis cows than the 
normal group. In cows with coliform clinical mastitis, CL increased as a function of disease 
severity and VD was lower. In milk, area under the curve (AUC) was substantially higher than 
serum. Compared to normal cows and normal quarters in cows with mastitis, quarters with sub-
clinical or clinical mastitis had lower milk concentrations and AUC. These findings were 
consistent with concentration predictions using the Henderson–Hasselbalch equation associated 
with mastitis induced milk pH changes (Gips and Soback, 1999). 
In a study on the effects of induced E. coli mastitis on the pharmacodynamics and 
pharmacokinetics of carprofen, Dutch researchers demonstrated decreased systemic CL and a 
longer T1/2 compared to the same animals under healthy conditions. In milk from healthy quarters, 
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carprofen was not detected, but in mastitic quarters it was detected for up to 45 hours after 
treatment (Lohuis et al., 1991). 
Egyptian researchers compared the PK of marbofloxacin in cattle with Mannheimia 
haemolytica pneumonia to healthy animals following IV or IM administration. After IV 
administration, CL was lower while steady state VD (VSS) was not affected by disease, resulting in 
longer T1/2, higher AUC, and higher MRT in the diseased animals compared to healthy animals. 
Intramuscular administration resulted in a higher Cmax, higher AUC and MRT, and longer T1/2. In 
the IM group, F and protein binding were not different between the two groups. As a result, the 
research indicated that the time above the minimum inhibitory concentration (MIC) was 12 hours 
in healthy cattle and 24 hours in diseased cattle (Ismail and El-Kattan, 2007). 
In a clinical case report, Illinois researchers investigated the impact of theophylline as an 
ancillary therapy to provide bronchodilation in a group of 20 calves with naturally developing 
respiratory disease. Twenty control calves, also with respiratory disease, received a placebo in 
place of the theophylline. All calves also received spectinomycin and lincomycin in a 2:1 ratio by 
milligram weight, subcutaneously one time per day for 3 days. There were no differences in the 
clinical parameters monitored following initial therapy between treatment and placebo groups. 
Within 24 hours of the third treatment, 5 of the calves that received theophylline died, while no 
calves died in the control group. In the 5 theophylline treated calves that succumbed, mean trough 
theophylline concentrations were significantly higher than the 15 that survived. Additionally, the 
mean peak concentrations for the 5 dead calves was > 20µg/mL, which is the reported toxic 
concentration of theophylline in people. Interestingly, CL has been shown to be reduced in humans 
with concurrent febrile disease or administration of erythromycin or troleandomycin. The authors 
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of the manuscript speculated that the cause of death was theophylline toxicity associated with the 
concurrent respiratory disease and/or administration of antimicrobials (McKenna et al., 1989).  
Kumar and Malik (1999) report that experimental infection with Theileria annulata and 
treatment with IM OTC resulted in Tmax, F, elimination T1/2, AUC, and MRT values that were 
smaller than the same calves treated with IM OTC prior to the experimental inoculation. There 
was no difference in Cmax. The authors postulate that a shorter Tmax is likely the result of increased 
blood flow to peripheral muscle tissues as a result of the febrile response initiated in response to 
the infection, as previously shown by Groothuis et al. (1978, 1980). They further suggested that a 
more rapid elimination of the drug is likely due to increased renal blood flow and higher glomerular 
filtration rate associated with the febrile response, which has been described by van Miert (1990).   
Taken together, these studies highlight the importance of investigating alterations in PK 
and potentially associated withdrawal times differences in diseased animals independently in each 
species, for each disease, and for each different drug. Additionally, physiological and genetic 
parameters must be considered. Veterinary practitioners need to consider whether it is prudent to 
extend withdrawal times with certain drugs and disease conditions.  
 
Antimicrobial Resistance Associated with Cephalosporin Use 
 
As dairy cattle are a dual-purpose breed, they provide food through milk and meat for 
human consumption. As there is potential for fecal contamination during the harvest process, both 
food sources could potentially deliver antimicrobial resistant bacteria to the consumer. Data gaps 
on the level of risk associated with the consumption of milk and dairy products are evident, 
particularly for extended spectrum beta-lactamase (ESBL) prevalence in pre-pasteurized milk, 
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whether from conventional or organic dairies (Horigan et al., 2016). A PubMed search using the 
keywords “ESBL” and “bulk tank milk” generated only four pieces of literature on the subject. 
From these, only three directly addressed EBSL prevalence in bulk tank milk (Geser et al., 2012; 
Sudarwanto et al., 2015; Odenthal et al., 2016). These manuscripts report ESBL prevalence in bulk 
tank milk to be non-existent in Switzerland (Geser et al., 2012) up to approximately 9% from 
Enterobacteriaceae in Indonesia (Sudarwanto et al., 2015) and Germany (Odenthal et al., 2016). 
However, when looking at the overall microbiota of bulk tank milk, coliforms represent a very 
small proportion of the total ecology. Additionally, several surveys studying prevalence of 
antimicrobial resistance (AMR) amongst mastitis pathogens have suggested that it is not increasing 
(Erksine et al., 2002; Makovec and Ruegg, 2003; Pol and Ruegg, 2007), despite the fact that 
mastitis therapy represents a substantial proportion of the total antimicrobial use on dairy farms 
(USDA, 2016a; Schuler et al., 2017). Therefore, the remainder of this literature review will focus 
on the impact of CEF therapy on the enteric microbial ecology and impact of delivery of AMR 
bacteria via meat from cull dairy cows.  
Estimates of AMR among non-type specific (NTS) fecal isolates in dairy cattle herds are 
difficult to compare due to differences in trial design. One of the most consistent sources of data 
throughout the years on this topic has been the USDA NAHMS. In the 1996, 2002, and 2007 dairy 
herd surveys, USDA investigators collected 35-50 fecal samples per farm from approximately 100 
dairy farms across 21 dairy states. The 2007 report summarized the data for Salmonella spp. 
isolates from the previous three surveys, including antimicrobial susceptibility data. To determine 
antimicrobial susceptibility, the gram-negative National Antimicrobial Resistance Monitoring 
System (NARMS) antimicrobial resistance plate was utilized. From the three surveys, 92.3%, 
82.3%, and 96.6% of the Salmonella spp. isolates were pan-susceptible to all antimicrobials for 
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1996, 2002, and 2007, respectively (USDA, 2011b). In 2002, survey investigators also studied 
AMR in E. coli isolates and reported that 85.3% of the isolates were pan-susceptible (Lundin et 
al., 2008).  
 
Policies and regulation regarding cephalosporin use 
The use of antimicrobials in the dairy industry is commonplace (Zwald et al., 2004; Swant 
et al., 2005; Schuler et al., 2017). Concerns over the lack of prudent use has led the FDA to issue 
Guidance Policy 209 (US FDA, 2012a), which is a guidance document that describes the FDA’s 
expectations for prudent antimicrobial use on farms. However, prudent use is still allusive on many 
dairy farms (Schuler et al., 2017). Lack of good antimicrobial stewardship may lead to loss of 
efficacy of the product against animal pathogens, but public health experts are mainly concerned 
about the development of AMR in commensal flora that may be spread via the food supply to 
humans (Doyle et al., 2013). In 2012, the US FDA implemented a restriction on the extralabel use 
of certain cephalosporin drugs in the major food producing species (cattle, swine, chickens, and 
turkeys). The prohibition did not include the first-generation cephalosporin, cephapirin, but 
prevents extralabel uses of all other cephalosporins labeled for the major food producing species 
for disease prevention or at unapproved doses, frequencies, durations, or routes of administration. 
Additionally, only cephalosporins specifically labeled for major food species can be used in these 
species. This prohibition was implemented due to the concerns about the development of AMR in 
food animals and the dissemination of the resistance determinants to humans through food 
consumption, thus risking public health (US FDA, 2012b). This action by the FDA represents the 
second time in which the agency has restricted certain uses of an approved antimicrobial over 
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concerns about the development of AMR, as fluoroquinolones also have extralabel restrictions for 
similar reasons to cephalosporins (US FDA, 1997). 
In 2003, the first of two expert workshops was organized and conducted by the Food and 
Agriculture Organization of the United Nations (FAO), the World Organization for Animal Health 
(OIE), and the World Health Organization (WHO). From these workshops, three conclusions were 
developed: 1) the non-human use of antimicrobials was creating a clear human health consequence 
due to the development of resistant organisms; 2) human exposure to resistant bacteria from the 
consumption of animal food products was associated with the amount and pattern of non-human 
usage; and 3) the consequences were particularly severe when pathogens were resistant to 
antimicrobials critically important antimicrobials to humans. In 2005, the WHO classified 3rd, 4th, 
and 5th generation cephalosporins as critically important antimicrobials for the preservation of 
public health. In 2016, they changed their classification scheme slightly and now 3rd, 4th, and 5th 
generation cephalosporins are among the highest priority, critically important antimicrobials for 
the preservation of human health (WHO, 2017). During the same time period, the US FDA released 
Guidance for Industry #152 - Evaluating the Safety of Antimicrobial New Animal Drugs with 
Regard to Their Microbiological Effects on Bacteria of Human Health Concern. The purpose of 
this document was to recommend an approach to assess the effects of animal drugs on bacteria of 
human health significance. Like the WHO, they created a list of important antimicrobials for public 
health, classifying 3rd generation cephalosporins as critically important and 4th generation 
cephalosporins as highly important antimicrobials (US FDA, 2003). 
Medically important cephalosporins listed by the WHO and the FDA include ceftriaxone, 
cefotaxime, ceftazidime, cefepime, and ceftaroline. Ceftiofur, a 3rd generation cephalosporin, is 
the only broad-spectrum cephalosporin approved for use in food animals in the US. It is the most 
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commonly utilized antimicrobial on dairy farms due to its broad spectrum of activity and short 
withdrawal periods (Zwald et al., 2004; Swant et al., 2005; Schuler et al., 2017). Resistance to 
ceftiofur results in cross-resistance to ceftriaxone and vice versa (US FDA, 2016b). Ceftriaxone is 
a 3rd generation cephalosporin often used in human medicine for the treatment of invasive enteric 
salmonellosis in children as fluoroquinolones are not approved for young children (Whichard et 
al., 2005; Doyle et al., 2013). Therefore, the use of ceftiofur in the veterinary industry is often 
scrutinized for its impact on cephalosporin AMR in humans, despite the fact that there is very 
limited evidence to support this accusation (Landers et al., 2012; Doyle et al., 2013).   
 
Mechanisms of antimicrobial resistance against cephalosporins 
For bacteria to develop resistance against cephalosporins and other ß-lactams, they must 
employ at least one of the following mechanisms: 1) develop mutations that alter the structure of 
their penicillin-binding proteins; 2) alter cell wall permeability through disruption of porin proteins 
or upregulation of efflux pumps; and/or 3) production of ß-lactamase enzymes which hydrolyze 
the ß-lactam ring of the antimicrobial (Seiffert et al., 2013). Extended spectrum ß-lactamases are 
the primary cause of AMR in Enterobacteriaceae isolates on a worldwide basis (Bonnet, 2004; 
Zhao and Hu, 2013). These ß-lactamases are encoded by genetics found on chromosomes or on 
plasmids. 
Currently there are >1000 ß-lactamase enzymes described in the literature (Bush and 
Fisher, 2011), which can be in one 34 families (NCBI, 2017). Classification of ß-lactamases occurs 
through placement into one of four Ambler class, which is a molecular classification system. 
Additionally, they are classified into one of four functional groups (Bush groups 1-4) (Bush and 
Jacoby, 2009). Ambler classes A, C, & D are serine enzymes, while class B are metallo enzymes. 
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Resistance to 3rd generation cephalosporins is primarily mediated by AmpC ß-lactamases from 
class C or ESBL’s, such as TEM, SHV, and CTX-M from class A (Bradford, 2001; Paterson and 
Bonomo, 2005; Bush and Jacoby, 2009). Over the last 20 years, plasmid-mediated AmpC-like 
(blaCMY) and blaCTX-M genes appear to be the most important for development of AMR in 
Enterobacteriaceae against cephalosporins in food producing animals (Li et al., 2007).   
 
AmpC ß-lactamases  
AmpC ß-lactamases can be found on chromosomes or plasmids. Chromosomal AmpC ß-
lactamases are commonly found in enteric bacteria, with their expression being constitutive or 
inducible. Inducible forms found in enteric bacteria often are controlled by several regulators. 
Novel mutations have been shown to increase the spectrum of chromosomal AmpC ß-lactamases 
to include 4th generation cephalosporins (Mammeri et al., 2006). 
BlaCMY genes are plasmid-mediated AmpC-like genes. They were described in a review 
article by Li et al. (2007) as the most widespread plasmid-mediated ß-lactamase genes found in E. 
coli and Salmonella spp. isolates of animal origin. In the US, 3rd generation cephalosporin 
resistance in E. coli and Salmonella enterica isolates from food animals from 2000 – 2010 was 
most commonly associated with the plasmid-borne blaCMY-2 gene (Daniels et al., 2009; Davis et 
al., 2015). BlaCMY ß-lactamases have a wide spectrum of activity against a variety of 
cephalosporins, including cephamycins (cefoxitin) and oxyimino-cephalosporins (e. g., 
cefotaxime, ceftriaxone, and ceftazidime). Plasmid-mediated blaCMY ß-lactamases are not inhibited 
by clavulanate but are inhibited by carbapenems. However, blaCMY ß-lactamases are not considered 
ESBL’s. (Bradford, 2001; Li et al., 2007). Plasmids encoding blaCMY resistance usually carry 
multiple AMR genes and are associated with transposons or integrons, allowing for this plasmid 
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to be easily disseminated within enteric bacteria and other genera (Li et al., 2007). Surveys of 
Salmonella isolates from several different outbreaks indicate that resistance genes against 
ampicillin, chloramphenicol, streptomycin, sulfisoxazole, and tetracycline (ACSSuT phenotype) 
have been found on blaCMY plasmids (Winokur et al., 2000; Rankin et al., 2002; Doyle et al., 2013). 
These resistance determinants have been associated with the Inc A/C plasmid, which is highly 
troublesome as this plasmid has the ability to acquire large numbers of resistance determinants and 
is easily able to circulate through wide variety of bacterial hosts, both commensals and pathogens 
(Doyle et al., 2013).  
 
Plasmid-mediated blaCTX-M ESBL’s 
While ESBL’s can be ß-lactamase derivatives of blaTEM, blaSHV, or blaOXA; currently, the 
dominant worldwide genetic profile of ESBL’s is that of blaCTX-M (Davis et al., 2015). These 
enzymes belong to Ambler class A or D and the Bush group 2be or 2d (Li et al., 2007). CTX-M 
ß-lactamase enzymes were first described in 1986 from a canine fecal E. coli isolate and have since 
been described worldwide (Bonnet, 2004). CTX-M genes are believed to have arisen from 
chromosomal genes of Kluyvera spp. (Canton et al., 2012). Dissemination of blaCTX-M genes are 
described as being plasmid associated, with incompatibility group I1, F, or N commonly found as 
the vehicle for dissemination (Mollenkopf et al., 2012).  
This enzyme is named due to its efficiency at hydrolyzing cefotaxime (Li et al., 2007). 
CTX-M ß-lactamase enzymes typically result in high levels of resistance in E. coli against 
ampicillin, amoxicillin, carbenicillin, ticarcillin, piperacillin, cephalothin, cephaloridine, 
cefuroxime, cefotaxime, and ceftriaxone; but maintain susceptibility to cefoxitin and carbapenems. 
These enzymes have a variable level of resistance against cefepime, cefpirome, and ceftazidime, 
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although it appears that variants of the CTX-M enzyme are emerging that improves activity against 
ceftazidime. Minimum inhibitory concentrations (MIC’s) against aztreonam are also high. 
Susceptibility to ß-lactamase inhibitors is variable. Combinations of clavulanate and either 
amoxicillin or ticarcillin usually demonstrate effectiveness or low-level resistance against bacteria 
expressing the CTX-M gene. Piperacillin/tazobactam combinations, as well as cefotaxime 
combined with clavulanate or tazobactam, are effective against CTX-M harboring bacteria 
(Bonnet, 2004; Wittum et al., 2010). These genes are predominantly responsible for the ESBL 
phenotype in E. coli and Klebsiella spp. in humans worldwide (Bonnet, 2004; Zhao and Hu, 2013). 
Plasmids encoding for blaCTX-M often harbor the blaTEM gene, as well as genes encoding for 
resistance to aminoglycosides, chloramphenicol, sulfonamides, trimethoprim, and tetracyclines (Li 
et al., 2007; Seiffert et al., 2013).  
In the mid-2000’s, blaCTX-M was beginning to be described from livestock in Europe and 
Asia (Watson et al., 2012). The first US description of E. coli with blaCTX-M in dairy cattle was in 
2009 from OH (Wittum et al., 2010). It is plausible that the recent description of blaCTX-M is only 
occurring because scientist did not specifically look for blaCTX-M genes in resistant isolates in early 
research. However, in a retrospective study, Washington State University researchers re-examined 
resistant E. coli isolates from previous studies to scan for additional resistance determinants. 
Eighty-nine percent of isolates obtained prior to 2011 were carrying the blaCMY-2 gene and none 
carried blaCTX-M genes. From isolates obtained in 2011, there was a combination of blaCMY and 
blaCTX-M resistance genetics prevalent in isolates from Washington state dairies (Davis et al., 2015).  
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Current status of antimicrobial resistance from cattle at processing 
 The National Antimicrobial Resistance Monitoring System (NARMS) is a collaborative 
effort between the US FDA; US Centers for Disease Control (CDC); USDA; state and local health 
departments; and universities to monitor AMR in humans, retail meats, and food producing 
animals. Additionally, NARMS scientists conduct epidemiological investigations about risk 
factors and clinical outcomes for certain infections and investigate molecular mechanisms for 
development of resistance. Prevalence of AMR in Salmonella and Campylobacter are monitored, 
as they are major causes of human food-borne bacterial illness. In addition, NARMS scientists 
also monitor E. coli and Enterococcus from retail meat and cecal samples as indicators of 
resistance development in gram-negative and gram-positive bacteria, respectively. The most recent 
data available from NARMS is from 2014 (US FDA, 2016b).  
The following NARMS data is summarized by production classes. Dairy samples are 
defined as dairy cull cows; while beef samples are defined as samples from steers, heifers, and cull 
beef cows. NARMS also includes sample data from the USDA Food Safety and Inspection 
Service’s (FSIS) Pathogen Reduction/Hazard Analysis and Critical Control Point (PR/HAACP) 
sampling program, in which they swab all classes of cattle carcasses at the end of processing.  
In 2014, the first evaluations of cecal samples were published, as this testing was only 
implemented in 2013. 10.1% of Salmonella isolates from cecal samples of dairy cattle were found 
to be multi-drug resistant (MDR), with MDR defined as being resistant to three or more 
antimicrobial classes. Beef samples had an MDR level in Salmonella of 5.8%, while USDA FSIS 
PR/HAACP testing revealed that 16.6% of the cattle carcasses had MDR Salmonella present. Of 
the E. coli cecal isolates, 12% of dairy cattle isolates were MDR. 
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Ceftriaxone resistance was reported at 7.6%, 1%, and 5.5% for PR/HAACP, beef, and dairy 
Salmonella isolates, respectively. The level reported in PR/HAACP testing is the lowest reported 
since 1999. Additionally, the level of isolates with MDR was also the lowest in cattle since 1999. 
However, Salmonella serotype Newport had a 53% level of ceftriaxone resistance from cattle 
isolates. Resistance among Salmonella serotype Dublin also continues to be a concern, with 29% 
of the isolates exhibiting ceftriaxone resistance. This was down substantially from 2013, when 
approximately 85% of the isolates were resistant. The FDA’s cephalosporin restriction was cited 
as one potential possibility for the decline in ceftriaxone resistance seen in 2014.  
Resistance determinants for ceftriaxone resistance in Salmonella and E. coli isolates in 
NARMS reports have traditionally been related to the blaCMY-2 gene. However, recent data suggests 
the blaCTX-M is increasing. 2014 cattle isolates from PR/HAACP testing of non-typhoid Salmonella 
exhibiting the ACSSuT phenotype were at 7.1%. This is down substantially from 2009, when the 
prevalence was 67%. However, in dairy cattle cecal samples, 6 of 10 samples exhibited the 
ACSSuT phenotype (US FDA, 2016b).    
 
Ceftiofur usage and the development of antimicrobial resistance 
One of the biggest challenges proving associations between ceftiofur usage and resistance 
among fecal NTS E. coli at the animal level is a failure to access individual animal records and 
quantitate antimicrobial usage (Horigan et al., 2016). There has been a plethora of studies looking 
at herd level associations between various antimicrobials and the presence of important resistance 
genes, but few have specifically accounted for individual antimicrobial usage and resistance 
patterns at the animal level 
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One of the more highly cited dairy surveys is work done by Tragesser et al. (2006). In a 
survey of 18 Ohio dairy herds, this research group collected 1266 fecal samples to determine the 
level of ceftriaxone resistance and attempt to correlate this resistance with CEF usage on the source 
farm. This research group found that at least one cow exhibited ceftriaxone resistance in 67% of 
the surveyed herds. Overall, 34.4% of the E. coli isolates had resistance to ceftriaxone. In herds 
that reported usage of CEF within the previous 6 months, the mean ceftriaxone resistance was 40% 
(range 0-97%), while the mean resistance in herds that reported no ceftiofur usage was 9% (range 
0-34%). The presence of the blaCMY-2 gene was found in 83% of the resistant isolates. Eighty-one 
of the ceftriaxone resistant isolates were further tested against a standard panel of antimicrobials, 
where resistance was confirmed for amoxicillin, clavulanic acid, ampicillin, cephalothin, cefoxitin, 
ceftiofur, streptomycin, sulfamethoxazole, and tetracycline. These researchers determined that 
there was a herd level association between the use of CEF and ceftriaxone resistance, but not a 
cow level association. However, the associated use on the participating farms could be as long as 
6 months prior to the time of sampling and did not identify individual animals that were treated 
with CEF (Tragesser et al., 2006).  
The following year, Lowrance et al. (2007) published similar results after following the 
treatment of beef feedlot steers with various dosage regimens of CEF CFA compared to 
commingled, non-treated control animals. In this work, they found 68.4% of fecal E. coli isolates 
harbored phenotypic resistance to at least one antimicrobial. Following CCFA therapy, treated 
animals experienced transient increases in CEF resistant E. coli populations that returned to pre-
treatment levels in approximately 2 weeks. As with the Tragessor et al. (2006) study, this research 
group determined a high level of correlation with CEF resistance and co-resistance against 
ampicillin, chloramphenicol, streptomycin, sulfisoxazole, and tetracycline (ACSSuT phenotype). 
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Additionally, they described an association between CEF usage and reduced susceptibility to 
ceftriaxone. While no direct testing of genetic determinants of resistance were undertaken in this 
trial, the authors hypothesized that resistance to CEF and ceftriaxone was likely due to the blaCMY 
gene.  
In a calf study evaluating ceftriaxone resistance, three dairy breed calves were injected with 
a 5-day course of CEF hydrochloride at therapeutic dosages and three were left as untreated 
controls. The two treatment groups were housed separately, so horizontal spread of resistant 
bacteria from treated to control calves was not possible. Total fecal bacterial counts and total 
ceftriaxone resistant fecal bacteria counts were compared between the two groups. Ceftriaxone 
growth was assessed on antimicrobial impregnated agar plates containing 16, 64, and 128 µg/mL 
of ceftriaxone. It should be noted that the CLSI breakpoint level of ≥64 µg/mL of ceftriaxone for 
determining resistance used in this study is higher than the current breakpoint of ≥4 µg/mL (CLSI, 
2010; CLSI, 2011). The calves were followed for 12 days following CEF treatment. Following 
CEF therapy, there was a 0.5-1 log reduction in total bacteria count, which persisted throughout 
the remainder of the study. However, 5 days following the last CEF treatment, the two groups had 
similar total bacteria counts. There was a significantly higher number of resistant bacteria in the 
CEF treated group on agar plates containing 16 and 64 µg/mL levels of ceftriaxone from the day 
of treatment throughout the remainder of the observation period. Additionally, the percent 
ceftriaxone resistant bacteria as a percentage of the total were determined to be significantly 
elevated on days 0, 1, 2, 3, and 17. It is interesting to note that ceftriaxone resistant bacteria were 
already significantly different in the treatment group at the time of the first treatment, whereas one-
day prior to CEF treatment they were not different. The resistance genes found in isolates were 
blaCMY-2. The authors concluded that CEF treatment in young calves can temporarily change the 
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bacterial flora in a calf’s intestine to favor the growth of ceftriaxone resistant bacteria (Jiang et al., 
2006).  
The trials conducted by Jiang et al. (2006) and Lowrance et al. (2007) were not designed 
to determine horizontal transmission of resistant bacteria genes. Therefore, Singer et al. (2008) 
designed a trial to mix treated and untreated groups in the same pens to assess horizontal transfer 
of resistance. Five lactating dairy cows received a five-day course of CEF hydrochloride at 
therapeutic dosages. The control group of five matched, untreated cows were penned in the same 
pen as the treated cows. From two days following the initial treatment through three days post-
treatment, the treatment group had a significantly reduced total E. coli count and significantly 
elevated antimicrobial resistance index. Antimicrobial resistance index was used by the study 
authors as a quantitative measure of antimicrobial resistance in a bacterial population. The total E. 
coli count and antimicrobial resistance index remained unchanged in the control cows throughout 
the study. The blaCMY-2 gene was detected in the majority of the resistant fecal isolates of treated 
animals through day 6 and at no point afterward. No resistance genes were detected in control 
animals. The authors employed community DNA polymerase chain reaction (PCR) analysis for 
this study, so were unable to determine the genera of the source bacteria of the blaCMY-2 gene 
(Singer et al., 2008).  
Prior to initiation of the above study (Singer et al., 2008), the investigators were able to 
detect resistant E. coli containing the blaCMY-2 gene from calves in the herd that had no prior 
antimicrobial treatment. They were also able to occasionally detect these resistance genes in 
untreated adult animals in the herd. The authors hypothesized that the presence of these resistant 
strains may be affected by bacterial fitness in relationship to other environmental factors. They 
summarized that these findings, along with the results of this trial, indicate that resistance genes 
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were circulating in the herd over time, but CEF treatment increased the probability of isolating 
resistant strains. The authors concluded the manuscript by stating “...this study emphasizes that 
the finding of resistant isolates following antimicrobial treatment is not sufficient to estimate the 
strength of a selection pressure, nor is it sufficient to demonstrate a causal link between 
antimicrobial use and the emergence or amplification of resistance” (Singer et al., 2008, p. 6961).  
In a later study by the same research group, fecal samples from the previous study (Singer 
et al., 2008) were utilized to perform community DNA profiling to seek out the blaCMY-2 gene using 
culture independent techniques. From this work, they confirmed their previous conclusions that 
treated animals had a transient increase in resistance genes in the bacterial community, which 
returned to pre-treatment levels by day 6. They also detected slight increases in resistant DNA in 
the five untreated cows, suggesting that resistant genes were being horizontally transmitted 
amongst animals. The bacterial species harboring the resistant genes in the control group were 
likely not E. coli as the previous study detected no increase in resistant E. coli (Boyer and Singer, 
2012).  
To understand the effects of CEF treatment on blaCMY-2 plasmid transfer, Daniels et al. 
(2009) inoculated calves with bacterial flora containing resistance plasmids and recipient bacterial 
flora to CEF treated and untreated controls. The hypothesis of the study was that movement of 
resistance plasmids would occur from donor bacteria to recipient bacteria not containing the 
plasmids and the CEF treatment would heighten the level of transmission. The results showed that 
transmission of plasmids between the donor and recipient bacteria did occur, but at a low 
frequency. Additionally, CEF treatment did not enhance the development of resistant strains 
(Daniels et al., 2009).   
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In the cited studies in this literature review, the CEF treated animals were healthy with the 
exception of Singer et al. (2008), where animals were positive for Leptospira borgpetersenii 
serovar Hardjo-bovis. This spirochete causes sub-clinical infections and purportedly was 
responsible for economically significant losses due to early embryonic death in dairy cattle. 
However, the animals did not appear clinically ill. The only other study found in the literature that 
dealt with clinically ill animals involved treatments for clinical metritis or foot rot. Cattle on two 
separate NY dairy farms with these ailments could be treated with either CEF or penicillin (Mann 
et al., 2011). Like the previously mentioned studies, a reduction in total E. coli colony forming 
units (cfu) counts was noted following CEF treatment. The authors also reported a significant 
association between CEF resistance from E. coli isolates and concurrent ampicillin and tetracycline 
resistance. Interpretation of levels of E. coli CEF resistance from this manuscript is confounded 
by data presentation, as the authors combined all collection days into one pool. The authors 
reported that a significant reduction in CEF susceptibility was not determined following treatment. 
In this study, there was no healthy group of animals treated with CEF to serve as a positive control 
group (Mann et al., 2011).   
One consistent pattern amongst the studies in this literature review is the transient reduction 
in fecal E. coli and in some cases increased proportions of resistant E. coli strains. These findings 
have also been reported with administration of florfenicol in feedlot cattle (Berge et al., 2005), 
tetracycline in feedlot cattle (Stabler et al., 1982), and penicillin in milk fed to Holstein calves 
(Langford et al., 2003).    
Several studies have looked for risk factors for presence of resistant E. coli associated with 
the blaCTX-M or blaCMY genes. Risk factors determined to be influential for an increased herd 
prevalence were: use of 3rd or 4th generation cephalosporin antimicrobials (Snow et al., 2012; 
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Gonggrijp et al., 2016); younger age of the studied animal (Snow et al., 2012; Geser et al., 2012; 
Schmid et al., 2013); not maintaining a closed herd or not quarantining new arrivals (Snow et al., 
2012; Schmid et al., 2013; Davis et al., 2015); recent addition of animals (Schmid et al., 2013; 
Davis et al., 2015); larger herd size (Davis et al., 2015; Hille et al., 2017); higher herd level milk 
production (Heider et al., 2009); treatment of all clinical mastitis cases with antimicrobials 
(Gonggrijp et al., 2016); use of dry cow teat sealant on selected cows versus all cows (Gonggrijp 
et al., 2016); not using a dry cow teat sealant on any cows vs all cows (Gonggrijp et al., 2016); 
using automated manure scraping (Snow et al., 2012; Gonggrijp et al., 2016); lack of fly control 
(Davis et al., 2015); increasing frequency of antimicrobial use in calves (Gonggrijp et al., 2016); 
less frequent bedding calf housing (Davis et al., 2015); and reduced frequency of cleaning calf 
rearing equipment (Snow et al., 2012; Davis et al., 2015). Interestingly, total antimicrobial use had 
no relationship with risk of finding resistant isolates in several studies (Snow et al., 2012; Davis et 
al., 2015; Gonggrijp et al., 2016).  
In one study, concurrent isolation of Salmonella spp. from fecal samples was correlated 
with isolating E. coli with reduced susceptibility to ceftriaxone. However, the Salmonella spp. 
isolates did not have reduced ceftriaxone resistance (Heider et al., 2009). Daniels et al., (2009) 
reported that farms with a higher prevalence of Salmonella isolation utilized more CEF. However, 
it is unlikely that this association is having an impact in the Heider et al. (2009) study, as higher 
CEF usage should lead to elevated levels of ceftriaxone resistance in Salmonella spp. isolates.  
In contrast to studies that found associations between cephalosporin use and presence of 
resistant strains of E. coli, several studies have not found an association between CEF use and 
isolation of ß-lactamase producing CEF resistant E. coli (Daniels et al., 2009; Heider et al., 2009; 
Mollenkopf et al., 2012; Ohnishi et al., 2013; Sato et al., 2014; Davis et al., 2015).  
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Two manuscripts have been recently published that have looked at prevalence of resistant 
E. coli associated with ESBL or AmpC genes on organic farms (Dolejska et al., 2011; Santman-
Berends et al., 2017). These studies were able to make comparisons to conventional farms using 
similar study designs. The first reported an animal level prevalence of resistance of 39% in 
conventional herds compared to <1% in organic herds. From these results, the authors suggested 
a possible link between cephalosporin use and resistance development (Dolejska et al., 2011). In 
the second study, Dutch researchers reported a 13% herd prevalence in organic herds (Santman-
Berends et al., 2017) compared to 41% in conventional herds (Gonggrijp et al., 2016). It should be 
noted that the latter organic study (Santman-Berends et al., 2017) followed organic definitions of 
the European registration program, which allows up to three antimicrobial treatments per cow per 
year, as long as the treatments are prescribed by a veterinarian. Like the conventional herds, there 
was no association between total antimicrobial use and prevalence of herds with resistant isolates. 
However, unlike the conventional herd study, there was no association between total doses of 3rd 
and 4th generation cephalosporins used and prevalence of herds with resistant isolates. There was 
an association between positive herds and vicinity to swine farms; occasionally treating clinical 
mastitis with parenteral antimicrobials; and feeding milk replacer instead of whole milk to calves 
(Santman-Berends et al., 2017). While not the intention of the study design, the aforementioned 
study by Daniels et al. (2009) contained 3 organic herds and 39 conventional herds. The only farm 
in their study that reported no resistance to ceftazidime was one of the organic farms. In this study, 
ceftazidime resistance was used as an initial marker for carriage of the blaCMY gene. Determination 
of the actual association between ceftazidime resistance and carriage of the blaCMY-2 gene was done 
by PCR, with 89% of the ceftazidime resistant isolates confirmed to be carrying the blaCMY-2 gene. 
Interestingly, the other two organic farms had prevalence frequencies of ceftazidime resistance 
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that were similar to the conventional farms. This indicates that antimicrobial usage, including CEF, 
is not necessary for the preservation of E. coli harboring the blaCMY-2 gene in the microenvironment 
(Daniels et al., 2009).  
 
Other risk factors associated with development of antimicrobial resistance 
It is clear that the use of antimicrobials will result in the development of AMR fecal NTS 
E. coli, at least transiently (Jiang et al., 2006; Lowrance et al., 2007; Singer et al., 2008). However, 
interactions with other environmental exposures may be associated with the development of AMR, 
without prior antimicrobial use. Examples include membrane efflux pumps that may be 
upregulated due to the presence of substrates, such as heavy metals or disinfectants (Summers, 
2002). Another example would be resistance genes that are housed on molecular structures that 
evolve in a population of bacteria. For instance, the genes for the siderophore aerobactin have been 
shown to be present on plasmids that also contain AMR genes. Low environmental iron conditions 
that favor the expression of bacteria with the aerobactin siderophore could also facilitate AMR in 
these bacteria (Delgado-Iribarren et al., 1987). In another example, Washington state investigators 
showed a positive relationship between feeding milk to calves containing a vitamin D supplement 
and the proliferation of E. coli with resistance to streptomycin, sulfadiazine, and tetracycline 
(SSuT strains). The investigators postulated that the presence of the resistance genes in the feces 
of supplemented calves was likely due to factors that provided either a direct and/or indirect 
competitive advantage to the bacteria in the presence of the supplement (Khachatryan et al., 2006). 
These findings indicate that epidemiological investigations into the presence of AMR need to fully 
investigate the complex mechanisms that may be involved in the exhibition of resistance genes, 
instead of simply assuming a cause and effect relationship of antimicrobial usage.   
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Summary - antimicrobial usage, resistance development, and spread to humans 
On a worldwide stage, the incidence of human infections caused by E. coli resistant to 3rd 
generation cephalosporins is increasing (de Been et al., 2014; Thaden et al., 2016). Public health 
experts fear that the use of antimicrobials in farm animals, especially CEF, is a major risk factor 
associated with the development of disease from ESBL Enterobacteriaceae (Doyle et al., 2013; 
Landers et al., 2012). Recent work utilizing whole genome sequencing is proving that previous 
work done using lower resolution methods have incorrectly characterized resistant E. coli isolates 
from human and poultry. These isolates from humans and poultry had previously been described 
as indistinguishable, but high-resolution sequencing has determined that the isolates are unrelated 
and that plasmids from distinctly different reservoirs are the cause of the AMR (de Been et al., 
2014).  
Characterizing CEF use in dairy herds and trying to associate this use with the development 
of resistance must be done with some caution due to the complex interactions that are taking place 
(Landers et al., 2012). One of the biggest challenges in herd-based risk assessments regarding the 
impact of antimicrobial use is confirming the actual antimicrobial consumption. As is evident from 
studies where known animals were treated (Lowrance et al., 2007; Jiang et al., 2006; Singer et al. 
2008), treatment with the CEF results in a transient decrease in total E. coli and an increased 
proportion of resistant strains. However, this is not unique to CEF, as data shows similar patterns 
when other antimicrobials are administered. Additionally, AMR has routinely been demonstrated 
in bacteria in which no antimicrobial use has occurred, suggesting a role of AMR genes in 
organism fitness. Previously published risk assessments looking at the relationships between the 
use of a single antimicrobial in livestock and adverse human effects have been shown to have data 
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gaps that call into question the estimation of risk (McEwen, 2012). Additionally, models studying 
AMR transmission between animals and humans suggest that reducing antimicrobial use in 
animals will have little effect on AMR development in humans (van Bunnik and Woolhouse, 
2017).  
In the future, the use of advanced diagnostic techniques, such as high-resolution 
sequencing, and well-designed risk assessments are paramount for a more thorough understanding 
of antimicrobial usage in food producing animals and subsequent impacts on public health. 
Additionally, there is little information about the impact of antimicrobials as they are introduced 
into the bio-system following animal use and the impact on bacterial ecology on plants and water 
reservoirs. There are also suggestions that models could be created utilizing pharmacological, 
microbiological, and animal production components to implement a post-treatment resistance 
reversion period, similar to withdrawal times to reduce the risk of spread of AMR mechanisms 
(Volkova et al., 2016). In the meantime, the implementation of effective preventative medicine 
programs and prudent antimicrobial use policies on farms will help relieve the need to use 
antimicrobials in food animals and will have some impact on development of AMR in farm 
animals. 
 
Conclusion 
Ceftiofur usage in the dairy industry is commonplace (Zwald et al., 2004; Swant et al., 
2005; Schuler et al., 2017) and violative antimicrobial residues associated with CEF usage have 
been the most common violative residue identified in cull dairy cattle since 2013 (USDA, 2015 
a,b; USDA, 2017 a,b).  The potential causes for said violative residues are many, but one potential 
source that has not been investigated is the impact of sickness on CEF pharmacokinetics, resulting 
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in prolonged drug elimination and the need to extend withdrawal periods prior to slaughter. The 
first objective of this dissertation project was to investigate the impact of moderate or severe 
clinical mastitis on the pharmacokinetics of CEF versus PK in healthy animals (Chapter 2 and 4). 
The second objective was to determine if the co-administration of two commonly used veterinary 
drugs in the treatment of clinical mastitis impacted the PK of each other (Chapter 3). The third 
objective was to determine the impact of moderate or severe clinical mastitis on the clearance of 
CEF from tissues of regulatory interest (Chapter 4).  
Antimicrobial resistance is an increasing public health concern on a worldwide basis. Third 
generation cephalosporins have been designated as medically important antimicrobials by the 
WHO (WHO, 2017) and the US FDA (US FDA, 2003). In the veterinary industry, CEF usage is a 
major concern as it is closely related to ceftriaxone, an antimicrobial commonly used in human 
medicine for the treatment of invasive enteric Salmonellosis in children (Whichard et al., 2005; 
Doyle et al., 2013). This has prompted the US FDA to implement a prohibition against extra-label 
CEF usage in the major food producing species (US FDA, 2012b). Several manuscripts have 
investigated AMR in NTS fecal E. coli and describes this to be transient in nature (Jiang et al., 
2006; Lowrance et al., 2007; Singer et al., 2008). However, there is little to no literature as to 
whether disease has any impact on the transient nature of AMR in NTS fecal E. coli. The transient 
nature of NTS E. coli has led at least one research group to suggest the implementation of 
withholding periods to minimize human exposure to resistant organisms, similar to those imposed 
to prevent drug residues in meat and milk (Volkova et al., 2016). These withholding periods would 
be established based on several variables, including pharmacokinetics of the drug administered. 
However, little information is available on persistence of AMR in NTS fecal organisms in ill versus 
healthy animals. The final objective is to investigate AMR patterns: 1) of E. coli isolated from 
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clinical mastitis cases; 2) of E. coli from systemic infections associated with clinical mastitis cases; 
and 3) of NTS fecal E. coli recovered from cattle experiencing clinical mastitis and healthy cattle 
treated with CEF (Chapter5).                                                                                                                                                                                                                             
45 
 
CHAPTER 2. 
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Abstract 
Mastitis is a frequent problem among dairy cows, reducing milk yield and 
increasing cull rates. Systemic therapy with the cephalosporin antimicrobial ceftiofur 
hydrochloride (CEF) may improve therapeutic outcomes, but the incidence of CEF 
violative residues has increased annually since 2011. One potential explanation is that 
disease status may alter the pharmacokinetics (PK) of CEF. To test this hypothesis, we 
compared the plasma PK of CEF in healthy cows with those with severe endotoxic mastitis. 
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Eight cows with naturally occurring mastitis and eight clinically healthy cows were treated 
with 2.2 mg of CEF/kg of body weight once daily for five days via the intramuscular route. 
Blood was collected at 0, 0.33, 0.67, 1, 1.5, 2, 3, 4, 8, 16, and 24 hours after the first CEF 
administration and every eight hours thereafter until 120 hours after the final dose. Plasma 
samples were analyzed for CEF concentrations using liquid chromatography coupled with 
mass spectrometry. With the exception of time 0, CEF was detected at all time points. The 
disease group had a significantly higher plasma CEF concentration at T=3 hours after the 
first injection and a significantly lower plasma concentration from 40-152 hours following 
the first injection, with the exception of the T=64 hour time point. Data following the first 
injection (Time 0-24 hour) were fit to a single dose, non-compartmental PK model. This 
model indicated that the disease group had a shorter plasma half-life. A multi-dose, non-
compartmental model was used to determine steady state PK. Compared to control cows, 
the disease group had an initially higher peak concentration, a higher volume of 
distribution, and higher drug clearance rates. The disease group also had a lower area under 
the curve per dosing interval, steady state concentration maximum, and dose-adjusted peak 
steady state concentration. All other PK parameters were not different between the two 
groups. Altered PK, as suggested by this trial, may contribute to an increased risk for the 
development of a violative residue in meat. Further research is needed to more completely 
characterize drug distribution in diseased cattle and to study the effect of co-administration 
of other drugs on drug distribution.  
Key words: bovine mastitis, ceftiofur, pharmacokinetics, drug residues 
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Introduction 
Mastitis is the most common reason for therapeutic antimicrobial use in dairy cattle, 
according to the 2007 USDA National Animal Health Monitoring Survey. This survey of 
the dairy industry in the United States indicated that 18.2% of respondents’ cows had been 
treated for mastitis during the previous 12 months (USDA, 2008a). Coliforms are the most 
common bacterial group causing clinical mastitis, and these infections generally result in 
more severe infections, with decreased survivability, than other pathogens (Oliveira et al., 
2013; Wenz et al., 1998; Erskine et al., 2002).  
Reasons for decreased survivability following mastitis include the development of 
endotoxic conditions with severe intramammary (IMM) tissue damage and, the potential 
development of secondary disease. Secondary bacteremia develops in 45% of cows with 
severe mastitis (Wenz et al., 2001a). Systemic ceftiofur (CEF) treatment can potentially 
address severe mastitis and secondary infections. When treated with CEF, fewer cows were 
sold or died as a result of severe coliform mastitis as compared to cows that were not treated 
(Erskine et al., 2002). CEF is a third-generation cephalosporin that is appropriate for use 
against coliform infections if effective concentrations can be achieved and maintained at 
the infection site. As a result, systemic treatment with CEF, with or without IMM therapy, 
has been included in many veterinary treatment protocols for moderate or severe clinical 
mastitis.  
Over the past several years, concerns about veterinary drug use have increased, 
especially around the impact on antimicrobial efficacy in humans and the presence of drug 
residues in milk and meat. Since FY2011, violative CEF residues in culled dairy cows from 
inspector-generated samples have increased more than 5-fold. (USDA, 2013; USDA, 
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2014a). In 2012, the US Food and Drug Administration (FDA) issued a prohibition against 
extra-label drug use of cephalosporins in bovines (US FDA, 2012). Given the prohibition 
of a drug so important to the dairy industry, there is clearly a significant regulatory concern 
about the increase in violative residues. Although the cause of increasing CEF residues is 
likely multi-factorial, one potential explanation may be altered pharmacokinetics (PK) and 
residue depletion of CEF in diseased dairy cattle.  
During the drug approval process, sponsoring companies must present the FDA 
Center for Veterinary Medicine (CVM) with toxicological and residue depletion studies. 
Based on these data, the FDA CVM establishes withdrawal periods for meat and milk, if 
approved for lactating dairy cattle. However, these studies are performed on healthy 
animals, not animals suffering from infectious diseases (US FDA, 2006a). Because 
antimicrobials are not intended for healthy animals, data on drug metabolism in diseased 
animals would provide veterinarians with evidence to more accurately prescribe veterinary 
drugs and to better predict residue depletion in these diseased animals. In turn, this could 
improve treatment efficacy and reduce the risk for violative residues in marketed animals. 
However, there are few data from cattle available in the veterinary literature addressing 
this topic. The objective of this study was to compare the plasma PK of CEF between 
healthy dairy cattle and those afflicted with severe clinical mastitis. Our hypothesis is that 
cows affected with severe infectious disease will have altered CEF PK relative to healthy 
cows, necessitating variance in dose regimens and withdrawal periods.  
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Materials and Methods 
Animals and eligibility criteria 
This study was completed at the Iowa State University (ISU) Dairy Farm. The ISU 
lactating herd consists of approximately 400 animals (approximately 90% Holstein and 
10% Jersey), with 365-day rolling herd averages of 11,324 kg milk, 415 kg fat, and 357 kg 
protein. Throughout the trial, cows were housed in a free-stall barn bedded with recycled 
manure solids, which is standard practice for this dairy. Cows were fed a total mixed ration 
and watered ad libitum. Cows were milked three times daily at 4 am, 12 pm, and 8 pm. 
Cow housing and management met or exceeded the recommendations listed in the Guide 
for Care and Use of Agricultural Animals in Research and Teaching (FASS, 2010). The 
herd was vaccinated with a J5 core antigen vaccine 42 and 28 days prior to calving and 
again 25 and 90 days following calving. ISU’s Institutional Animal Use and Care 
Committee approved the research protocol prior to commencement of trial procedures 
(protocol number 6-14-7820-B).  
Eight cows that presented with naturally occurring, acute severe toxic clinical 
mastitis, as described by Wenz et al. (2001b), were selected to participate in the trial 
(disease group). The disease group had a mean (± SD) weight of 607 ± 77 kg (range 453-
689 kg). The farm’s milking crew first identified each disease group cow based on an acute 
drop in milk production, abnormal milk, and severe swelling in the affected gland. At 
enrollment, all cows had evidence of systemic clinical signs associated with endotoxemia. 
In order to qualify, cows had to present with: 1) at least one hot, swollen quarter secreting 
abnormal milk; 2) an acute decrease in milk production; and 3) evidence of systemic 
disease involvement determined by the presence of an elevated rectal temperature, 
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depression, dehydration, anorexia, and decreased blood circulation as determined by the 
presence of congested mucous membranes or delayed capillary refill time.  
Upon identification of a disease cow with severe mastitis, a healthy herd mate was 
matched by breed, days in milk, and lactation number to serve as a control. The control 
group’s mean (± SD) weight was 650 ± 100 kg (range 462-751 kg). Disease and control 
cows were eligible for the trial if they had not been treated with systemic or IMM CEF 
within the past 20 days and were healthy prior to enrollment. Furthermore, the cows needed 
to be ten or more days from their next scheduled dry period. 
 
Study design 
Disease and control cows were enrolled immediately following the noon milking. 
Throughout the trial, cows were milked by trial personnel per the farm’s milking protocol. 
Prior to the noon milking of the disease group cows, a milk sample was aseptically 
collected from the mastitic quarter for bacterial culture. This sample was kept on ice until 
it was transferred to the laboratory for microbiological analysis.  
After milking, disease and control cows were weighed and placed in treatment 
chutes; two 10-mL blood samples were collected from the jugular vein in blood tubes 
containing freeze-dried heparin for plasma harvest (Becton, Dickinson and Co., Franklin 
Lakes, NJ). Disease and control cows then received 2.2 mg CEF equivalents (CE) per kg 
of body weight in the form of CEF hydrochloride (Excenel RTU EZ, Zoetis, Florham Park, 
NJ) via intramuscular (IM) injection on the left side of the neck. Injections were given on 
alternating sides of the neck each day. In accordance with the manufacturer’s 
recommendations, injection volumes were divided so that no more than 10 mL was 
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administered per injection site. CEF hydrochloride injections were repeated at 
approximately 24-hour intervals for five days. At the discretion of the treating veterinarian, 
ancillary therapies of flunixin meglumine (FLU) (2.2 mg/kg intravenously [IV]) (Prevail, 
VETONE, Boise, ID), 7.2% hypertonic saline (3-5 mL/kg IV) (Hypertonic Saline 7.2%, 
VETONE, Boise, ID), and oral fluids (20-40 L) were also provided for the disease group 
per standard treatment protocols in place for the dairy farm, as needed. The oral fluids 
consisted of tap water with 0.5 kg of an oral electrolyte powder (Fresh Cow Drench, IBA 
Inc., Millbury, MA) and 0.5 kg of dehydrated alfalfa meal added. The control cows 
received no ancillary therapy.  
According to the farm’s treatment protocols, intramammary (IMM) therapy was 
based on the results of bacterial culture. For cows with gram-negative mastitis, negative 
culture results, or agents determined to be non-responsive to IMM therapy (e.g., Prototheca 
zopfii or yeast), no IMM therapy was to be utilized. If a gram-positive agent was identified, 
IMM tubes that did not contain CEF were to be utilized according to label directions. 
Blood samples were collected using venipuncture from the jugular vein into 
heparinized tubes at 0.33, 0.67, 1, 1.5, 2, 3, 4, 8, 16, and 24 hours after the first dose of 
CEF and approximately every 8 hours thereafter, concluding 120 hours after the last dose. 
After blood was collected, samples were immediately placed on ice until plasma could be 
harvested. Within one hour of collection, blood samples were centrifuged for ten minutes 
at 1000× g, and 5 mL of plasma was collected and frozen at -70°C until it was analyzed for 
CEF plasma concentration. 
Milk samples were cultured on Brain Heart Infusion Agar containing 5% sheep 
blood and MacConkey Agar (Remel Microbiology Products, Lenexa, KS) using sterile, 
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cotton-tipped swabs. Plates were inverted, incubated at 37°C, and evaluated after 24 and 
48 hours for bacterial growth. Bacteria were identified based on visual appraisal of the 
plates utilizing typical colony characteristics as described by the National Mastitis Council 
(1999).   
 
Plasma ceftiofur concentration analysis 
Plasma concentrations of CEF were determined using liquid chromatography 
coupled with mass spectrometry (LC-MS). The LC-MS system consisted of an Agilent 
1100 pump, autosampler, and column compartment (Agilent Technologies, Santa Clara, 
CA) coupled to an ion trap mass spectrometer (LTQ, Thermo Scientific, San Jose, CA). 
Total CEF concentrations (expressed as CE) were determined by cleavage of CEF, its 
metabolites, and protein-bound residues to desfuroylceftiofur (DFC) using dithioerythritol 
(DTE), followed by derivatization with iodoacetamide. The resulting stable derivative, 
desfuroylceftiofur acetamide (DCA), was then analyzed by LC-MS. The internal standard 
was deuterated CEF (d3-CEF), which became d3-DCA upon cleavage and derivatization.  
Clean up of the derivatized samples was performed by solid phase extraction (SPE) 
using Oasis HLB cartridges (Waters Corp., Milford, MA). Plasma samples, plasma 
calibrators, and quality control samples (200 µL) were treated with 3 mL of 0.5% DTE in 
borate buffer (0.05 N, pH 9.0) after addition of 10 µL of a 10 ng/µL solution of the internal 
standard, d3-CEF. The samples were then vortexed for 5 seconds and placed in a 50°C 
water bath for 15 minutes. Upon removal from the water bath and cooling to room 
temperature, 0.5 mL of 14% iodoacetamide in phosphate buffer (0.025 M, pH 7) was 
added, and the samples were left in the dark for 30 minutes.  
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Following derivatization, the samples were cleaned on an Oasis HLB SPE column 
(60 mg/3 mL) that was preconditioned with 1 mL of methanol followed by 1 mL of water. 
The sample was then transferred to the SPE column and allowed to pass slowly through 
the HLB column. The column was washed with a 1 mL portion of 5% (v/v) solution of 
methanol in water and then dried for 5 minutes with a flow of nitrogen. Elution of the 
derivatized samples was then performed with two 0.75-mL portions of 5% (v/v) acetic acid 
in acetonitrile. The eluate was dried at 50°C with a stream of nitrogen in a Turbovap 
evaporator (Biotage, Charlotte, NC).  
The dry residue was then reconstituted with 100 µL of 25% (v/v) acetonitrile in 
water and vortexed, then diluted with 50 µL of water and vortexed again. The tube contents 
were transferred to an autosampler vial fitted with a glass insert and the injection volume 
was set to 15 µL. The mobile phases consisted of A) 0.1% formic acid in water and B) 
0.1% formic acid in acetonitrile at a flow rate of 0.25 mL/min. The mobile phase began at 
10% B with a linear gradient to 95% B at 8 minutes, which was maintained for 1.5 minutes, 
followed by re-equilibration to 10% B. Separation was achieved with an ACE C18 column 
(ACE 3 C18, 150 mm × 2.1 mm, 3 µm particles, Mac-Mod Analytical, Chadds Ford, PA, 
USA) maintained at 40°C. DCA was eluted at 3.70 minutes and the internal standard, d3-
DCA, was eluted at 3.66 minutes.  
Sequences consisting of plasma blanks, calibration spikes, quality control samples, 
and bovine plasma samples were then batch-processed with an automated processing 
method developed in the Xcalibur software (Thermo Scientific, San Jose, CA, USA), 
which identified and integrated each sample peak. The calibration curve was calculated 
based on a weighted (1/X), linear fit. Plasma concentrations of CEF in trial samples were 
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calculated based on this calibration curve. Results were then viewed in the Quan Browser 
portion of the Xcalibur software. Calibration spikes were utilized from 1 to 10,000 ng/mL. 
The standard curve had a linear range from 1 to 2000 ng/mL with a correlation coefficient 
of 0.998.  All standards were within +/- 10 % of the nominal value in this range.  A 
quadratic fit was needed to fit in the last two calibrators at 5000 and 10,000 ng/mL. The 
limit of detection was 0.4 ng/mL and the limit of quantification was 2 ng/mL. 
 
Pharmacokinetic analysis 
Due to the trial design, the PK data could not be modeled using only one model. 
Therefore, both a single dose and multi-dose PK analysis was performed with computer 
software using non-compartmental methods (Phoenix WinNonlin, Certara, L.P., Princeton, 
NJ, USA). For the single dose PK analysis, the maximum plasma concentration for the first 
dose (Cmax1st dose), time to Cmax (Tmax1st dose), and	area under the curve from 0-24 hours 
(AUC0-24) among all cows was determined directly from plasma samples collected after 
the first dose of CEF until the second dose was administered. The terminal half-life of the 
first dose (T½1st dose) was determined from at least three time points on the terminal portion 
of the plasma profile before the second dose was administered. 
To complete the multi-dose model, time points that were equally distributed were 
used, starting with T=8 hours and continuing with the time points every eight hours through 
the end of the trial. The maximum plasma concentration at steady state per dose 
administered (CmaxD) was determined by dividing steady state maximum plasma 
concentration (Cmaxss) by the actual dose administered. The terminal half-life following 
the last dose (T½last dose) was determined from at least six time points on the terminal portion 
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of the plasma profile after the last dose. The area under the curve at steady state for the 
dosing interval (AUCtau) was determined directly from the data at 96–120 hours after the 
first dose of CEF.  The volume of distribution (area method) per fraction of the dose 
absorbed (Vz/F) was calculated with the following equation:  /01234 ∗ 6789:; 
where 34 represents the individual estimate of the terminal elimination rate constant, which 
is calculated by determining the log-linear regression of the terminal portions of the plasma 
concentration versus the time curves. The plasma clearance per fraction of the dose 
absorbed at steady state (CL/F) was calculated with the following equation: /0126789:; 
The accumulation ratio was determined by dividing AUCtau by AUC extrapolated to 
infinity after the last dose. The mean residence time (MRT) was calculated by dividing the 
area under the moment curve (AUMC) extrapolated to infinity after the last dose by the 
AUC extrapolated to infinity after the last dose. 
 
Data analysis 
Statistical analysis was performed using SAS 9.4 (SAS Institute, Cary, NC). All 
PK data are reported as geometric means. Disease and control groups were compared using 
the Wilcoxon two-sample rank-sum test (Mann-Whitney test). Multiple variables (i.e. 
drug concentrations and PK values) had distributions that were right skewed with long 
tails. Therefore, non-parametric methods were used to analyze the data in this 
situation.  Statistical significance was established when P < 0.05. 
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Results 
Eight cows (seven Holstein, one Jersey) were enrolled in the trial as disease group 
animals. At enrollment, disease group cows ranged from 2–5 lactations and 2–354 days in 
milk. All cultures from mastitis samples were pure cultures and identified as either E. coli 
(n=5) or Klebsiella spp. (n=3). Following the 10-day trial period, five of the eight disease 
group cows were immediately culled from the herd and one additional cow was culled 
within 60 days; all culls resulted from the clinical mastitis episode that initiated their 
enrollment in the trial. The remaining two cows, one with mastitis caused by E. coli and 
one by Klebsiella spp., remained in the herd for at least 60 days following the clinical 
episode of mastitis. There were no statistical differences in any comparative parameters 
between disease and control cows (Table 1). 
Seven of the eight disease group cows received ancillary therapy of FLU for an 
average of 2.3 days (range 1-5), five of the eight received hypertonic saline an average of 
1.2 days (range 1-2), and all eight received oral fluids an average of 3.9 days (range 2-9). 
None of the cows received IMM antimicrobial therapy. 
No cow had detectable plasma CEF at enrollment (time 0) and CEF was detected 
in all subsequent samples throughout the entire study period. CEF concentrations were 
significantly higher in the disease group 3 hours after the first injection and then 
significantly lower at 40, 48, 56, 72, 80, 88, 96, 104, 112, 120, 128, 136, 144, and 152 
hours after the first injection (Figures 1 and 2).  
Several PK parameters differed between disease and control cows. The results of 
the single dose PK model are displayed in Table 2 and those from the multi-dose model 
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are displayed in Table 3. Compared to control cows, the single dose PK model indicated a 
shorter T½1st dose (P = 0.038) for the disease group. The multi-dose PK model indicated that 
the disease group had a higher Vz/F (P = 0.001) and CL/F (P = 0.0006) compared to the 
control group. The disease group had lower AUCtau (P = 0.0006), Cmaxss (P = 0.0006), 
and CmaxD (P = 0.0006). There was also a tendency for a longer T1/2 last dose in the disease 
group (P = 0.065). All other PK parameters were not different between the two groups in 
both models.  
 
Discussion 
Ceftiofur is a third-generation cephalosporin marketed for use in multiple food 
animal species. In the dairy industry, CEF is marketed for systemic and IMM use. Based 
on our experience and that of others (Zwald et al., 2004; Sawant et al., 2005), CEF is likely 
the most commonly used antimicrobial in the United States dairy industry due to its broad 
spectrum of activity, multiple formulations, and short milk and meat withholding periods. 
Within an hour of injection with CEF products, the parent compound is almost completely 
metabolized by the liver to DFC and small concentrations of other non-polar and polar 
metabolites (Jaglan et al., 1989; S. A. Brown et al., 1991). DFC has an exposed sulfhydryl 
group that forms reversible disulfide bonds with other sulfurous compounds, such as 
sulfhydryl-containing proteins and glutathione. These protein-bound CEF metabolites are 
not biologically active but can dissociate quickly in reduced environments to form active 
metabolites (Clarke et al., 1996). In cattle, protein binding is age-dependent, with low 
levels in calves while healthy adult cows have CEF metabolites that are >90% bound (S. 
A. Brown et al., 1991). Repeated dosing with CEF may result in saturation of protein 
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binding sites, resulting in the presence of more unbound, active metabolites over time 
without increasing T1/2 (Halstead et al., 1992). More than 95% of administered CEF sodium 
is excreted within 24 hours; with 61-77% of the total drug excreted through urine and the 
balance excreted in feces (S. A. Brown et al., 1991). Drug approval studies show that 
metabolism and excretion of CEF hydrochloride by cattle is similar to that of CEF sodium 
(US FDA, 1998), and tissue distribution of CEF is similar regardless of the CEF salt 
administered (US FDA, 1998; KuKanich et al., 2005).  
Over the last several years, concerns about veterinary drug use, its impact on 
antimicrobial efficacy in humans, and the presence of drug residues in milk and meat have 
increased. This is especially true for medically important drugs, including cephalosporins 
(US FDA, 2006b). In 2012, the FDA issued a prohibition against extra-label drug use of 
cephalosporins in bovines for those cephalosporins with analogs in human medicine (US 
FDA, 2012b). While mastitis is an extra-label condition for all systemic CEF products, 
there are no FDA restrictions on extra-label conditions as long as the dose, duration, and 
route of administration label conditions are followed (US FDA, 2012b). Using published 
literature, (e.g. Wenz et al. (2001a) and Erskine et al. (2002)) veterinarians can justify this 
extra-label therapy provided it is in compliance with the requirements of the Animal Drug 
Use Clarification Act (US FDA, 1996).  
In the dairy industry, CEF is primarily affected by the FDA prohibition; however, 
CEF residues have increased substantially since FY2011. Between FY2011 and 2012, 
confirmed violative residues from inspector-generated samples in culled dairy cattle 
increased from 53 to 130 (USDA 2013, 2014a), rising to 283 in FY2014 (USDA, 2014b). 
These reports indicate that CEF residues are now the most common violative residues 
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found in cull dairy cattle. Given the extra-label prohibition and the importance of the drug 
to the dairy industry, there is extreme concern about this level of violative residues. 
Although the reason for this level of violative residues is likely multi-factorial, one 
potential cause may be altered PK and residue depletion of CEF in diseased dairy cattle.  
The objective of this trial was to determine if plasma PK for CEF were different 
between healthy cows and cows with severe disease. The findings suggest that disease may 
indeed alter the PKs of CEF in diseased cattle, resulting in a shorter T1/21st dose in the disease 
group when the data was modeled for a single dose. When multi-dose modeling was 
applied, there was more than a two-fold increase in Vz/F and a nearly two-fold increase in 
the plasma clearance rate. Additionally, Cmaxss, CmaxD, and AUC were significantly lower 
in the disease group, resulting in more than a 40% reduction in each parameter. Following 
the first injection, our single PK data was close for Cmax1st dose and Tmax1st dose compared 
to package insert data supplied with the product (Zoetis, 2013a). However, the T1/21st dose 
data was substantially shorter than the package insert (8.13 hours for the control group vs. 
29.3 hours from the package insert). The likely explanation for this difference was the 
limited amount of time available (T=3 hours to T=24 hours) to follow the depletion curve 
after the Cmax1st dose before the second dose was administered. During that time, the 
depletion curve was fairly linear unlike the depletion curve that occurred following the fifth 
dose, leading to a much shorter depletion estimate for the single PK model (see Figure 1). 
In contrast, the T1/2 last dose was much closer to the value reported in the package insert.  
A weakness of the multi-dose PK model was that the first time point (T=8 hours) 
to be included in this model occurred after the Cmax1st dose and Tmax1st dose. This biased the 
reported value for AUCtau lower. As a result, the values for Vz/F and CL/F are over-
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estimates in the data reported. However, since this occurred in both groups and Cmax1st dose 
and Tmax1stdose were not statistically different, the changes should be proportional between 
the two groups, indicating that while the values are not exact, the change between the two 
groups for AUCtau, Vz/F, and CL/F are true. This can be verified by studying the 
concentration curves presented in Figure 2 and noting that a statistically significant change 
in concentrations started to occur at T=40 hours through T=152 hours, with the exception 
of T=64 hours. 
Many physiological changes could explain the PK changes we found, including 
altered absorption of the drug due to altered blood flow to the injection site; reduced plasma 
protein levels in diseased animals that allowed unbound CEF to move more freely to tissue 
or be excreted; competition with co-administered drugs (e.g., FLU) for protein binding 
sites; changes in membrane permeability in tissue, such as the mammary gland; altered 
liver and kidney function due to altered blood flow or altered enzyme systems (van Miert, 
1990); or altered function of membrane-bound drug transporters (Petrovic et al., 2007).  
Despite the widespread use of CEF in dairy cattle, there is a paucity of data 
comparing PK parameters of CEF between healthy and diseased cows. In one trial, Erskine 
et al. (1995) compared drug concentrations in healthy cows versus cows experimentally 
challenged with IMM E. coli; however, they utilized a different dosing strategy (3 mg/kg 
IV every 12 hours for 3 treatments), which resulted in all drug administration occurring 
within 24 hours. In accordance with our findings in the single dose PK model, they reported 
no difference in peak concentrations of CEF in the serum of treated vs. healthy control 
cows. In their trial, they found higher serum concentrations of active CEF metabolites in 
the control group, suggesting that diseased cattle had increased distribution out of the 
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plasma pool. We found a similar increase in plasma distribution of drug, but we did not 
measure active compound. However, in contrast to our results, they reported peak serum 
concentrations 90% less than the values measured in our trial. This disparity may be due 
to methodological differences; their assay did not account for protein-bound metabolites, 
which could make CEF concentrations appear low.  
Other researchers have compared CEF concentrations using both high performance 
LC and microbiological assay in feedlot cattle implanted with tissue chambers; half of the 
chambers were later inoculated with Mannheimia haemolytica.  Both methodologies 
indicate that total DCA is significantly higher in infected than uninfected tissue chambers, 
even within a single animal. Interestingly, the ratio of active CEF to total DCA was higher 
in the infected chamber than uninfected chamber (Clarke et al., 1996). Thus, it appears that 
a higher concentration of total CEF (both bound and active) accumulates at the site of 
infection by passively moving through disrupted endothelial cell barriers and from the 
binding of CEF to acute phase proteins, such as a1-anti-trypsin, which rapidly move to 
sites of infection (Clarke et al., 1996; Walker et al., 1994). There could also be impairment 
of outward fluxing membrane transporter pumps due to inflammation (Petrovic et al., 
2007). Movement through impaired membranes of the mammary gland may explain the 
higher Vz/F in diseased cattle described in our study.   
Other comparisons of antimicrobial PK in diseased versus healthy animals have 
been completed in swine (Tantituvanont et al., 2009; Day et al., 2015) and chickens (Amer 
et al., 1998). The swine trials included pigs experimentally infected with porcine 
reproductive and respiratory syndrome virus (PRRSV) (Tantituvanont et al., 2009) and pigs 
co-infected with PRRSV and Streptococcus suis (Day et al., 2015), both of which were 
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compared to healthy control animals. In these trials, volume of distribution and CL were 
higher and plasma concentration values lower in diseased than healthy animals 
(Tantituvanont et al., 2009; Day et al., 2015). In the poultry trial, one group of healthy 
chickens was exposed to aflatoxin in their diet while the control group was fed a diet devoid 
of aflatoxin. Both groups were treated with CEF via the IV, IM or oral route. In the chickens 
treated via the oral and IV route, tissue concentrations of CEF were lower and CEF was 
eliminated more quickly (Amer et al., 1998). Taken together, these three trials 
(Tantituvanont et al., 2009; Day et al., 2015; Amer et al., 1998), combined with our work, 
suggest that more research on drug disposition is needed in disease-challenged animals. 
Future trials for drug approval should investigate the effect of disease when establishing 
therapeutic dosages and residue depletion time.  
In this trial, the goal was to approximate treatment strategies utilized on commercial 
dairy farms. Therefore, research personnel did not interfere with treatment decisions 
regarding co-administered therapies. Administration of CEF to cows with moderate or 
severe mastitis reduces culling as a result of the mastitis event (Erskine et al., 2002). 
Therefore, it is included in treatment protocols for mastitis by many veterinarians. FLU is 
commonly included in the treatment of moderate to severe clinical mastitis (Kissell et al., 
2015), despite inconsistent evidence of clinical benefits (Dascanio et al., 1995; Anderson 
et al., 1986; Wagner and Apley, 2004; Yeiser et al., 2012). Admittedly, the co-
administration of CEF and FLU potentially confounds the outcome. FLU is reported to be 
greater than 98% protein bound (Anderson, 1990; Odensvik, 1995) which may actively 
compete with CEF for the same protein binding sites. While the PK changes that occur 
with the co-administration of CEF and FLU are not known, theoretically protein binding 
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could be reduced for one or both drugs. If CEF was less protein bound as a result of co-
administration of FLU, this could account for the changes that were noted for Vz/F and CL. 
However, in a pair of manuscripts, Whittem et al. (1995 and 1996) reported no PK 
differences with ceftiofur or aspirin following co-administration of single doses of each 
drug.  Like FLU, aspirin is a non-steroidal anti-inflammatory drug that achieves high 
protein binding in the bovine (Lees, 2009). Additional research is needed to determine the 
effects of highly protein-bound drugs co-administered with other such drugs, including the 
co-administration of CEF and FLU, because this is how the drugs are typically used on 
dairy farms.     
In conclusion, these data, coupled with that of other researchers, show that 
significant PK changes occur in diseased animals administered CEF relative to healthy, 
control animals. These outcomes potentially have public health significance in that: 1) drug 
efficacy could be lower than expected; 2) there may be an increase in violative drug 
residues in tissues of cull animals or milk; and 3) this may lead to increases in antimicrobial 
resistance. This body of evidence suggests that the drug approval process should be 
changed such that the physiological changes of health-challenged cows are addressed. It 
does not, however, lead to any conclusions regarding the outcomes of treating health-
challenged cows nor the contribution of altered PK on the increasing violative CEF 
residues found in culled dairy cattle. Further work examining protein binding, tissue 
distribution, and tissue depletion of drugs and their influence on residue levels in diseased 
animals at the end of their withdrawal periods is necessary to more thoroughly characterize 
this problem. 
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Table 1. Mean ± SD days in milk, lactation number, cow weight, and milk production for 
eight severe mastitis cows (disease group) and eight control cows. 
 
Parameter Disease group Control group 
Days in milk 119.2 ± 122.6  119.5 ± 125.6 
Lactation number 3.4 ± 0.9 3.1 ± 1.0 
Age of cow (yr) 5.0 ± 1.4 4.6 ± 1.3 
Cow weight (kg) 607 ± 77  650 ± 100  
305-day mature equivalent milk production (kg) 10246 ± 1118  
 
9996 ± 1352  
 
 
 
 
 
 
 
Table 2. Single dose plasma pharmacokinetic parameters of ceftiofur equivalents after 
the first dose for disease and control cows using a multi-dose regimen. Results are 
presented as geometric mean for ceftiofur equivalents1.  
 
Parameter Disease group2 Control group 
Cmax1st dose (µg/mL) 11.75 (7.73-17.80) 9.58 (7.73-13.26) 
Tmax1st dose (h) 2.54 (2-4) 2.87 (2-4) 
T1/21st dose (h) 6.57 (5.04-8.04) 8.13 (6.59-9.80)* 
AUC0-24 (h × µg/mL) 106.4 (85.94-124.54) 95.43 (63.82-117.00) 
1Values in parentheses are the range. 
2Cows with severe toxic mastitis. 
Cmax = maximum plasma concentration for the first dose; Tmax = time to Cmax; T1/2 1st 
dose = terminal half-life of the first dose; AUC0-24 = area under the concentration curve 
from 0-24 hours.  
*Geometric means within the columns differ (P < 0.05). 
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Table 3. Multi-dose plasma pharmacokinetic parameters of disease and control cows. 
Results are presented as geometric mean for ceftiofur equivalents1.   
 
Parameter Disease group2 Control group 
Vz/F (L/kg) 3.08 (1.96-5.18) 1.44 (1.08-2.19)** 
CL/F (mL/min/kg) 0.850 (0.61-1.06) 0.466 (0.334-0.666)** 
MRT (h) 23.6 (20.5-30.0) 22.3 (18.4-27.4) 
AUCtau (h × µg/mL) 44.7 (36.0-63.0) 81.2 (56.6-114.4)** 
Cmaxss (µg/mL) 3.28 (2.87-4.26) 5.56 (3.44-7.31)** 
CmaxD (µg/mL) 1.44 (1.25-1.84) 2.45 (1.52-3.19)** 
T1/2 last dose (h) 41.9 (33.7-70.9) 35.8 (31.2-40.5) 
Accumulation ratio  1.55 (1.43-1.80) 1.48 (1.33-1.67) 
1Values in parentheses are the range. 
2Cows with severe toxic mastitis. 
Vz/F = volume of distribution per fraction of the dose absorbed; CL/F = plasma clearance 
per fraction of the dose absorbed at steady state; MRT = mean residence time; AUCtau = 
area under the curve at steady state for the dosing interval; Cmaxss = steady state 
maximum plasma concentration; CmaxD = maximum plasma concentration at steady state 
per dose administered; T1/2 last dose = terminal half-life following the last dose. 
**Geometric means within the columns differ (P < 0.005).  
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Figure 1. Log transformations of mean plasma ceftiofur equivalents (CE) concentration 
(± 1 SE) for eight disease group cows with severe mastitis and eight healthy control cows 
following a single administration of ceftiofur hydrochloride at 2.2 mg CE/kg of body 
weight. 
 
 
 
 
Figure 2. Log transformations of mean plasma ceftiofur equivalents (CE) concentration 
(± 1 SE) for eight disease group cows with severe mastitis and eight healthy control cows 
following five administrations of ceftiofur hydrochloride at 2.2 mg CE/kg of body 
weight. 
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Abstract 
Ceftiofur (CEF) and flunixin meglumine (FLU) are two drugs approved for use in 
beef and dairy cattle that are frequently used in combination for many diseases. These two 
drugs are the most commonly used in dairy cattle in their respective drug classes. Two 
research groups have recently published manuscripts demonstrating altered 
pharmacokinetics of FLU and CEF in cows affected with naturally occurring mastitis. The 
objective of this study was to determine if pharmacokinetics of flunixin meglumine 
administered intravenously or intramuscularly administered ceftiofur hydrochloride would 
be altered when co-administered versus individual administration to healthy dairy cattle. 
Ten cows were utilized in a three-period, three-treatment crossover design, with all cows 
receiving each treatment one time with a 10-day washout period between treatments. 
Following treatment, plasma and interstitial fluid samples were collected and stored for 
later analysis. Additionally, plasma ultrafiltrate was collected using microcentrifugation to 
determine plasma protein binding of each drug. Drug concentrations in plasma, plasma 
ultrafiltrate, and interstitial fluid were determined using high pressure liquid 
chromatography coupled with mass spectrometry. The results of this trial indicate that drug 
interactions between FLU and CEF do not occur when the two drugs are administered 
simultaneously in healthy cattle. Further work is needed to determine if this relationship is 
maintained in the presence of severe disease.  
Key words: flunixin meglumine, ceftiofur, pharmacokinetics, drug residues, dairy cattle 
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Introduction 
Ceftiofur (CEF) and flunixin meglumine (FLU) are two drugs approved for use in 
beef and dairy cattle that are frequently used in combination for many diseases, including 
mastitis, metritis, and pneumonia (Schuler et al., 2017). Ceftiofur is a third-generation 
cephalosporin antimicrobial that is the most widely used antimicrobial in the dairy industry 
(Swant et al., 2005; Zwald et al., 2004; Schuler et al., 2017), due to its broad spectrum of 
antimicrobial activity and short withdrawal periods for milk and meat. Flunixin meglumine 
is a non-steroidal anti-inflammatory drug (NSAID) approved for use in lactating dairy 
cattle with indications for control of pyrexia associated with bovine respiratory disease, 
endotoxemia, and acute bovine mastitis. Additionally, FLU is labeled to control 
inflammation associated with endotoxemia. Flunixin meglumine is the most commonly 
prescribed analgesic in cattle in the US (Fajt et al., 2011). 
During the drug approval process, sponsoring companies must present the FDA 
Center for Veterinary Medicine (CVM) with toxicological and residue depletion studies. 
Based on these data, the FDA CVM establishes withdrawal periods for meat and milk, if 
approved for lactating dairy cattle. However, these studies are performed on healthy 
animals, not animals suffering from infectious diseases. Additionally, there is only one 
drug administered at a time in these trials (US FDA, 2006b). During veterinary treatment 
of severe clinical disease (e.g., mastitis or metritis) in the lactating dairy cow, multiple 
drugs, like CEF and FLU, are often administered simultaneously to combat the clinical 
signs of the disease in question (Schuler et al., 2017). As most veterinary drugs are not 
intended for use in healthy animals, data on drug metabolism in diseased animals would 
provide veterinarians with evidence to more accurately prescribe veterinary drugs and to 
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better predict residue depletion in these diseased animals. Furthermore, data examining 
drug metabolism in sick animals and how this compares with healthy animals are deficient 
in the veterinary literature. Recently, two research groups have published manuscripts 
demonstrating altered pharmacokinetics (PK) of FLU (Kissell et al., 2015) and CEF 
(Gorden et al., 2016) in cows affected with naturally occurring mastitis. In both trials, 
mastitic cows received both FLU and systemic CEF simultaneously. In plasma, FLU 
(Anderson et al., 1990; Odensvik et al., 1995) and metabolites of CEF (S. A. Brown et al., 
1991) are both reported to be >90% protein bound in adult cattle, leading to a question as 
to whether co-administration of two highly protein bound drugs may result in an interaction 
affecting protein binding of one or both drugs.  
The objective of this study was to compare the plasma and interstitial fluid (ISF) 
concentrations; plasma protein binding; and plasma PK of CEF and FLU in healthy dairy 
cattle when administered separately versus concurrently. Our hypothesis was that co-
administration of CEF via the intramuscular route and FLU via the intravenous route would 
result in altered plasma and ISF concentrations and altered PK relative to individual 
administration, necessitating variance in dose regimens or withdrawal periods.  
 
Materials and Methods 
Experimental cattle 
This study was completed at the Iowa State University Dairy Farm. The lactating 
herd consists of approximately 400 animals (approximately 90% Holstein and 10% Jersey), 
with 365-day rolling herd averages per cow of 11,026 kg milk, 399 kg fat, and 341 kg 
protein. Ten Holstein cows were utilized in a three-period, three-treatment crossover design 
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with all cows receiving each treatment one time with a 10-day washout period between 
treatments. Cows were eligible for the trial if they had not been treated with systemic FLU 
and systemic or IMM CEF within the past 20 days and were healthy prior to enrollment. 
Furthermore, the cows were thirty or more days from their next scheduled dry period. The 
cows were in their 2nd lactation with a mean (± SD) days in milk of 181.7 ± 19.7 (range 
136-207 days in milk) with a mean (± SD) daily milk production of 39.1 ± 5.7 kg (range 
27.6-47.1 kg). The cows had a mean (± SD) weight of 654.2 ± 17.5 kg (range 573.3-722.2 
kg). 
During each treatment period, cows were housed in individual box stalls bedded 
with deep, long-stem straw. Each stall had individual access to feed and water. Cows were 
milked three times daily (4 am, 12 pm, and 8 pm). During the treatment periods, trial 
personnel milked trial cows per the farm’s milking protocol. Between treatments, cows 
were housed in a free-stall barn bedded with recycled manure solids, which is standard 
practice for this dairy. Cows were fed a total mixed ration and watered ad libitum. Ration 
parameters met or exceeded those recommended by the NRC guidelines (NRC, 2001). Cow 
housing and management met or exceeded the recommendations listed in the Guide for 
Care and Use of Agricultural Animals in Research and Teaching (FASS, 2010). Iowa State 
University’s Institutional Animal Use and Care Committee approved the research protocol 
prior to commencement of trial procedures (protocol number 6-14-7820-B).  
 
Experimental design 
Cows received each of the three treatments with a ten-day washout period between 
the treatments. Prior to the first replicate, the cows were randomly assigned to one of three 
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treatment groups using the RAND function in a spreadsheet program. Cows remained in 
the same groups for all three replicates. Assignment of the treatment at each replicate was 
also randomly assigned. The treatments were: FM = one dose flunixin meglumine (FLU) 
at 2.2 mg/kg IV (Prevail, VETONE, Boise, ID); C = one dose CEF (Excenel RTU EZ, 
Zoetis, Florham Park, NJ) at 2.2 mg ceftiofur equivalents (CE)/kg IM; and CF = one dose 
FLU at 2.2 mg/kg IV and one dose CEF at 2.2 mg CE/kg IM administered simultaneously. 
In accordance with the manufacturer’s recommendations, CEF injection volumes were 
divided so that no more than 10 mL was administered per injection site. 
One day prior to each treatment, cows were weighed and moved to their box stall.  
Intravenous catheters were placed in one jugular vein of all cows to facilitate blood 
collection. Cows that were to receive FLU during the replicate received a second catheter 
in the opposite jugular vein. Following restraint in a stanchion, cows were sedated with 
xylazine at approximately 0.025 mg/kg IV; the skin over the jugular furrow was clipped 
and aseptically prepped using alternating scrubs of 2% chlorhexidine acetate and 70% 
isopropyl alcohol. Prior to catheter placement, the area under the skin was infiltrated with 
2% lidocaine. Following catheter placement, the catheter was sutured in place using #3 
nylon suture. To maintain catheter patency, 3 mL of a heparin saline solution containing 3 
USP units of heparin sodium/mL was infused into the catheters every 8 hours until 
treatments were initiated. 
While sedated, all cows had one subcutaneous, in vivo ultrafiltration probe (RUF 
3-12, BASi, West Lafayette, IN) placed dorsal-caudal to the scapula to facilitate ISF 
collection. Briefly, the area was prepped as described above and the probe was placed by 
passing a 10-gauge introducer needle between two small stab incisions through the skin. 
73 
 
Following probe placement, the collection tube was stitched in place and connected to a 7-
mL red top glass vacuum tube (Becton, Dickinson and Co, Franklin Lakes, NJ) for ISF 
collection.     
 
Collection of blood and interstitial fluid samples 
At T0 hour, two 10-mL blood samples were collected from the jugular catheter into 
blood tubes containing freeze-dried heparin (Becton, Dickinson and Co, Franklin Lakes, 
NJ) for plasma harvest. Subsequent blood samples were collected from the jugular catheter 
into heparinized tubes at 0.083, 0.166, 0.33, 0.5, 0.75, 1, 1.5, 2, 4, 6, 8, 12, 18, 24, 30, 36, 
42, 48, 54, 60, 66, and 72 hours after drug administration. After blood was collected, 
samples were immediately placed on ice until plasma could be harvested. Within 2 hours 
of collection, blood samples were centrifuged for 20 minutes at 1000× g at 4 °C, then 5 mL 
of plasma was harvested and frozen at -70 °C until analyzed for drug concentration.  
Simultaneous with drug administration (time 0), a new vacuum tube was attached 
to the ultrafiltration probe. Interstitial fluid samples were collected at 1, 2, 4, 6, 8, 12, 18, 
24, 30, 36, 42, 48, 54, 60, 66, and 72 hours following drug administration by changing the 
vacuum tube. The tubes were immediately frozen at -70 °C until analyzed for drug 
concentration. 
 
Determination of plasma protein binding 
Bound plasma drug concentration of FLU and CEF was determined on each cow 
on the T4 hour plasma samples using a microcentrifugation system (Centrifree 
Ultrafiltration Device, EMD Millipore Corp., Billerica, MA). The microcentrifugation 
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device had a molecular weight cut-off of 30,000. Following plasma harvest, 1 mL of 
plasma was transferred to the microcentrifugation device and then the device was 
centrifuged at 1700× g for 30 minutes. The collection cups were then capped and frozen at 
-70 °C until analyzed for drug concentration. These samples were analyzed for drug 
concentration in the same manner as for ISF samples described below, except spike and 
quality control (QC) samples were prepared using blank plasma. For FLU, the spike range 
was from 3 to 5000 ng/mL, with QC samples at 30, 300, and 3000 ng/mL. For CEF, the 
spike range was from 1 to 5000 ng/mL, with QC samples at 15, 150, and 1500 ng/mL. 
Following determination of drug concentration of both the plasma and the 
microcentrifugation sample containing unbound drug, protein-binding percentage was 
determined using the following formula: 
%	protein	binding = (total	drug − unbound	drug)total	drug ∗ 100	 
 
Plasma and interstitial fluid ceftiofur concentration analysis 
Plasma and ISF concentrations of CEF were determined using liquid 
chromatography coupled with mass spectrometry (LC-MS) as described in Gorden et al. 
(2016). The limit of detection (LOD) was 1 ng/mL, and the limit of quantification (LOQ) 
was 10 ng/mL. The accuracy and coefficient of variation for the quality control (QC) 
samples were 97% and 11.2% for the 15 ng/mL QC; 96% and 6.4% for the 150 ng/mL QC; 
and 95% and 9.3% for the 1,500 ng/mL QC.  
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Plasma and interstitial fluid flunixin concentration analysis 
Plasma and ISF concentrations of FLU were determined using LC-MS as 
previously described (Kleinhenz et al., 2016). The LOD was 3 ng/mL and the LOQ was 5 
ng/mL. The accuracy and coefficient of variation for the QC samples were 106% and 4.4% 
for the 30 ng/mL QC; 112% and 4.2% for the 300 ng/mL QC; and 111% and 4.2% for the 
3,000 ng/mL QC. 
 
Pharmacokinetic analysis 
The plasma drug concentration-time profiles were analyzed using non-
compartmental methods implemented in a commercially available software program 
(Phoenix WinNonLin 6.4, Certara, Cary, NC, USA). Pharmacokinetic parameters 
calculated for FLU with this method included: λz (1/h), slope of the terminal phase; T1/2 λz 
(h), terminal half-life; CO (µg/mL), the initial concentration immediately after drug 
administration calculated by back-extrapolating from the straight line model fit to the first 
two measured concentrations following IV administration; AUC0-tlast (h*µg/mL), area 
under the curve from T0 to the last detectable concentration; AUC0-∞ (h*µg/mL), area 
under the curve extrapolated to infinity using the equation IJKLMNO ; Varea (mL/kg), volume of 
distribution based on the terminal phase of the time-concentration curve; CL (mL/h/kg), 
clearance; and MRT (h), mean residence time. For CEF, λz; T1/2 λz; Cmax (µg/mL), 
maximum plasma concentration; Tmax (h), time of Cmax; AUC0-tlast; AUC0-∞; Varea/F, 
volume of distribution per fraction of the dose absorbed; and CL/F, clearance per fraction 
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of the dose absorbed; and MRT were determined. Both AUC and MRT were extrapolated 
to infinity to account for the total exposure to the drug.  
 
Data analysis 
Statistical analysis was performed using a commercially available software 
program (JMP Pro 11.0.0, SAS Institute, Cary, NC). All data is expressed as arithmetic 
mean ± SE and geometric mean. Comparison of plasma concentrations for each drug over 
time were evaluated using repeated measures in a multivariate analysis of variance 
analysis. Drug concentrations were compared at each time point using contrasts. 
Comparison of variables between treatment groups that were single observations (i.e., 
enrollment variables and PK parameters) were made using a paired t-test when data were 
normally distributed and with a Wilcoxon signed rank test when distributions were not 
normally distributed (FLU variables λz and T1/2 λz). Comparisons of ISF concentrations at 
each time point were made using the Wilcoxon signed ranked test by time if there were 
sufficient sample to facilitate analysis. Statistical significance was established when P < 
0.05. 
 
Results 
At enrollment, there was no statistical difference for any of the animal enrollment 
variables between the treatment groups. 
No cow had detectable FLU or CEF in plasma or ISF at the beginning of each 
replicate (time 0). Plasma and ISF concentrations for FLU are displayed in Figure 1. 
Following drug administration, FLU was detected in all subsequent plasma samples 
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through 18 hours. No cow had quantifiable FLU concentrations in plasma past 30 hours. 
For the ISF samples, appearance of FLU concentrations above the LOQ was variable, with 
no cows having quantifiable values 1 hour after FLU administration and only 4 having 
quantifiable values at 2 hours after FLU administration. One cow had no quantifiable ISF 
FLU in both treatments (FM and CF) at any time point. At eleven time points throughout 
the trial, there was insufficient sample volume available to complete the analysis. No cow 
had quantifiable FLU concentrations in ISF past 30 hours.  There were no significant 
differences in plasma or ISF concentrations between the FM and CF treatment groups 
throughout all the time points measured, except at the T2 hour time point for plasma FLU 
concentration (FM=0.52 µg/mL vs. CF=0.33 µg/mL, P = 0.005). Pharmacokinetic 
parameters for FLU are displayed in Table 1. There were no significant differences for PK 
variables between the FM and CF treatments for FLU.  
Plasma and ISF concentrations of CEF are displayed in Figure 2. Following drug 
administration, CEF was detected in all subsequent plasma samples throughout the entire 
study period. For the ISF samples, none of the cows had CEF concentrations above the 
LOQ at one hour after drug administration and only 3 cows had quantifiable CEF 
concentrations in their ISF by 2 hours post-administration. At four hours after therapy, all 
but one cow (in the CF treatment group) had quantifiable CEF concentrations in their ISF, 
with CEF depleted below the LOQ from the ISF of all cows by 72 hours after treatment. 
There were no significant differences in plasma or ISF CEF concentrations between the C 
and CF treatment groups throughout all the time points measured. Pharmacokinetic 
parameters for CEF are displayed in Table 2. There were no significant differences for PK 
variables between the C and CF treatments for CEF.    
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Mean protein binding (± 1 SE) for FLU at T4 h was 98.6% ± 0.19 for the FM 
treatment and 98.6% ± 0.06 for the CF treatment. Mean and protein binding (± 1 SE) for 
CEF at T4 hours was 94.6% ± 0.003 for both treatments. There were no significant 
differences in protein binding between any of the treatments.    
 
Discussion 
This trial utilized only cattle from the Holstein breed and only in their second 
lactation. This was done to reduce any variation that may have been introduced by breed 
or age differences in drug metabolism.  
Flunixin meglumine and CEF are two veterinary drugs that are often used in 
combination for the treatment of severe infectious processes, such as mastitis or metritis 
(Schuler et al., 2017). Kissell et al., (2015) recently demonstrated that cows treated with 
FLU and CEF for clinical mastitis had different metabolism for FLU than healthy cows, 
necessitating a recommendation for an increased milk withdrawal time. Our group recently 
undertook a similar trial and demonstrated that cows with severe clinical mastitis had 
higher volume of distribution and plasma clearance of CEF in comparison to healthy cows 
(Gorden, et al., 2016). One potential explanation for this phenomenon is that the co-
administration of FLU and CEF may have resulted in an interaction that interfered with 
protein binding, as both drugs are better than 90% protein bound in plasma (Anderson et 
al., 1990; Odensvik et al., 1995; S. A. Brown et al., 1991). The objective of this trial was 
to compare the plasma and tissue concentrations and plasma PK of CEF and FLU in healthy 
dairy cattle when administered separately versus concurrently. Based on the results of this 
trial, the data do not support our hypothesis that drug metabolism would be affected by a 
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drug interaction between FLU and CEF, at least in healthy animals. This finding is 
consistent with that reported by Whittem et al. (1995 and 1996) in a pair of manuscripts 
showing no difference in PK of ceftiofur or aspirin, another NSAID, following co-
administration of single doses of each drug.   
Compared with the FLU PK parameters reported by Kissell et al. (2015), similar 
values were found for MRT but higher values were found for Varea and CL. This trial also 
reported substantially lower values for AUC. Kissell et al. (2015) reported a mean peak 
plasma concentration of 18.35 µg/mL, which occurred 15 minutes following injection and 
not being able to find flunixin in plasma after 12 hours following treatment. Our initial 
plasma observed concentration (CO) was determined to be 22.62 ± 1.06 µg/mL and 20.52 
± 2.22 µg/mL for the FM and CF treatments, respectively. However, by 10 minutes after 
FLU injection, mean plasma values had already dropped to 10.84 ± 0.97 µg/mL and 12.49 
± 0.73 µg/mL for the FM and CF treatments, respectively. Flunixin was detected in plasma 
samples up to 30 hours post-treatment, 18 hours longer than reported by Kissell et al. 
(2015), however lower LOD and LOQ levels were implemented in this trial. Mean FLU 
protein binding was determined to be 98.6% in both treatment groups, which is slightly 
lower than values reported by Anderson, et al. (1990) and Odensvik, et al. (1995). This 
change, while small, may have a dramatic effect on PK of FLU. A change of 1% would 
approximately double the unbound FLU, making it more available to distribute out of the 
plasma and thus alter the volume of distribution and clearance.   
Regarding the CEF treatments, mean Cmax and Tmax values were approximately 
equal to healthy cows from our previous work and those reported on the package insert 
supplied with the product. Additionally, the mean CL/F was similar to our previous data. 
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However, the T1/2 determined here is much shorter than the previous work or the package 
insert. The current work also had a higher AUC and lower Varea and MRT than the previous 
work (Gorden et al., 2016; Zoetis, 2013a). These differences are potentially due to variation 
in animals used between our trials, differences in types of animals used in our trial and the 
manufacturer’s trials, and differences in assay sensitivity between our trials and those of 
the manufacturer. Protein binding of CEF in both treatments was determined to be 94.6%, 
which is similar to that reported by S. A. Brown et al. (1991). Ceftiofur sodium is reported 
to have nearly a 100% bioavailability (S. A. Brown et al., 1991) and the kinetics between 
ceftiofur sodium and ceftiofur hydrochloride are similar (Pharmacia and Upjohn, 1998). 
Therefore, bioavailability of ceftiofur hydrochloride should have little impact on the 
kinetics data provided here.   
Protein binding in blood of weak acids, such as FLU and CEF, is primarily 
associated with albumin (Riviere, 2009a). Although we did not see a difference in FLU 
and CEF pharmacokinetics in this trial, additional work is needed to further characterize 
drug distribution and protein binding in ill animals. Animals that experience an 
inflammatory process undergo hepatic down-regulation of albumin synthesis, which spares 
amino acids for acute phase protein synthesis (Ceciliani et al., 2012), thus reducing 
available plasma protein binding sites for drugs. In health, protein binding of a drug 
prevents movement across membranes and into ISF; however, during inflammation, 
plasma proteins exude into inflamed tissues, potentially causing an increase in the volume 
of distribution of highly protein bound drugs. The degree of affinity a drug has for a protein 
will dictate its biological function (Lees, 2009). Protein-bound CEF metabolites are not 
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biologically active but dissociate quickly to form active metabolites in the chemically 
reduced environments found in sites of inflammation, (Clarke et al., 1996).  
This trial employed three time per day milking schedule. According to the National 
Animal Health Monitoring System Dairy 2014 survey, 10.2% of herds that participated in 
the survey milked cows 3x/day. However, 56.8% of herds with 500 cows or greater used 
this practice (USDA, 2016a). Three times per day milking is utilized by herds as a 
mechanism to increase milk production per cow (Smith et al., 2002). Several studies have 
looked at drug clearance from milk following IMM infusion and determined that either 
increased frequency of removal of milk or increased production of milk per day, as a result 
of utilizing 3x versus 2x milking, are associated with increased clearance of the drug from 
the udder (Whittem, 1999; Knappstein et al., 2003; Stockler et al., 2009). The enhanced 
clearance would also be expected with drugs administered via the parenteral route as lipid 
solubility and dissociation constant (pKa) of the drug, which are responsible for allowing 
drugs to move into milk, are not impacted by milking frequency (Ziv and Sulman, 1975). 
Therefore, the process of establishing equilibrium of the non-ionized fraction of a drug 
between blood and milk will result in a higher clearance of drug following parenteral 
administration in cows milked 3 times per day.   
In conclusion, the results of this trial indicate that drug interactions between FLU 
and CEF do not occur when the two drugs are administered simultaneously in healthy 
cattle. Future work needs to look more closely at CEF movement into diseased tissues and 
the implications this may have on treatment efficacy and antimicrobial residues.  
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Figure 1. Semi-logarithmic transformations of mean plasma and interstitial fluid flunixin 
meglumine concentration (± 1 SE) for ten healthy cows following a single IV 
administration of flunixin compared to a single IV dose of flunixin and a single IM dose 
of ceftiofur administered simultaneously. Means within time points that differ (P < 0.05) 
are represented by the downward arrow. The x-axis represents the limit of detection for 
the assay. 
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Figure 2. Semi-logarithmic transformations of mean plasma and interstitial fluid 
ceftiofur equivalents concentration (± 1 SE) for ten healthy cows following a single IM 
administration of ceftiofur hydrochloride compared to a single IV dose of flunixin and a 
single IM dose of ceftiofur hydrochloride administered simultaneously. There were no 
significant differences found between any of the data points. The x-axis represents the 
limit of detection for the assay. 
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Table 1. Plasma pharmacokinetic parameters for flunixin meglumine for ten cows that 
received a single IV dose of flunixin meglumine only compared to a single IV dose of 
flunixin meglumine and a single IM dose of ceftiofur hydrochloride. Results are 
presented as arithmetic mean ± SE.1  
 
Parameter Flunixin only treatment Ceftiofur & flunixin treatment 34 (h-1) 0.18 ± 0.02 (0.17) 0.19 ± 0.02 (0.17) 
T1/2 34 (h) 4.49 ± 0.65 (4.14) 4.92 ± 1.44 (4.08) 
CO(µg/mL) 
22.62 ± 1.06 (22.40) 20.52 ± 2.22 (19.6) 
AUC0-tlast (h × µg/mL) 10.80 ± 0.74 (10.57) 10.32 ± 0.41 (10.25) 
AUC0-∞ (h × µg/mL) 
10.88 ± 0.74 (10.65) 10.39 ± 0.40 (10.32) 
Varea (mL/kg) 547.69 ± 36.28 (537.68) 560.26 ± 47.43 (542.83) 
CL (mL/h/kg) 217.10 ± 15.48 (212.54) 225.20 ± 13.23 (221.84) 
MRT (h) 2.58 ± 0.18 (2.53) 2.48 ± 0.15 (2.45) 
1Values in parentheses are the geometric mean. 
λz = slope of the terminal phase; T1/2	34 = terminal half-life; CO = the initial concentration 
immediately after drug administration calculated by back-extrapolating from the straight 
line model fit to the first two measured concentrations following IV administration; 
AUC0-tlast = area under the curve from T0 to the last detectable concentration; AUC0-∞ = 
area under the curve extrapolated to infinity using the equation IJKLMNO ; Varea = volume of 
distribution based on the terminal phase of the time-concentration curve; CL = clearance; 
and MRT = mean residence time.  
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Table 2. Plasma pharmacokinetic parameters for ceftiofur for ten cows that received a 
single IM dose of ceftiofur hydrochloride only compared to a single IV dose of flunixin 
meglumine and a single IM dose of ceftiofur hydrochloride. Results are presented as 
arithmetic mean ± SE.1 
 
Parameter Ceftiofur treatment only Ceftiofur & flunixin 
treatment 34 (h-1) 0.05 ± 0.003 (0.05) 0.05 ± 0.003 (0.05) 
T1/2 34 (h) 13.42 ± 0.72 (13.23) 13.96 ± 0.75 (13.78) 
Tmax (h) 4.0 ± 0.67 (3.52) 3.2 ± 0.44 (2.94) 
Cmax (µg/mL) 9.42 ± 0.62 (9.26) 10.46 ± 0.78 (10.24) 
AUC0-tlast (h × µg/mL) 129.90 ± 5.24 (129.0) 139.62 ± 6.62 (138.25) 
AUC0-∞ (h × µg/mL) 131.48 ± 5.28 (130.56) 141.54 ± 6.72 (140.15) 
Varea/F (mL/kg) 352.84 ± 28.97 (341.62) 332.91 ± 24.40 (324.86) 
CL/F (mL/h/kg) 18.14 ± 0.99 (17.90) 16.58 ± 0.96 (16.34) 
MRT (h) 14.03 ± 0.15 (14.03) 13.91 ± 0.41 (13.86) 
1Values in parentheses are the geometric mean. 
λz = terminal elimination rate constant; T1/2	34 = terminal half-life; Tmax = time of Cmax; 
Cmax = maximum plasma concentration; AUC0-tlast = area under the curve from T0 to the 
last detectable concentration; AUC0-∞ = area under the curve extrapolated to infinity 
using the equation IJKLMNO ; Varea/F = volume of distribution per fraction of the dose 
absorbed; CL/F = clearance per fraction of the dose absorbed; and MRT = mean 
residence time. 
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Abstract 
Ceftiofur (CEF) is a third-generation cephalosporin that is the most widely used 
antimicrobial in the dairy industry. Currently, violative meat residues in cull dairy cattle 
are commonly associated with CEF. One potential cause for violative residues is altered 
pharmacokinetics of the drug due to disease, which could increase the time needed for the 
residue to deplete. The objectives of this study were: 1) to determine the absolute 
bioavailability of CEF crystalline free acid (CFA) in healthy versus diseased cows; 2) to 
compare the plasma and interstitial fluid pharmacokinetics and plasma protein binding of 
CEF between healthy dairy cows and those with disease; and 3) to determine the CEF 
residue profile in tissues of diseased cows. For this trial, disease was induced through 
intramammary E. coli infusion. Following disease induction and CEF CFA administration, 
for plasma concentrations, there was not a significant effect of treatment (P=0.068) but the 
treatment by time interaction (P=0.005) was significant. There was a significantly greater 
concentration of CEF in the plasma of the DIS cows at T2 hours (P=0.002), T8 hours 
(P<0.001), T12 hours (P=0.001), and T16 hours (P=0.002). For PK parameters in plasma, 
the slope of the terminal phase of the concentration versus time curve was significantly 
lower (P=0.007), terminal half-life was significantly longer (P=0.014), and apparent 
volume of distribution during the elimination phase was significantly higher (P=0.028) in 
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the disease group. There was no difference in plasma protein binding of CEF and interstitial 
fluid pharmacokinetics. None of the cows had kidney CEF residues above the US tolerance 
level following observation of the drug’s withdrawal period but one cow with a larger 
apparent volume of distribution and longer terminal half-life had tissue residues slightly 
below the tolerance. While these findings do not support the hypothesis that severely ill 
cows need longer withdrawal times, alterations in the terminal half-life suggest that it is 
theoretically possible. 
Key words: ceftiofur crystalline free acid, pharmacokinetics, drug residues, dairy cattle 
 
Introduction 
Ceftiofur (CEF) is a third-generation cephalosporin antimicrobial that is the most 
widely used in the dairy industry due to its broad spectrum of activity and short withdrawal 
periods for milk and meat (Zwald et al., 2004; Swant et al., 2005; Schuler et al., 2017). 
Broad spectrum antimicrobials are important for both human and veterinary medicine, 
leading the World Health Organization to classify 3rd, 4th, and 5th generation cephalosporins 
amongst the highest priority critically important antimicrobials for the preservation of 
human health (WHO, 2017). Additionally, due to concerns about the development of 
antimicrobial resistance to cephalosporins in humans from use in farm animals, extra-label 
usage of CEF was restricted in major food animal species by the United States Food and 
Drug Administration (US FDA, 2012b).  
In CY2013 violative CEF residues became the most frequent residue found in cull 
dairy cattle at slaughter, surpassing penicillin. Since then, CEF has continued to be the 
most frequent violative residue in the tissues of cull dairy cattle United States Department 
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of Agriculture (USDA, 2017b). The reason for this increase in violative ceftiofur residues 
is likely multi-factorial, including changes to the USDA testing programs that have been 
implemented over the years (USDA, 2012b), producers unintentionally marketing cattle 
before the meat withdrawals have elapsed due to record keeping errors, producers 
intentionally marketing cattle before the meat withdrawals have elapsed to avoid losses 
from animal death, and potentially alterations in drug metabolism in ill animals compared 
to healthy counterparts. During the drug approval process, sponsoring companies must 
present the FDA’s Center for Veterinary Medicine (CVM) with toxicological and residue 
depletion studies. Based on these data, the FDA CVM establishes withdrawal periods for 
meat and milk, if approved for lactating dairy cattle. However, these studies are performed 
on healthy animals, not animals suffering from infectious diseases. Data examining drug 
metabolism in sick animals and how this compares with healthy animals are deficient in 
the veterinary literature. As most veterinary drugs are not intended for use in healthy 
animals, data on drug metabolism in diseased animals would provide veterinarians with 
evidence to more accurately prescribe veterinary drugs and to better predict residue 
depletion in these diseased animals.  
Previous research by the authors recently demonstrated that CEF pharmacokinetics 
(PK) are altered in dairy cows affected with naturally occurring mastitis compared to 
healthy cattle (Gorden et al., 2016). In that study, plasma terminal half-life (T1/2 34) of the 
diseased group was not statistically different from the control group; however, one of the 
cows in the diseased group had a T1/2 34 that was nearly twice as long as the mean of the 
control group (70.9 hours vs. 35.8 hours). In that study, animals were not sacrificed upon 
completion of the study, so tissue residue concentrations were not determined. However, 
90 
 
assuming tissue residue depletion follows plasma PK, this doubling of the T1/2 34 would 
indicate that it would take twice as long for the tissues to deplete to the tolerance as would 
be the case in healthy animals (Riviere et al., 1998). This would necessitate an extension 
of the withdrawal time by the prescribing veterinarian, even if the drug is used in an on-
label manner for dose, duration, and route of administration.  
In our previous study (Gorden et al., 2016), the apparent volume of distribution 
during the elimination phase (Vz/F) and apparent systemic clearance (CL/F) values for CEF 
were significantly elevated in diseased group. This alteration has also been reported in 
swine with porcine respiratory and reproductive virus (PRRSv) that were treated with CEF 
(Tantituvanont et al., 2009; Day et al., 2015; Sparks et al., 2017). In studies where drugs 
are not administered via intravenous injection, alterations in bioavailability (F) confound 
the interpretation of VZ and CL. None of the swine experiments or the previous study 
included an IV administration component to directly determine F of CEF, but Sparks et al. 
(2017) estimated a relative bioavailability of 0.8. When relative bioavailability was 
inputted into Vz/F and CL/F parameters for their study, the differences in these two 
parameters decreased between the control group and animals challenged with PRRSv 
(Sparks et al., 2017). Therefore, determination of CEF bioavailability will help determine 
the underlying cause for changes in Vz and CL.  
The objectives of this study were to: 1) complete an IV study using CEF sodium to 
later determine the absolute bioavailability of CEF administered as CEF crystalline free 
acid (CFA) sterile suspension via a subcutaneous route in healthy versus diseased animals; 
2) compare the plasma and interstitial fluid (ISF) concentrations; plasma protein binding; 
and plasma and ISF PK of CEF following administration as CEF CFA to healthy dairy 
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cows versus those with disease; and 3) determine the CEF residue profile in kidney, liver, 
muscle, and fat of diseased cows. In this trial, disease was induced via the administration 
of Escherichia coli via the intramammary (IMM) route. Specifically, we desired to induce 
the same degree of severity in the disease (DIS) group of animals to mimic the PK profiles 
of our previous study (Gorden et al., 2016). Our hypothesis was that administration of CEF 
would result in altered plasma and ISF concentrations, and altered PK in diseased animals 
compared to healthy animals, necessitating variance in dose regimens and/or withdrawal 
periods.  
 
Materials and Methods 
Experimental cattle 
This study was completed at the Iowa State University Dairy Farm. The lactating 
herd consists of approximately 400 animals (approximately 90% Holstein and 10% Jersey), 
with 365-day rolling herd averages per cow of 10,991 kg milk, 404 kg fat, and 342 kg 
protein. Twenty healthy Holstein cows were utilized in two separate segments to complete 
the objectives of the trial. Ten cows were assigned to the DIS group and ten cows of similar 
age and lactation status were assigned to the control group (CON). In the first segment, all 
20 cows received intravenous CEF as CEF sodium to obtain data to later calculate 
bioavailability of subcutaneously administered CEF as ceftiofur crystalline free acid (CEF 
CFA). Segment 2 consisted of the IMM challenge to determine CEF concentrations, PK, 
and residue depletion. Due to the availability of housing, each segment of the trial was 
done in two consecutive replicates. The trial was carried out as a 1-sequence, 2-treatment, 
2-period cross over design, as the cows that would later be challenged with mastitis were 
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to be sacrificed at the end. See Figure 1 for a diagram explaining the chronological flow of 
the trial. Cows were eligible for the trial if they had not been treated with systemic or IMM 
CEF within the past 20 days of the first segment and were healthy prior to enrollment. 
Furthermore, the cows were thirty or more days from their next scheduled dry period.  
During each treatment segment, cows were housed in individual box stalls bedded 
with deep, long-stem straw. Each stall had individual access to feed and water. Cows were 
milked three times daily (4 am, 12 pm, and 8 pm). During the treatment periods, trial 
personnel milked trial cows per the farm’s milking protocol. Between treatments, cows 
were housed in a free-stall barn bedded with recycled manure solids, which is standard 
practice for this dairy operation.  
Throughout the entire period of this trial, cows were fed a total mixed ration and 
watered, ad libitum. Ration parameters met or exceeded those recommended by the NRC 
guidelines (NRC, 2001). Cow housing and management met or exceeded the 
recommendations listed in the Guide for Care and Use of Agricultural Animals in Research 
and Teaching (FASS, 2010). Iowa State University’s Institutional Animal Use and Care 
Committee approved the research protocol prior to commencement of trial procedures 
(protocol number 6-15-8030-B).  
 
Experimental design – Segment 1 - Ceftiofur bioavailability 
One day prior to treatment, cows were weighed and moved to their box stall. One 
intravenous catheter was placed in each jugular vein of all cows to facilitate CEF 
administration and blood collection. Following restraint in a stanchion, cows were sedated 
with xylazine at approximately 0.025 mg/kg IV; the skin over the jugular furrow was 
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clipped and aseptically prepped using alternating scrubs of 2% chlorhexidine acetate and 
70% isopropyl alcohol. Prior to catheter placement, the area under the skin was infiltrated 
with 2% lidocaine. Following catheter placement, the catheter was sutured in place using 
#3 nylon suture. To maintain catheter patency, 3 mL of a heparin saline solution containing 
3 USP units of heparin sodium/mL was infused into the catheters every eight hours until 
treatments were initiated. Subsequently, catheters were flushed following each blood 
collection. 
On the day of treatment, cows were restrained in a stanchion, where cows received 
CEF as ceftiofur sodium (Naxcel Sterile Powder, Zoetis Inc., Kalamazoo, MI) at a dose of 
2.2 mg/kg via the IV route. Following CEF administration, 3 mL of a heparin saline 
solution was infused into the catheters to assure complete delivery of the drug. The catheter 
used for CEF administration was then removed.  
At T0 hour prior to CEF administration, two 10-mL blood samples were collected 
from the jugular catheter into blood tubes containing freeze-dried heparin (Becton, 
Dickinson and Co, Franklin Lakes, NJ) for plasma harvest. Subsequent blood samples were 
collected from the jugular catheter into heparinized tubes at 0.05, 0.10, 0.25, 0.5, 0.75, 1, 
2, 4, 6, 8, 16, 24, 32, 40, and 48 hours after drug administration. After blood was collected, 
samples were immediately placed on ice until plasma could be harvested. Within two hours 
of collection, blood samples were centrifuged for 20 minutes at 1000 g at 4 °C, then 5 mL 
of plasma was harvested and frozen at -70°C until analyzed for drug concentration.  
Following the 48 hour time point, IV catheters were removed and the cows were 
moved back to the free stall housing for the herd. The cows had a minimum of a ten-day 
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washout period between the two segments of this trial. Both replicates of this segment of 
the trial were completed prior to initiation of the second segment of the trial. 
 
Experimental design – Segment 2 – Pharmacokinetics and tissue residue depletion of 
CEF CFA in healthy versus diseased cows 
One day prior to treatment, cows were moved to box stalls and had one IV catheter 
inserted as described above. While sedated, all cows had one subcutaneous, in vivo 
ultrafiltration probe (RUF 3-12, BASi, West Lafayette, IN) placed dorsal-caudal to the 
scapula to facilitate ISF collection. Briefly, the area was prepped as described for inserting 
catheters above and the probe was placed by passing a 10-gauge metal introducer needle 
between two small stab incisions previously made with a #10 scalpel blade into the skin. 
Following probe placement, the collection tube was stitched in place and connected to a 7-
mL red top glass vacuum tube (Becton, Dickinson and Co, Franklin Lakes, NJ) for ISF 
collection.     
 
Intramammary Challenge 
To induce disease, cows in the DIS group were inoculated with 100-150 colony 
forming units (cfu) of E. coli (strain 487) via the streak canal of a selected mammary gland 
quarter. To prepare the challenge inoculum, an aliquot of frozen stock culture was streaked 
onto a trypticase soy agar plate and incubated overnight at 37 °C. The following day, two 
well isolated colonies were inoculated into trypticase soy broth and incubated overnight in 
a shaker incubator at 37 °C to achieve stationary growth phase. Two-mL aliquots of the 
broth culture were centrifuged in microcentrifuge tubes and the pellet was washed twice in 
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phosphate buffered saline (PBS) and then re-suspended in PBS to achieve an optical 
density of 0.35 at 495 nm. Seven 9:1 serial dilutions were then made in PBS and 0.1 mL 
was plated on trypticase soy agar and incubated overnight. The following day, cfu counts 
were enumerated. The process was then completed to acquire a challenge inoculum with a 
desired cfu count of 100-150 diluted in 5 mL of PBS. 
Approximately 12 hours prior to CEF administration (T -12 hours), all cows in the 
DIS group were inoculated with the challenge inoculum in either the right or left front 
quarter following aseptic preparation of the teat end. Simultaneously, cows in the CON 
group underwent a placebo challenge by infusing 5 mL of sterile PBS into the right or left 
front quarter following aseptic preparation of the teat end. The decision on whether to 
challenge the left or right front quarter was based on position of the dividing gate between 
stalls. Therefore, the challenged quarter was always opposite from the dividing gate.  
Following completion of the IMM challenge, 0.1 mL of challenge inoculum was 
plated onto trypticase soy agar and incubated overnight to determine E. coli challenge dose.   
    
Drug administration 
At time 0 (T0), all cows received CEF, as CEF CFA (Excede, Zoetis Inc., 
Kalamazoo, MI), at 6.6 mg CEF equivalents per kg of body weight administered at the 
base of either ear, following instructions on the package insert. As part of the trial design, 
rescue therapies (anti-inflammatories and fluid support) were included in the trial protocol 
if needed. No further medications were administered throughout the remainder of the trial.  
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Collection of blood and ISF samples 
Prior to CEF administration (T0), two 10-mL blood samples were collected from 
the jugular catheter into blood tubes containing freeze-dried heparin (Becton, Dickinson 
and Co, Franklin Lakes, NJ) for plasma harvest. Subsequent blood samples were collected 
from the jugular catheter into heparinized tubes at 2, 4, 8, 12, 16, 20, 24, 32, 40, and 48 
hours and then every 24 hours after drug administration through 312 hours After blood was 
collected, samples were processed as described above.  
Simultaneous with drug administration (T0), a new vacuum tube was attached to 
the ultrafiltration probe. Interstitial fluid samples were collected at 4, 8, 12, 16, 20, 24, 32, 
40, and 48 hours following drug administration and then every 24 hours through 312 hours, 
by changing the vacuum tube. The tubes were immediately frozen at -70 °C until analyzed 
for drug concentration. 
 
Daily observations and infrared thermography 
At every milking for the first five days following IMM challenge and then daily 
through the conclusion of the trial, cows were assigned a mastitis severity score as 
previously described by Wenz et al. (2001b). Additionally, rectal temperatures were 
recorded at T0 and then every 8 hours for the first 24 hours and then every 24 hours for the 
remainder of the trial.  
Infrared images of the eye on the side of CEF CFA injection, the ear where the CEF 
CFA injection was placed, and quarter of the mammary gland that was challenged were 
obtained using a research quality infrared camera (FLIR SC 660, FLIR Systems, AB, 
Danderyd, Sweden). Images were obtained prior to IMM challenge (T -12 hours), at T0 
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prior to CEF CFA injection, at 8, 16, and 24 hours following injection, and then every 24 
hours through T168 hours. At each measurement period, three images each (nine total) 
were collected from the eye, ear, and mammary gland, respectively. Images of the eye and 
ear were obtained by holding the camera at approximately a 45° angle and 0.5 meters from 
the head. Mammary gland images were collected by placing the camera in a parallel plane 
lateral to the challenged quarter, approximately 0.5 meters from the gland. Camera 
calibration was done prior to each measurement period by entering current ambient 
temperature and relative humidity into the camera’s software. Throughout each 
measurement period, the camera collected changes to ambient temperature and relative 
humidity and recalibrated automatically. 
Analysis of infrared images was completed using research grade software provided 
by the camera manufacturer (FLIR ExaminIR, North Billerica, MA). For each 
measurement period, the maximum, minimum, and mean temperature was recorded for 
each image and a mean value for each the parameters (maximum, minimum, and mean) 
was determined from the three images for the eye, ear, and mammary gland, respectively.  
  
Trial conclusion  
At T312 hours, all DIS cows were humanely euthanized with a captive bolt 
followed by exsanguination. Following euthanasia, kidney, liver, skeletal muscle, fat, and 
injection site tissues were collected, weighed, and frozen at -70 °C until analyzed for drug 
concentration. 
Cows in the CON group were returned to the herd following catheter and 
subcutaneous ultrafiltration probe removal.  
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Determination of plasma protein binding 
Bound plasma drug concentration of CEF was determined on each cow on the T24, 
T96, and T192 hours plasma samples using a microcentrifugation system (Centrifree 
Ultrafiltration Device, EMD Millipore Corp., Billerica, MA) to collect plasma ultrafiltrate 
(UF), as previously described (Gorden et al., 2017). Following collection of plasma UF, 
samples were immediately frozen at -70 °C until analyzed for drug concentration. 
 
Plasma, interstitial fluid, and plasma ultrafiltrate ceftiofur concentration analysis 
Ceftiofur and its metabolites from plasma were converted to a stable derivative, 
desfuroylceftiofur acetamide (DCA) and total CEF concentration (as DCA) was then 
determined using liquid chromatography coupled with mass spectrometry (LC-MS) as 
previously described (Gorden et al., 2016). Plasma UF and ISF samples were analyzed for 
free drug concentration in the same manner, except spike and quality control (QC) samples 
were prepared using blank ISF for ISF sample analysis. The limit of detection (LOD) of 
the assay was 1 ng/mL, and the limit of quantification (LOQ) was 10 ng/mL. The accuracy 
and coefficient of variation for the quality control (QC) samples were 98% and 9.4% for 
the 15 ng/mL QC sample; 105% and 8.7% for the 150 ng/mL QC sample; and 107% and 
10.6% for the 1,500 ng/mL QC sample.  
 
Screening of kidney samples – Kidney Inhibition Swab (KIS™) test 
At tissue harvest, a section of kidney from each cow was bagged and frozen 
separately. After at least 24 hours of freezer storage, all ten samples were thawed at 4 °C 
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and tested for inhibitory residues using the Kidney Inhibition Swab (KIS™) test (Charm 
Sciences Inc., Lawrence, MA) as described (USDA, 2010). Additionally, kidney tissue 
from a negative control animal was also thawed and tested. Briefly, the cap portion of the 
swab was used to cut a circular incision into the kidney parenchyma approximately 1-2 cm 
in depth. The swab was then placed into the incised area and rotated for approximately 30 
seconds to saturate the swab with kidney fluid. This procedure was repeated on up to four 
swabs in total at one time. The swab was then pierced through the foil and into the clear 
liquid in the bottom vial of the test, but not perforating the bottom seal. After two minutes, 
the swab was completed screwed down to pierce the bottom seal and to the point where it 
was just above the agar in the bottom of the vial. The tube was then tapped firmly five 
times on the countertop, after which the swab was rotated in the opposite direction and 
tapped five times again on the countertop. Up to four swabs were then placed into the 
heating block provided with the test kit and incubated at 64 °C for three hours. Following 
incubation, the agar color was compared to the reference card provided by the manufacturer 
to determine the test result.     
 
Ceftiofur concentration analysis-tissue samples 
Determination of ceftiofur concentrations in kidney tissues was completed using an 
official method as described by the USDA (2016c), with minor alterations to the protocol. 
The method determines the concentration desfuroylceftiofur cysteine disulfide (DCCD) as 
a proxy for the marker compound for ceftiofur, desfuroylceftiofur (DFC). Briefly, 0.4 g 
aliquots of blank bovine kidney for blank, spike, fortified analyst recovery, and QC 
samples; in addition to 0.4 g aliquots of test kidney samples, were weighed into 15-mL 
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conical bottom, polypropylene tubes. Known concentration of DCCD were added to spike 
kidney samples to create a calibration curve from 50 – 2000 ng/g. 5000 ng of internal 
standard, DCCD-d3, was then added to all spike, QC, blank, and test samples but not the 
fortified recovery analyst tube. All tubes were treated with 3.5 mL of 1% phosphate buffer 
and shaken on an automated shaker for ten minutes at 1000 rpm. Following shaking, all 
tubes were centrifuged at ~4000 rpm for 20 minutes at room temperature. Solid phase 
extraction (SPE) cartridges (Strata-X SPE cartridges (60 mg/3 mL), Phenomenex, 
Torrance, CA, USA) were conditioned with 2 mL of methanol, followed by 2x2 mL 
fractions of ultrapure water. The supernatant following centrifugation was then loaded onto 
the SPE cartridges and allowed to percolate via gravity. After all the supernatant had 
percolated through the SPE cartridges, they were washed with 2 mL ultrapure water. Target 
analytes were eluted with 2x1 mL fractions of 50% acetonitrile/ultrapure water (v/v). 
Following elution, the fortified analyst recovery tube was spiked with sufficient DCCD to 
create a concentration of 400 ng/g and 5000 ng of the internal standard, DCCD-d3. The 
acetonitrile was then evaporated from the samples under a stream of nitrogen at 15 psi and 
48 °C to a volume of <1 mL. Ultrapure water was added to each sample to bring the total 
volume to approximately 1 mL and then all samples were vortexed. 150 µl of sample was 
transferred to labelled auto-sampler vials equipped with glass inserts for analysis by LC-
MS. Auto-sampler vials were centrifuged for 20 minutes at 1000 g at room temperature 
and then loaded onto the auto-sampler tray.  
The LC-MS system consisted of an Agilent 1100 pump, auto-sampler, and column 
compartment (Agilent Technologies, Santa Clara, CA) coupled to an ion trap mass 
spectrometer (LTQ, Thermo Scientific, San Jose, CA). The injection volume was set to 25 
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µL. The mobile phases consisted of A) 0.1% formic acid in water and B) 0.1% formic acid 
in acetonitrile at a flow rate of 0.25 mL/min. The mobile phase began at 5% B with a linear 
gradient to 95% B at 6.5 minutes, which was maintained for 1.75 minutes, followed by re-
equilibration to 5% B. Separation was achieved with an ACE C18 column (ACE 3 C18, 
150 mm × 2.1 mm, 3 µm particles, Mac-Mod Analytical, Chadds Ford, PA, USA) 
maintained at 40 °C. DCCD was eluted at 3.63 minutes and the internal standard, DCCd-
d3, eluted at 3.61 minutes.  
Sequences consisting of plasma blanks, calibration spikes, quality control samples, 
fortified analyst recovery, and bovine kidney samples were then batch-processed with an 
automated processing method developed in the Xcalibur software (Thermo Scientific, San 
Jose, CA, USA), which identified and integrated each sample peak. The calibration curve 
was calculated based on a weighted (1/X), linear fit. Tissue concentrations of DCCD in 
trial samples were calculated based on this calibration curve. Results were then viewed in 
the Quan Browser portion of the Xcalibur software. The standard curve had a linear range 
from 50 to 2000 ng/g, with a correlation coefficient of 0.993. All standards were within +/- 
15 % of the nominal value in this range with the exception of the lowest (50 ng/g) standard, 
which was within + 20% of the nominal value. The accuracies for the QC samples were 
91% for the 75 ng/g QC, 106% for the 750 ng/g QC, and 110% for the 1,500 ng/g QC. The 
accuracy of the fortified analyst recovery sample was 94%. The limit of detection and the 
limit of quantification for this assay was 50 ng/g. 
In the US, the official marker residue for CEF in the bovine is DFC, measured as 
DCA. In the bovine, the current US tolerance is 0.4 parts per million (400 ng/g), with 
kidney serving as the marker residue. The method described above has been published as 
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an alternate method to determining DCA in tissues, in which DCCD is measured as a 
surrogate marker residue for DFC (Feng et al., 2014). In order to convert measured DCCD 
concentrations to DFC, the following regression equation was utilized: P	 = 0.21557	 + 1.801	×	V 
where P = the DFC concentration being calculated and V = the DCCD determined 
concentration (Feng et al., 2014). 
After results from determination of DCCD in kidney tissues were evaluated, other 
tissue samples were not analyzed.  
 
Pharmacokinetic analysis 
The total plasma drug and ISF concentration-time profiles from CEF CFA treated 
cows were analyzed using non-compartmental methods implemented in a commercially 
available software program (Phoenix® Win-Nonlin® 7.0, Certara, Inc. Princeton, NJ) to 
generate the following PK parameters: λz (h-1), slope of the terminal phase; T1/2λz (h), 
terminal half-life; Cmax (µg/mL), maximum plasma concentration; Tmax (h), time of Cmax; 
AUC0-∞ (µg/mL x h), area under the curve extrapolated to infinity using the equation 
IJKLMNO ; 
AUC0-24hr (µg/mL x h), area under the curve from T0 to T24 hours; Vz/F (mL/kg), apparent 
volume of distribution during the elimination phase; and CL/F (mL/h/kg), apparent 
systemic clearance; and MRT0-∞ (h), mean residence time extrapolated to infinity using the 
equation IJKLMNO . AUC and MRT were extrapolated to infinity to account for the total exposure 
to the drug.  
Determining the absolute bioavailability for extended release drugs like CEF CFA 
is often complicated due to flip-flop kinetics as clearance can be affected by the rate of 
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absorption. To determine if there was a difference in CL when CEF CFA was administered, 
the absorption rate constant (ka) was determined first determining the mean absorption time 
(MAT) using the equation: MAT = MRT SQ − 	MRT(IV) 
where MRT SQ  = the mean residence time via the subcutaneous route and MRT IV  = 
the mean residence time via the intravenous route. The ka for each treatment group was 
then determined using the equation:  
Absorption	rate	constant	(ka) = 1MAT 
  To determine the apparent bioavailability (F) in cows treated with CEF CFA, the 
AUC0-∞ was determined from plasma samples collected following IV ceftiofur sodium 
administration. Bioavailability was then determined and corrected for differences in CL 
between the two routes of administration using the equation:  
F(%) = 100 ∗	AUC SQ ∗ D IV ∗ CL(SQ)AUC IV ∗ D SQ ∗ CL(IV)  
where AUC(SQ) = AUC0-∞ determined for CEF CFA via the subcutaneous route; D(IV) = 
dose of ceftiofur sodium administered via the IV route; CL(SQ) = clearance following 
subcutaneous administration; AUC(IV) = AUC0-∞ determined for ceftiofur sodium via the 
IV route; D(SQ) = dose of CEF CFA administered via the subcutaneous route; and CL(IV) 
= clearance following IV administration. 
 
Data analysis 
Statistical analysis was performed using a commercially available software program (SAS 
9.4, SAS Institute, Cary, NC). All data are expressed as arithmetic mean ± SE and 
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geometric mean. Comparison of variables between treatment groups that were single 
observations (e.g., enrollment variables and PK parameters) were made using a paired t-
test unless the values were not normally distributed (ISF Cmax and AUC0-∞). For these 
parameters, means were compared using the Wilcoxon two-sample rank-sum test. Drug 
concentrations in plasma and ISF, protein binding, rectal temperatures, and IRT values for 
the DIS and CON groups were analyzed via the GLIMMIX procedure using repeated 
measures, with the animal being the subject of repeated measures. Fixed effects were 
treatment (DIS or CON), time, and the interaction between treatment and time. Replicate 
was included as a random effect. Statistical significance was established when P < 0.05. 
 
Results 
At enrollment, there was no statistical difference for any of the animal enrollment 
variables between the treatment groups. Between the first and second segments of this trial, 
two CON cows were removed due to illness that was treated with systemic CEF therapy. 
Therefore, only the eight remaining cows were used in the calculation of F of CEF CFA in 
the CON group. The two animals were replaced for the completion of the second segment 
of the trial, therefore all other parameters have 10 animals per treatment. 
Following IMM challenge, E. coli concentration in the challenge inoculum was 
determined to be 105 cfu for replicate 1 and 184 cfu for replicate 2. Following challenge, 
all cows in the DIS group developed clinical mastitis within 12 hours (by T0 hour). As a 
result, four of ten cows developed clinical mastitis classified as moderate and the remaining 
were classified as severe. However, none of the cows developed clinical signs necessitating 
rescue therapy.  
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No cow had detectable CEF in plasma or ISF at the beginning of either segment 
(time 0). Following IV administration of CEF sodium, all cows had measurable CEF in 
their plasma throughout the 48-hour monitoring period (data not shown). Plasma and ISF 
concentrations of CEF for cows in segment 2 are displayed in Figure 2. Following CEF 
CFA administration, CEF was detected in all subsequent plasma samples throughout the 
entire study period. For plasma concentrations, there was not a significant effect of 
treatment (P=0.068) but the treatment by time interaction (P=0.005) was significant. There 
was a significantly greater concentration of CEF in the plasma of the DIS cows at T2 hours 
(P=0.002), T8 hours (P<0.001), T12 hours (P=0.001), and T16 hours (P=0.002). There 
were no other time points that were significantly different between the two groups for the 
remainder of the trial.  
For the ISF samples, only eight cows had quantifiable CEF concentrations in their 
ISF four hours after therapy, but by eight hours, all cows with functional ultrafiltration 
probes had quantifiable CEF concentrations in their ISF. One cow had a malfunctioning 
ultrafiltration probe for the first 16 hours after CEF CFA administration. Two cows did not 
have quantifiable CEF in ISF past 48 hours and seven cows had quantifiable CEF through 
192 hours. There was a significant effect for time (P<0.001) but treatment and the treatment 
by time interaction were not significant. 
Mean protein binding (± 1 SE) of CEF at T24 hours was 91.1% ± 0.93 for the CON 
group and 93.0% ± 0.93 for the DIS group. At T96 hours, mean protein binding was 92.5% 
± 0.93 and 90.6% ± 0.93 for the CON and DIS groups, respectively; while at T192 hours, 
the bound fraction was 93.8% ± 1.3 and 94.3% ± 1.03, respectively.  There were no 
significant differences in protein binding between any of the groups.    
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Plasma pharmacokinetic parameters are shown in Table 1. Between the two groups, 
λz was significantly lower (P=0.007), T1/2 λz was significantly longer (P=0.014), and Vz/F 
was significantly higher (P=0.028) in the DIS group. The mean (and range) value for T1/2 
λz was 58.52 (44.82-80.37) hours for the DIS group and 45.87 (39.05-58.01) hours for the 
CON group. For Vz/F, the mean (and range) of value for the CON group was 1.745 (1.230-
2.146) L/kg while the DIS group was 2.135 (1.574-2.910) L/kg.  
Comparisons of λz following IV administration to calculated ka are presented in 
Table 2. The ka /λz ratio was 0.16 for the CON group and 0.25 for the DIS group, indicating 
the CEF CL following subcutaneous CEF CFA administration was much lower than 
following IV administration. Additionally, the mean difference between the ka/λz ratios was 
significant (P=0.003), indicating CL in the DIS group was impacted by disease. The mean 
apparent bioavailability was significantly lower in the DIS group (P<0.001). The mean 
apparent bioavailability in the DIS group was 98.75% while the mean in the CON group 
was 110%.  
There were no other statistically significant differences between any of the PK 
parameters. 
Interstitial fluid PK parameters are displayed in Table 3. There were insufficient 
samples from three cows (2 CON and 1 DIS) to determine all the PK variables, so their 
data was excluded. There were no statistically significant differences between any of the 
ISF PK parameters between the two groups.  
All kidney KIS tests were negative. Kidney DCCD concentrations in are presented 
in Table 4. Only two cows had DCCD concentrations in kidney tissue above the LOQ for 
the assay. When converted to DFC, both cows had concentrations below the US tolerance 
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for CEF in bovine kidney tissues. As none of the kidney tissues had violative kidney 
residues, the remaining tissues were not analyzed.  
There was no effect of treatment or time by treatment interaction on rectal 
temperature; however, time had a significant effect (P<0.001). Specifically, T0 hour 
(P<0.001) and T8 hours (P= 0.031) were significantly elevated, while T288 (P=0.004) and 
T312 hours (P<0.001) were lower than the mean temperature. Thermography was 
evaluated at the base of the ear at the injection site, on the ipsilateral eye, and on the 
challenged quarter of mammary gland. For ear images, there were no significant treatment, 
time, or treatment by time interactions between the two groups, except the time variable 
for maximum (P=0.016) and minimum (P=0.012) temperature. For eye images, the time 
variable for maximum, minimum, and average temperatures were significant (P<0.001). 
There was no effect for treatment or the interaction of treatment by time for eye images. 
There were also significant time differences for maximum (P=0.033), minimum (P<0.001), 
and average (P=0.009) mammary gland temperatures, but not treatment or treatment by 
time interaction.  
 
Discussion 
 
In this trial, no cow required rescue therapy as a consequence of their illness. 
Compared to previous work (Gorden et al., 2016), the cows in the current trial did not get 
as clinically ill and the duration of illness was shorter. Additionally, all cows continued 
lactating as compared to the previous work where five of eight cows developed agalactia 
as a result of their illness. 
Plasma Cmax concentrations of CEF following administration of CEF CFA were 
approximately equal to those published for dairy cattle in the package insert and lower than 
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those for beef cattle from the package insert (Zoetis Inc., 2013b). Cmax values were also 
lower for a beef cattle study published by others (Washburn et al., 2005). Time to maximum 
concentration was approximately four hours shorter in this work compared to the package 
insert, the AUC0-∞ was slightly lower in this work, and the T1/2 in the CON group was 
approximately equal to the package insert (Zoetis Inc., 2013b).   
Initially, the cows in the DIS group had a numerically higher CEF plasma 
concentration, which persisted through 40 hours post-treatment. This phenomenon was 
also present in our previous work for approximately ten hours after the first dose of CEF 
hydrochloride (Gorden et al., 2016). While Cmax in this trial was not determined to be 
significantly higher in the DIS group, there was a tendency for a higher Cmax (P=0.081). It 
is plausible that the febrile response associated with the clinical mastitis in the DIS group 
could have resulted in more blood flow to the injection site as previously described by 
Groothuis et al. (1978, 1980), resulting in numerically higher plasma drug concentrations 
early in the course of disease.  
Additionally, the cows in this trial had saw tooth-like DCA plasma concentrations 
that continued until approximately 32 hours after treatment. This was also noted in the 
previous work on individual cows, but was not apparent on the mean concentration graph 
(Gorden et al, 2016). Desfuroylceftiofur is reported to have a lower initial volume of 
distribution than CEF (Whittem et al., 1995), which will likely account for the up and down 
pattern of plasma concentrations as CEF is absorbed from the injection site. Additionally, 
altered hepatic metabolism of parent CEF to the DFC metabolite in the DIS group could 
have contributed in differences in plasma concentration over time between groups. In 
segment 1 of this trial, plasma DCA concentrations following IV administration of CEF 
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increased from T0.05 to T0.5 hours (data not shown). This phenomenon has previously 
been described and is apparently the result the lower initial volume of distribution of DFC 
compared to its parent compound (Whittem et al., 1995).  
Data from the IV CEF study was used to calculate the absolute bioavailability of 
CEF administered as CEF CFA. In both groups, F was determined to be approximately 
160%, which is a reason for concern as bioavailability values >100% are theoretically 
implausible in cases of linear clearance (Toutain and Bousquet-Mélou, 2004). There are 
three potential issues at hand that could contribute to this phenomenon. First, this trial was 
conducted as a 1-sequence, 2-treatment, 2-period crossover design, as compared to the 
recommended 2-sequence crossover approach when completing bioavailability trials. This 
potentially introduces the risk of having a period effect and/or a carry-over effect from the 
first period to the second on the exposure estimates. Another consideration is that the 
extrapolated portion of AUC0-∞, from the last plasma measurement to infinity could make 
up a large portion of the estimated AUC value. However, in this trial, the extrapolated 
portion was <2.5% for all AUC0-∞ determinations. The third, and likely explanation for the 
elevated bioavailability value is due to changes in CL associated with extravascular 
administration. Following administration of a drug exhibiting flip-flop kinetics, values for 
λz for the IV route and ka (termed ka,fl in the remainder of the manuscript) should be 
approximately equal if CL is unaffected. However, in this trial the value for ka,fl was 16% 
and 25% of the value for λz in the CON and DIS groups, respectively. As ka,fl is substantially 
lower, the CL following subcutaneous administration of CEF CFA is lower than the CL 
following IV administration. This results in increased exposure of drug following the 
subcutaneous administration and an elevated AUC(SQ), which resulted in a bioavailability 
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value that was much greater than 100%. Insertion of IV and subcutaneous CL values into 
the bioavailability equation corrected for the lower subcutaneous CL, resulting in an 
apparent bioavailability value closer to 100% for both treatment groups. Interestingly 
enough, in an equine trial using a parallel design versus IV CEF sodium, the absolute 
bioavailability of CEF CFA has been reported to be 100%, with a 90% confidence interval 
ranging from 92.4 to 109% (Collard et al. 2011), supporting our findings in dairy cattle. 
Maximum CEF concentrations in ISF were lower and time to reach maximum 
concentration was longer in the current trial compared to previous work (Gorden et al., 
2017). In addition, CEF was detected in ISF for approximately 120 hours in the current 
study compared to 60 hours in the previous work. Given that CEF CFA exhibits flip-flop 
kinetics, this is not surprising. Foster et al. (2015) have also reported ISF PK parameters 
using similar tissue probes utilized in the current study. In their work, they reported higher 
ISF CEF Cmax, a more rapid Tmax, but nearly identical AUC compared to the current work 
in a study utilizing healthy six-month old Holstein steers administered CEF sodium at 2.2 
mg/kg. These Cmax and Tmax values were similar to the previous work, where ISF CEF 
concentration following CEF hydrochloride administration was determined (Gorden et al., 
2017). Again, differences in kinetics of absorption likely account for these differences. 
Washburn et al. (2005) also reported lower Cmax and a longer Tmax using fluid collected 
from uninfected tissue cages following CEF CFA administration in trials using feedlot 
animals, compared to earlier work by the same research group when CEF sodium was 
administered via the IV route (Clarke et al., 1996). However, the Cmax and AUC values 
reported by Washburn et al. (2005) are significantly higher than those reported in our 
current work or that reported by Foster et al. (2015). Washburn et al. (2005) also observed 
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even higher CEF Cmax and AUC values in tissue cages infected with Mannheimia 
haemolytica compared to uninfected cages. Tissue cage data should be interpreted 
carefully, as these create an artificial fluid filled space that allows protein to escape the 
vasculature and enter the tissue cage (Davis et al., 2005). As CEF is reported to be 50-90% 
protein bound (S. A. Brown et al., 1991), a major portion of the drug represented in the 
Washburn et al. (2005) would be protein bound and not biologically active. Clarke et al. 
(1996) state that bound fractions of CEF will dissociate quickly in chemically reduced 
environments found in areas of inflammation. However, it would seem prudent to utilize 
tissue probe data to interpret biological function of CEF in ISF.  
The fact that none of the kidney inhibition swab (KIS™) tests were positive on the 
DIS animals is not surprising given the fact that all the kidney tissues were below the 
tolerance. Additionally, the reported sensitivity of this assay is 4 ppm, which is 10-fold 
higher than the tolerance for CEF (Jones et al., 2014), making it a questionable choice for 
screening cull dairy cattle for CEF residues. This is thought-provoking since cull dairy 
cows have the highest incidence of violative residues amongst adult cattle classes (USDA, 
2017b) and CEF is the most commonly used antimicrobial in the US dairy industry (Zwald 
et al., 2004; Swant et al., 2005; Schuler et al., 2017). Taken together, it is highly likely that 
animals with violative residues for CEF are not being submitted for confirmatory testing 
due to the limited sensitivity of this screening test for CEF. 
During the drug approval process, sponsoring companies must present the FDA 
CVM with toxicological and residue depletion studies. Based on these data, the FDA CVM 
establishes withdrawal periods for meat and milk, if approved for lactating dairy cattle. 
However, these studies are performed on healthy animals, not animals suffering from 
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infectious diseases. In this study, we were able to determine CEF residue levels in kidney 
tissues following CEF CFA treatment in animals that experienced induced coliform clinical 
mastitis. Of the ten animals that were challenged, only two had kidney residues for DCCD 
above the LOQ for the assay. In order to convert measured DCCD concentrations to DFC, 
a regression equation was utilized (Feng et al., 2014). As a result, one cow was determined 
to have a DFC residue level of 0.32 µg/g (cow #9389) and another of 0.38 µg/g (cow 
#9206). These are both are below the established tolerance for DFC in kidney tissue of 0.4 
µg/g (US FDA, 2006a). When looking at the individual PK parameters for cow #9206, her 
plasma CEF T1/2 34 (80.3 hours) was the highest of all the DIS cows. This is nearly two 
times as long as the CON average. Additionally, this cow was the one who suffered the 
most severe clinical disease based on clinical appearance, rectal temperature, and daily 
feed refusal. In the previous work (Gorden et al., 2016), a much wider range for Vz, CL, 
and subsequently T1/2 34 was observed. If tissue residue depletion follows plasma PK, this 
doubling of the T1/2 34 would indicate that it would take twice as long for the tissues to 
deplete to the tolerance as would be the case in healthy animals (Riviere et al., 1998). In 
order to account for variation in tissue depletion amongst animals, the FDA utilizes a 
process based on the statistical tolerance limit procedure (De Gryze et al., 2007). In 
applying this procedure to the determination of withdrawal periods for a drug, FDA selects 
the 99th percentile tolerance limit with a 95% confidence. This should mean that 99% or 
more of tissue samples are at or below the tissue tolerance in the target tissue when the 
withdrawal period has elapsed (US FDA, 2006b).  
The primary weakness of this trial was not creating the level of illness in DIS group 
animals as was seen in the previous trial (Gorden et al., 2016). In that trial, five of eight 
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trial cows developed severe disease and agalactia, despite aggressive supportive therapy. 
In this work, no cows required rescue therapy. Additionally, the attempts to objectively 
characterize febrile responses using rectal temperature and IRT measurements to separate 
out treatment effects between the DIS and CON animals proved to be unsuccessful. In both 
replicates of segment 2, high ambient temperatures during the first 48 hours of each 
challenge period likely confounded our ability to assess differences in rectal and IRT 
temperatures. Future research should focus on identifying clinical parameters that are 
associated with altered PK parameters, which would allow producers to implement longer 
withdrawal periods in order to minimize risk of marketing an animal with a violative 
residue.   
In conclusion, the results of this trial support previous work that cows suffering 
clinical disease associated with mastitis may have altered CEF volume of distribution and 
terminal half-life. It did not however support the hypothesis that severely ill cows need 
longer withdrawal times following CEF therapy. However, substantially larger Vz/F and 
longer T1/2 34 on some cows suggest that this may be possible in a clinical disease in a large 
population. Future work needs to identify parameters in cattle that should be monitored in 
order to implement longer withdrawal periods on cows potentially at risk for maintaining 
violative residues past their withdrawal period.   
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Figure 1. Flow diagram showing the chronological flow of the segments. Boxes in the 
same row occurred at the same time.  
10 healthy cows -
Control (CON) group
Segment 1- Replicate 1                       
5 cows - IV CEF sodium
Segment 1- Replicate 2                
5 cows - IV CEF sodium
Minimum 10-day washout period
Segment 2 - Replicate 1              
5 cows - Placebo (saline)           
SQ CEF CFA
Replicate 1 complete
Cows returned to herd
Segment 2 - Replicate 2                       
5 cows - Placebo (saline)                   
SQ CEF CFA
Replicate 2 complete
Cows returned to herd
10 healthy cows -
Disease (DIS) group
Segment 1- Replicate 1                       
5 cows - IV CEF sodium
Segment 1- Replicate 2                
5 cows - IV CEF sodium
Minimum 10-day washout period
Segment 2 - Replicate 1               
5 cows - Induce mastitis            
SQ CEF CFA
Replicate 1 complete
Cows sacrificed
Segment 2 - Replicate 2                       
5 cows - Induce mastitis                   
SQ CEF CFA
Replicate 2 complete
Cows sacrificed
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Figure 2. Semi-logarithmic transformations of mean plasma and interstitial fluid 
ceftiofur equivalent concentrations (± SD) for ten healthy cows (CON) versus ten cows 
with induced coliform mastitis (DIS) following a single subcutaneous administration of 
ceftiofur crystalline free acid. The concentration at which the x-axis intersects the y-axis 
represents the level of quantification for the analytical assay. The insert represents the 
same data, except only for plasma during the first 72 hours. The arrows indicate the time 
points where there are significant differences between the mean plasma concentrations.  
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Table 1. Plasma pharmacokinetic parameters for ceftiofur for ten cows with induced 
coliform mastitis (DIS) compared to ten healthy cows (CON) following a single 
subcutaneous injection of 6.6 mg/kg of ceftiofur crystalline free acid at the base of the 
ear. Results are presented as arithmetic mean ± SE.1 
 
Parameter Disease (DIS) Control (CON) 34 (h-1) 0.012 ± 0.0007 (0.012)  0.015 ± 0.0006 (0.015)**  
T1/2 34 (h)	 58.52 ± 4.0 (57.35) 45.87 ± 2.08 (45.47)**  
Cmax (µg/mL) 4.74 ± 0.58 (4.43)  3.47 ± 0.35 (3.33)* 
Tmax (h) 15.0 ± 2.62 (12.4) 15.4 ± 2.39 (12.8) 
AUC0-24 (µg/mL x h) 78.01 ± 9.0 (73.29) 57.82 ± 5.66 (55.44)* 
AUC0-∞ (µg/mL x h) 263.3 ± 13.3 (260.1) 253.03 ± 11.91(251.2) 
Vz/F (L/kg) 2.135 ± 0.134 (2.098) 1.745 ± 0.090 (1.723)** 
CL/F (mL/h/kg) 25.69 ± 1.42 (25.36) 26.45 ± 1.03 (26.27) 
MRT0-∞  (h) 66.87 ± 4.23 (65.68) 72.14 ± 4.57 (70.87) 
F (%) 98.8 ± 0.25 (98.8) 110.0 ± 0.03 (110.0)** 
1Values in parentheses are the geometric mean. 
**Means within the columns differ (P < 0.05). 
*Means within the columns differ (P < 0.10). 
λz (1/h), slope of the terminal phase; T1/2 λz (h), terminal half-life; Cmax (µg/mL), 
maximum plasma concentration; Tmax (h), time of Cmax; AUC0-24hr (µg/mL x h), area 
under the curve from T0 to T24 hours; AUC0-∞ (µg/mL x h), area under the curve 
extrapolated to infinity using the equation IJKLMNO ; Vz/F (mL/kg), volume of distribution per 
fraction of the dose absorbed; and CL/F (mL/h/kg), clearance per fraction of the dose 
absorbed; MRT0-∞ (h), mean residence time extrapolated to infinity using the equation IJKLMNO ; and F, apparent bioavailability. 
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Table 2. Comparison of the elimination rate constant (λz) of CEF determined via the 
intravenous route and the absorption rate constant (ka) of CE determined following 
administration of CEF CFA via the subcutaneous route.  
 
Cow Elimination rate 
constant (λz) 
Absorption rate 
constant (ka) 
Ratio  
ka/λz 
Control group (CON) 
9156 0.085 0.019 0.22 
9244 0.055 0.015 0.27 
9325 0.113 0.015 0.14 
9353 0.114 0.016 0.14 
9480 0.110 0.014 0.12 
9657 0.110 0.013 0.12 
9725 0.109 0.011 0.10 
9760 0.130 0.017 0.13 
Mean (CON) 0.100 0.015 0.16** 
Disease group (DIS) 
8972 0.081 0.018 0.22 
9146 0.089 0.017 0.19 
 9206 0.045 0.018 0.39 
 9233 0.067 0.020 0.30 
 9389 0.082 0.020 0.24 
 9456 0.056 0.013 0.23 
 9709 0.103 0.027 0.26 
 9728 0.062 0.016 0.27 
 9776 0.077 0.018 0.24 
 9779 0.065 0.012 0.18 
Mean (DIS) 0.070 0.018 0.25** 
**Means within the columns differ (P < 0.05). 
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Table 3. Comparative interstitial fluid pharmacokinetic parameters (arithmetic ± SE1) for 
ceftiofur in DIS and CON cows (n=10) following a single injection of 6.6 mg/kg of 
ceftiofur crystalline free acid.  
 
Parameter Disease (DIS) Control (CON) 34 (h-1) 0.018 ± 0.0012 (0.018)  0.020 ± 0.0012 (0.020)  
T1/2 34 (h) 39.75 ± 3.03 (39.02) 35.06 ± 2.16 (34.54)  
Cmax (µg/mL) 0.24 ± 0.047 (0.21)  0.24 ± 0.015 (0.24) 
Tmax (h) 33.2 ± 2.53 (32.3) 35.2 ± 1.77 (34.7) 
AUC0-24 (µg/mL x h) 2.75 ± 0.49 (2.48) 2.30 ± 0.27 (2.15) 
AUC0-∞ (µg/mL x h) 15.72 ± 1.56 (15.26) 16.17 ± 1.33 (15.74) 
MRT0-∞  (h) 69.84 ± 3.51 (69.24) 65.54 ± 2.51 (65.16) 
1Values in parentheses are the geometric mean. 
 
λz (1/h), slope of the terminal phase; T1/2 λz (h), terminal half-life; Cmax (µg/mL), 
maximum ISF concentration; Tmax (h), time of Cmax; AUC0-24hr (µg/mL x h), area under 
the curve from T0 to T24 hours; AUC0-∞ (µg/mL x h), area under the curve extrapolated 
to infinity using the equation IJKLMNO ; CL/F (mL/h/kg), and MRT0-∞ (h), mean residence 
time extrapolated to infinity using the equation IJKLMNO . 
 
 
 
Table 4. Kidney concentration of desfuroylceftiofur cysteine disulfide (DCCD) and 
calculated desfuroylceftiofur (DFC) in DIS cows (n=10) following a single SQ injection 
of 6.6 mg/kg of ceftiofur crystalline free acid.  
 
Cow Measured DCCD concentration 
(µg/g) 
Calculated DFC concentration1  
(µg/g) 
8972 <LOD - 
9146 <LOD - 
 9206 0.094 0.38 
 9233 <LOD - 
 9389 0.057 0.32 
 9456 <LOD - 
 9709 <LOD - 
 9728 <LOD - 
 9776 <LOD - 
 9779 <LOD - 
<LOD = below the limit of detection of the assay 
1 Desfuroylceftiofur (DFC) concentrations were calculated from DCCD values.   
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Abstract 
There are concerns that the use of broad spectrum antimicrobials in veterinary 
medicine may lead to the development of antimicrobial resistance in animals and that these 
resistance genes may be transmitted to humans. Previous research has indicated that 
ceftiofur (CEF) treatment results in a transient change in resistance amongst fecal bacterial 
populations. Resistance amongst Enterobacteriaceae is commonly associated with the 
blaCMY-2 or blaCTX-M gene. The objectives of this study were: 1) to isolate bacteria in the 
blood of cows afflicted with moderate or severe clinical mastitis and determine AMR 
patterns of these isolates;  2) to enumerate total fecal E. coli bacteria and resistant E. coli 
to CEF following administration of CEF CFA versus non treated control animals; 3) to 
compare phenotypic antimicrobial resistance and underlying genetic mechanisms from 
isolated bacteria; and 4) to determine if there was an impact of clinical disease on the 
development of AMR. The hypothesis was that administration of CEF would result in 
altered resistance patterns in diseased animals compared to healthy animals. Coliform 
blood culture prevalence was 9.1%. Following CEF treatment, there was a decrease in total 
E. coli cfu count and an increase in CEF resistant E. coli and proportion of CEF resistant 
E. coli. There was a significant effect of treatment (P=0.012) on resistant E. coli and a 
treatment (P=0.0191) and day (P=0.011) effect on the proportion of resistant bacteria. All 
CEF resistant isolates were also resistant to ceftriaxone and ampicillin. In addition, 64.3% 
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were also resistant to tetracycline. Forty-eight of 129 CEF resistant isolates harbored the 
blaCTX-M gene, while nine harbored the blaCMY gene, and two isolates harbored both genes. 
Isolates that were determined to be phenotypically CEF resistant were resistant to 4.72 
while isolates that were CEF sensitive were resistant to 1.1 antimicrobials. The current 
study suggests that changes in bacterial populations following clinical disease are not 
different from those of healthy cows treated with CEF.  
Key words: ceftiofur crystalline free acid, antimicrobial resistance, blaCTX-M, blaCMY, 
dairy cattle 
 
Introduction 
Ceftiofur (CEF) is a commonly used third-generation cephalosporin antimicrobial 
in the dairy industry (Zwald et al., 2004; Swant et al., 2005; Schuler et al., 2017). There 
are concerns that the use of broad spectrum antimicrobials in veterinary medicine may lead 
to the development of antimicrobial resistance (AMR) in animals and that these resistance 
genes may be transmitted to humans (WHO, 2017), resulting in AMR against 
antimicrobials like ceftriaxone. Ceftriaxone is also a third-generation cephalosporin often 
used in human medicine for the treatment of invasive enteric salmonellosis in children 
(Whichard et al., 2005; Tragesser et al., 2006). Currently, extended spectrum beta-
lactamases (ESBL) are the primary cause of resistance within human Enterobacteriaceae 
isolates on a worldwide basis (Zhao and Hu, 2013). This has led to the World Health 
Organization to classify 3rd, 4th, and 5th generation cephalosporins amongst the highest 
priority critically important antimicrobials for the preservation of human health (WHO, 
2017).  
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Escherichia coli is a common mastitis pathogen (Oliveira et al., 2013; NMC, 1999), 
which is primarily of environmental origin (NMC, 1999). In 2001, Wenz et al. estimated 
the prevalence of bacteremia secondary to moderate and severe clinical mastitis to be 32% 
(Wenz et al., 2001a). For this reason, many veterinarians include systemic antimicrobials, 
like CEF, in clinical mastitis treatment protocols in order to reduce the potential negative 
effects of a bacteremia (Schuler et al., 2017). In the manuscript describing the prevalence 
of bacteremia, the authors suggested that the source of these bacteria was likely enteric 
(Wenz et al., 2001a).  
In a survey of 18 OH dairy herds, Tragesser et al. (2006) collected 1,266 fecal 
samples from 18 dairy herds to determine the level of ceftriaxone resistance and attempted 
to correlate this resistance with ceftiofur use. They found that 34.4% of the E. coli isolates 
had resistance to ceftriaxone and at least one cow exhibited ceftriaxone resistance in 67% 
of the surveyed herds. In herds that reported usage of CEF within the previous 6 months, 
the mean ceftriaxone resistance was 40% (range 0-97%), while the mean resistance in herds 
that reported no ceftiofur usage was 9% (range 0-34%). The presence of the blaCMY-2 gene 
was found in 83% of the resistant isolates. The research group determined that there was a 
herd level association between the use of CEF and ceftriaxone resistance, but not a cow 
level association.  
The next year, Lowrance et al. (2007) published similar results following the 
treatment of beef feedlot steers with various dosage regimens of CEF CFA compared to 
commingled, non-treated control animals. In this work, they found 68.4% of fecal E. coli 
isolates harbored phenotypic resistance to at least one antimicrobial. Following CEF 
therapy, treated animals experienced transient increases in CEF resistant E. coli 
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populations, which returned to pre-treatment levels in approximately 2 weeks. As with the 
Tragessor et al. (2006) work, this research group determined a high level of correlation 
with CEF resistance and co-resistance against ampicillin, chloramphenicol, streptomycin, 
sulfisoxazole, and tetracycline (ACSSuT phenotype). Additionally, they described an 
association between CEF usage and reduced susceptibility to ceftriaxone. While no direct 
testing of genetic determinants of resistance were undertaken in this trial, the authors 
hypothesized that resistance to CEF and ceftriaxone was likely due to the blaCMY gene.  
In the US, third generation cephalosporin resistance in E. coli and Salmonella 
enterica isolates from food animals from 2000 – 2010 was most commonly associated with 
the plasmid borne blaCMY-2 gene (Daniels et al., 2009; Davis et al., 2015). However, in 
2010, Wittum et al. reported the first dairy cattle isolation of E. coli with blaCTX-M from 
sick and healthy dairy cattle in OH. CTX-M ß-lactamase enzymes were first described in 
1986 from a canine fecal E. coli isolate and have since been described worldwide (Bonnet, 
2004). CTX-M ß-lactamase enzymes typically result in high levels of resistance in E. coli 
against ampicillin, amoxicillin, carbenicillin, ticarcillin, piperacillin, cephalothin, 
cephaloridine, and cefuroxime, but maintain susceptibility to cefoxitin, ß-lactamase 
inhibitors, and carbapenems (Bonnet, 2004; Wittum et al., 2010). These genes are 
predominantly responsible for the ESBL phenotype in E. coli and Klebsiella spp. in humans 
worldwide (Bonnet, 2004; Zhao and Hu, 2013).  
The concern with CEF usage in food animals is that fecal contamination of meat 
products may result in the transfer of resistance genes to humans (US FDA, 2016b). 
However, as shown in the studies cited previously, presence of AMR in NTS fecal E. coli 
seems to be transient following CEF therapy. To reduce the prevalence of AMR genes in 
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feces of processed livestock, computer models utilizing pharmacological, microbiological, 
and animal production components have been developed to predict a post-treatment 
resistance reversion period. These would be similar to withdrawal times to reduce the risk 
of violative drug residues being present at processing (Volkova et al., 2016). However, 
there is little to no literature as to whether disease has any impact on the transient nature of 
AMR in NTS fecal E. coli.  
The objectives of this study were: 1) to isolate bacteria in the blood of cows afflicted 
with moderate or severe clinical mastitis and determine AMR patterns of these isolates;  2) 
to enumerate total fecal E. coli bacteria and CEF resistant E. coli following administration 
of CEF CFA versus non-treated control animals; 3) to compare phenotypic antimicrobial 
resistance and underlying genetic mechanisms from isolated bacteria; and 4) to determine 
if there was an impact of clinical disease, like mastitis, on the development of AMR. The 
hypothesis was that administration of CEF would result in altered resistance patterns in 
diseased animals compared to healthy animals.  
 
Materials and Methods 
Animals and Eligibility Criteria  
This study was completed at the Iowa State University Dairy Farm. The lactating 
herd consists of approximately 400 animals (approximately 90% Holstein and 10% Jersey), 
with 365-day rolling herd averages per cow of 10,991 kg milk, 404 kg fat, and 342 kg 
protein. Cows were eligible for the trial if they had not been treated with systemic or 
intramammary CEF within the past 20 days and were healthy prior to enrollment. 
Furthermore, the cows were thirty or more days from their next scheduled dry period.  
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Cows were housed in a free-stall barn bedded with recycled manure solids, which 
is standard practice for this dairy. Cows were fed a total mixed ration and watered, ad 
libitum. Ration parameters met or exceeded those recommended by the NRC guidelines 
(NRC, 2001). Cow housing and management met or exceeded the recommendations listed 
in the Guide for Care and Use of Agricultural Animals in Research and Teaching (FASS, 
2010). Cows were milked by farm personnel three times each day (4 am, 12 pm, and 8 pm). 
Iowa State University’s Institutional Animal Use and Care Committee approved the 
research protocol prior to commencement of trial procedures (protocol number 6-15-8030-
B).  
 
Experimental design – Detection of bacteremia 
Cows detected with clinical mastitis by farm personnel were referred to the trial 
veterinarians for a full physical exam, including assignment of a severity score, as 
previously described by Wenz et al. (2001b). An aseptically collected milk sample was 
collected for bacterial culture. Cows identified as having either moderate or severe clinical 
mastitis that met the above selection criteria were enrolled in the trial.  
Prior to administration of any medication, cows were restrained with a halter to 
expose one jugular vein to facilitate blood collection. The area over the jugular vein was 
clipped and then disinfected using at least three alternating scrubs of chlorhexidine and 
70% ethanol. Following skin prep, 10 mL of blood was collected into a sterile 12-mL 
syringe via an 18-gauge x 1-inch needle. A new needle was placed on the syringe and the 
blood was aseptically transferred to a blood culture vial (BD Bactec, Fisher Scientific, 
Waltham, MA) containing sodium polyanethol sulfate, which binds ß-lactam 
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antimicrobials that may be present in the blood. A second blood sample was collected for 
blood culture 48 hours later using the same technique as described above.  
Following the first blood collection, cows received CEF hydrochloride (Excenel, 
Zoetis Inc., Kalamazoo, MI) at a dose of 2.2 mg/kg via the IM route. In addition, cows 
were allowed to receive any ancillary therapies prescribed in the farm’s veterinary 
treatment protocols, at the discretion of the trial veterinarian assessing the animal. Ceftiofur 
therapy was continued for a total of 3 or 5 days and ancillary therapies provided at the 
discretion of the examining veterinarian, following the daily examination of the cow per 
the trial protocol.  
 
Microbiological analysis of blood culture vials 
Inoculated vials were transferred to the laboratory where a vent was aseptically 
placed in the vial per the manufacturer’s instructions and then incubated at 37 °C. Blood 
culture vials were sub-cultured onto 5% sheep blood agar and MacConkey agar (Remel 
Microbiology Products, Lenexa, KS) 1, 2, and 7 days following inoculation by dripping 2-
3 drops of solution onto each agar plate. Plates were then be streaked for isolation and 
incubated at 37 °C. Plates were read 24 and 48 hours after streaking. Bacteria isolated on 
culture plates were identified using standard techniques and confirmed with MALDI-TOF 
(MALDI Biotyper, Bruker Daltonics Inc., Billerica, MA). After completion of bacterial 
identification, isolates were frozen in a 50:50 mixture of brain heart infusion media and 
glycerol at -80 °C for later testing. 
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Microbiological analysis of milk samples 
The milk sample was transported to the laboratory and cultured on 5% sheep blood 
agar and MacConkey agar plates (Remel Microbiology Products, Lenexa, KS) as described 
by the National Mastitis Council (NMC, 1999). The plates were examined the following 
day and confirmed as a coliform based on growth on MacConkey agar and typical colony 
morphology.  
 
Experimental design – Enumeration of fecal E. coli organisms 
Thirty Holstein cows were utilized in three separate groups to complete the 
objectives of the trial. The treatment group (TRT) consisted of cows that developed 
moderate or severe clinical mastitis (CM) using a scoring system described by Wenz et al. 
(2001b). Subsequently, two cows were selected from a pool of available cows that were 
within the same lactation group and approximately the same days in milk. One of those 
cows was assigned as the positive control (PC) and the other the negative control (NC). An 
attempt was made to select cows from the same pen and maintain those cows in this pen 
throughout the remainder of the trial, but this did not occur with all groups due to issues 
with management of cow flow. Cows were eligible for the trial using the same inclusion 
criteria as described above.  
Following identification of the case of CM, the cow had a milk sample collected 
from the mastitic quarter for culture following aseptic preparation of the teat. The milk 
sample was cultured as described previously. Additionally, a fecal sample was collected 
from the rectal vault using a clean obstetrical sleeve. The fecal sample was transferred to a 
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50-mL conical tube, marked as Day 0 (D0), placed on ice, and transported to the laboratory 
for bacterial enumeration.  
The cow was then weighed and treated with a single dose of CEF CFA (Excede, 
Zoetis Inc., Kalamazoo, MI) at 6.6 mg CEF equivalents/kg of body weight, administered 
at the base of either ear following instructions on the package insert. As part of the trial 
design, additional ancillary therapies (anti-inflammatories, fluid support, etc.) were 
administered per the farm’s treatment protocols as determined by veterinarians on the 
research team. Additional antimicrobial therapies were not administered throughout the 
remainder of the trial. If the TRT cow was severely affected and showing clinical signs of 
muscular weakness, she was moved to the hospital pen until an improvement in clinical 
illness occurred. Otherwise she remained in her home pen throughout the trial. Cows in the 
PC and NC group were not enrolled until the next day, when results of the milk culture 
confirmed the causative agent was a coliform. 
Upon confirmation of the culture result, fecal samples were collected from the PC 
and NC cows and processed in the same manner as the TRT cow. Cows in the PC group 
were then weighed and treated as described previously. Cows in the PC and NC groups 
were then returned to their home pen. All groups had additional fecal samples collected 
and processed in a similar manner as described above on days 3, 7, 14, 21, and 28 days 
following enrollment.  
 
Microbiological analysis of fecal samples 
Enumeration of NTS E. coli and CEF resistant E. coli was completed using a direct 
plating method on plain MacConkey agar plates and MacConkey agar plates impregnated 
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with 8 µg/mL of CEF, which is equivalent to the minimum inhibitory concentration to 
determine E. coli resistance to CEF (CLSI, 2015). A 1 g aliquot of feces was placed into a 
sterile stomacher bag, diluted with 9 mL of peptone water, and placed in a stomacher device 
for 1 minute. Ten-fold serial dilutions were then completed in peptone water from the bag 
up to 10-5. From each of the dilutions, 100 µL was pipetted onto duplicate plain MacConkey 
plates and duplicate MacConkey plates with CEF. Plates were incubated for 18-24 hours 
at 37 °C. Following incubation, total NTS E. coli and CEF resistant E. coli were 
enumerated based on colony morphologically. Colony counts from duplicate plates were 
averaged to determine the cfu count at each time point. 
Up to three CEF resistant E. coli colonies were individually isolated onto trypticase 
soy agar plates and incubated for 24 hours at 37 °C for further screening. Confirmation of 
E. coli identification was completed using a spot indole test. Further identification steps 
were not completed as the combination of growth on selective media, colony morphology, 
and results of the spot indole test provided >99% probability of correct identification 
(Kanwar et al., 2013). Isolates were then transferred to a 50:50 mixture of brain heart 
infusion broth and glycerol and frozen at -80 °C for later analysis. 
 
Antimicrobial susceptibility testing  
Antimicrobial susceptibility testing was completed on all suspect CEF resistant E. 
coli fecal isolates and all E. coli isolates from blood culturing, post-mortem, and mastitis 
samples. Broth micro-dilution susceptibility analysis was completed using the gram-
negative National Antimicrobial Resistance Monitoring System (NARMS) plate 
(CMV3AGNF, Thermo Scientific Trek Diagnostic Systems, Waltham, MA). On the day 
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prior to susceptibility testing, frozen isolates were struck onto 5% sheep blood agar plates 
and incubated overnight at 37 °C. To inoculate the susceptibility plates, 2-3 isolated NTS 
E. coli colonies were transferred to 5 mL of sterile 0.85% physiologic saline adjusted to a 
0.5 McFarland standard using automated methods (Sensititre Nephelometer, Thermo 
Scientific Trek Diagnostic Systems, Waltham, MA). 10 µL of the adjusted standard was 
then transferred to 5 mL of Mueller-Hinton broth. Following vortexing, each well of the 
antimicrobial susceptibility plate was inoculated with 50 µL of broth suspension using an 
automated inoculator (Sensititre AutoInoculator, Thermo Scientific Trek Diagnostic 
Systems, Waltham, MA). Plates were then incubated for 18 hours at 37 °C and results 
recorded with an automated system (Sensititre ARIS 2X, Thermo Scientific Trek 
Diagnostic Systems, Waltham, MA). Determination of sensitive, intermediate, or resistant 
classification was based on the current version of the Clinical and Laboratory Standards 
Institute (CLSI) guidelines (CLSI, 2017) when available. As a breakpoint is not established 
azithromycin, a breakpoint of ≥32 µg/ml was used, as defined by NARMS (US FDA, 
2016b). For data analysis, all isolates that were classified as intermediate were considered 
susceptible when converting to binary classification. Quality control of the antimicrobial 
susceptibility testing was completed using E. coli ATCC 25922 (American Type Culture 
Collection, Manassas, VA) and compared to quality control ranges recommended by CLSI 
(CLSI, 2015).  
Following completion of antimicrobial resistance testing, enumeration of CEF 
resistant bacterial numbers were corrected to account for isolates that failed to confirm as 
resistant.  
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Determination of resistance genes 
Determination of the presence of blaCTX-M and blaCMY resistance genes was 
completed using previously described PCR protocols (Zhao et al., 2001; Zhao and Hu, 
2013; Davis et al., 2015). Briefly, boiled cell lysates were used for the reaction template. 
Standard amplification reaction volumes were 25-µL final concentrations of 1x PCR 
buffer, 200 µM of each deoxynucleoside triphosphate (dNTP), 1.5 µM MgCl2, 1 pmol/µL 
primer, and 2.5 U Taq. Cycling conditions for blaCMY-2 PCR included an initial 
denaturation of 95 °C for 15 minutes, and 35 cycles of 94 °C for 30 seconds, 55 °C for 30 
seconds, 72 °C for 1 minute, and 70 °C for 10 minutes. Cycling conditions for the        
blaCTX-M PCR included an initial denaturation of 95 °C for 15 minutes, and 35 cycles of 94 
°C for 30 seconds, 52 °C for 30 seconds, 72 °C for 1 minute, and 70 °C for 10 minutes. 
Primer sequences are shown in Table 1. Positive control samples were field isolates that 
were obtained from the Centers for Disease Control. Visualization and separation of PCR 
amplicons were performed using the QIAxcel Advanced capillary electrophoresis system 
(QIAGEN, Hilden, Germany). The PCR positive samples were purified and sequenced at 
The DNA Facility of the Iowa State University Office of Biotechnology using standard 
Sanger sequencing (3730xl DNA Analyzer, Applied Biosystems, Foster City, CA). Contig 
assembly was performed using the SeqManPro module in DNAStar (DNA Star Lasergene, 
Madison, WI).  Comparisons among the sequences in this study were made using Clustal 
W alignment, and the phylogenetic tree was generated using the Neighbor Joining Tree 
method (MEGA6: Molecular Evolutionary Genetics Analysis Version 6.0, Tamura et al., 
2013).  
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Data analysis 
Statistical analysis was performed using a commercially available software 
program (SAS 9.4, SAS Institute, Cary, NC). Log cfu bacterial counts and proportions 
between groups were analyzed via the GLIMMIX procedure using repeated measures 
analyses of variance (ANOVA), with animal being the subject of repeated measures. Fixed 
effects were treatment (TRT, PC, or NC), time, and the interaction between treatment and 
time. Statistical significance was established when P < 0.05. 
 
Results 
Detection of bacteremia 
Over the course of 13 months, 33 cows had blood cultures following development 
of clinical mastitis. Two cows from the sampled group were culture positive for E. coli and 
an additional cow was culture positive with Klebsiella spp. (9.1%; 95% CI= -1.3-19.4). 
There were eight cows that were culture positive with Bacillus spp. or staphylococci, which 
were assumed to be contaminants associated with sampling. The two cows from which E. 
coli was isolated were also culture positive for E. coli from the milk culture. In addition, 
one of these two cows died as a result of the clinical case and underwent a full post-mortem 
examination at the ISU Veterinary Diagnostic Laboratory. Liver tissue from this cow was 
culture positive for E. coli. These five E. coli isolates were included in the antimicrobial 
susceptibility testing and PCR analysis. Additionally, E. coli isolates from four of the IMM 
infections from the clinical cases in the enumeration study were retained for future analysis.  
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Enumeration of fecal E. coli organisms 
At enrollment, there was no statistical difference for any of the animal enrollment 
variables between the treatment groups. During the study, one of the TRT group cows died 
between 14 and 21 days of the study from complications associated with the clinical 
mastitis case. One additional cow was enrolled in place of this cow to assure ten complete 
groups. However, her fecal isolates were still included in the pool to be analyzed along 
with the replacement animal.  
In total, 265 fecal isolates that were initially screened as CEF resistant using the 
CEF impregnated agar plates were isolated for further testing. Comparing the isolates from 
each cow at each time point following completion of antimicrobial susceptibility and PCR 
analysis, 222 unique isolates were identified. After completion of antimicrobial 
susceptibility testing, 129 of the 222 (58.1%, 95% CI=51.6-64.6) fecal isolates that were 
originally screened as resistant using CEF impregnated agar plates were confirmed to be 
phenotypically resistant.  
Estimated log total E. coli counts are displayed in Figure 1. There was not an effect 
of treatment on total cfu count, but there was an impact by day (P<0.0001) and treatment 
by day interaction (P=0.049). At day 0, all of the cows had approximately the same total 
E. coli count. Cows that received CEF (TRT and PC) had a significant reduction in total 
cfu count from day 0 to 3 in the PC group (P=0.0063) and from day 0 to 7 in the TRT group 
(P=0.0001). From these time points, the total cfu count rebounded towards the pre-
treatment levels. Throughout the entire time period, the NC group had no significant 
changes in cfu count.  
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Estimated log CEF resistant E. coli counts are displayed in Figure 2. There was a 
significant effect of treatment (P=0.012), but no effect by day or treatment by day 
interaction. Prior to treatment with CEF, the TRT cows had a numerically higher CEF 
resistant cfu count compared to the PC and NC groups. Following treatment, both the TRT 
and PC groups had an increase in cfu counts associated with resistant E. coli organisms. In 
the TRT group, peak CEF resistant organisms occurred on day 3 resulting in a statistically 
significant difference compared to the NC group (P=0.0373), which continued through day 
7 (P=0.379). There was a tendency for the PC group to be significantly lower than the TRT 
group at day 7 (P=0.0671). By day 14, resistant bacteria in the TRT group returned to pre-
treatment levels and there was no difference in the three groups throughout the remainder 
of the monitoring period.  
The proportion of total bacteria represented by resistant E. coli are shown in Figure 
3. There was significant effect of treatment (P=0.0191) and day (P=0.011), but no effect of 
the treatment by day interaction. Similar to the resistant cfu count, the proportion increased 
from day 0 to day 3 for both the TRT and PC groups and then decreased until day 14, when 
they were approximately the same for all groups numerically.  The TRT group was 
significantly different from the NC group at day 3 (P=0.0436) and day 7 (P=0.0147). 
As stated above, from the fecal isolates, 265 were initially determined to be CEF 
resistant using the CEF impregnated plate method. All of these samples, plus ten samples 
from mastitis cases in the TRT group and from systemic cultures (blood cultures and post-
mortem exams), underwent antimicrobial susceptibility testing. All plates had correct 
responses for individual positive and negative controls. All quality control samples met 
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CLSI recommended ranges, with the exception of tetracycline for which all outcomes were 
4 µg/mL compared to the reference range of 0.5-2 µg/mL (CLSI, 2015).  
From the 10 non-fecal origin samples, eight were pan-susceptible while one was 
resistant to tetracycline and another was resistant to ampicillin, streptomycin, 
sulfisoxazole, and tetracycline.  
Antimicrobial susceptibility testing results for the 129 unique isolates that were 
CEF resistant are shown in Table 2. All 129 CEF resistant isolates were also resistant to 
ceftriaxone and ampicillin. In addition, 83 (64.3%; 95% CI=56-72.7%) of the CEF resistant 
isolates were also resistant to tetracycline. Including all 222 unique fecal isolates, 140 and 
156 isolates were resistant to ceftriaxone and ampicillin, respectively. 
In total, 55 fecal isolates had at least one ß-lactamase resistance gene detected by 
PCR. Forty-eight harbored the blaCTX-M gene while nine harbored the blaCMY gene, with 
two of these isolates harboring both genes. A dendrogram of the phylogenetic tree for 
blaCTX-M is shown in Figure 4, while the blaCMY isolates are shown in Figure 5. Phylogenetic 
analysis indicated that the blaCTX-M isolates were 98 to 100% similar, while the blaCMY were 
99.7-100% similar. Seventy-seven isolates had CEF resistance mechanisms other than 
blaCTX-M or blaCMY. 
The distribution of days in the trial when an isolate was identified with blaCTX-M is 
shown in Figure 6. Of the 48 blaCTX-M positive isolates, 37 occurred on separate cow days. 
This indicates that there were 11 isolates for which two unique isolates were found from 
the same cow on the same day. Eighteen of 21 the cows that were treated with CEF had at 
least one point in time when an isolate was positive for blaCTX-M versus only 4 of the cows 
in the NC group. The blaCTX-M gene was more likely to be found on day 0 or 3 and by day 
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28, no cows had a blaCTX-M isolate present. In contrast, the blaCMY gene was equally 
distributed across the follow-up period (data not shown). This gene was found in isolates 
from five TRT cows and 3 NC group cows.  
Histograms representing the total number of antimicrobials for which isolates are 
resistant are shown in Figure 7. Isolates that were determined to be phenotypically CEF 
resistant were resistant to 4.72 antimicrobials on average (range 3-8; 95% CI=4.53-4.91), 
while isolates that were CEF sensitive were resistant to 1.1 antimicrobials (range 0-7; 95% 
CI=0.69-1.5). Isolates that were blaCTX-M positive were resistant to 4.7 antimicrobials 
(range 3-7; 95% CI=4.42-5.05), while those with the blaCMY gene were resistant to 5.5 
antimicrobials (range 5-8; 95% CI=4.61-6.4). Bacterial isolates that were resistant to CEF 
and did not contain either of the bla genes were resistant to 4.65 antimicrobials (range 3-
8; 95% CI=4.11-4.89).    
For isolates that were CEF resistant, resistance to four antimicrobials had the 
highest frequency (n=60). The resistance phenotype was ampicillin, CEF, ceftriaxone, and 
then either tetracycline (n=51) or streptomycin. This phenotype was also the most common 
amongst the blaCTX-M positive isolates (n=17). If the phenotype was resistant to five 
antimicrobials (n=40), the most common phenotype present was amoxicillin/ clavulanic 
acid, ampicillin, cefoxitin, CEF, and ceftriaxone (n=29). The remaining 11 isolates 
resistant to five antimicrobials showed the ampicillin, CEF, ceftriaxone, streptomycin, and 
tetracycline phenotype (n=9). The other two showed the same phenotype, except one with 
resistance to cefoxitin and one to chloramphenicol instead of tetracycline.  
Isolates carrying the blaCTX-M gene that were resistant to six antimicrobials (n=12) 
always exhibited the ampicillin, CEF, ceftriaxone, chloramphenicol, streptomycin, and 
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tetracycline phenotype. Nine blaCTX-M positive isolates that were resistant to five 
antimicrobials predominantly exhibited the ampicillin, CEF, ceftriaxone, streptomycin, 
and tetracycline phenotype. From the isolates that were blaCTX-M positive, only one of the 
isolates showed resistance to amoxicillin/ clavulanic acid, but it also carried the blaCMY 
gene.  
All but one of the isolates carrying the blaCMY gene were resistant to amoxicillin/ 
clavulanic acid. That isolate was also the only blaCMY positive one that was not resistant to 
cefoxitin, which potentially brings the results of the antimicrobial susceptibility test into 
question for this isolate. The most common phenotype for blaCMY positive isolates was 
amoxicillin/clavulanic acid, ampicillin, cefoxitin, CEF, and ceftriaxone.    
If isolates had no resistance gene determined and were resistant to four 
antimicrobials, the resistance phenotype was ampicillin, ceftiofur, ceftriaxone, and 
tetracycline. In contrast, if the isolates were resistant to five antimicrobials and did not have 
a resistance gene present, the phenotype was amoxicillin/clavulanic acid, ampicillin, 
cefoxitin, ceftiofur, and ceftriaxone.  
There were eight CEF-susceptible isolates that were resistant to amoxicillin/ 
clavulanic acid, ampicillin, cefoxitin, ceftriaxone, chloramphenicol, streptomycin, and 
tetracycline.  
 
Discussion 
In contrast to Wenz et al. (2001a), this study had a much lower prevalence of 
bacteremia. In the comparison study, a larger number of animals were sampled (n=144) 
over six farms. It is possible for there to be an influence of farm; however, risk by farm 
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was not reported in the comparison study. Additionally, the comparison study used a 
different blood culturing system than in the current trial due to discontinuation of the 
product (Wenz et al., 2001a).  
In this study, bacterial isolates from mastitis cases and bacteremia isolation were 
more susceptible compared to fecal isolates. However, fecal isolates that underwent 
antimicrobial susceptibility testing were screened for CEF resistance and only selected 
based on the phenotype. Mastitis cases associated with E. coli are environmental in nature 
and would be expected to be associated with the fecal microbiota of the source dairy. 
Additionally, isolates from systemic samples were suggested to have an origin of the 
intestinal tract (Wenz et al., 2001a). The finding of a high level of susceptibility amongst 
E. coli mastitis isolates is consistent with recent submissions to diagnostic laboratories at 
Iowa State University (Adam Krull, DVM, personal communication) and the University of 
Minnesota (Erin Royster, DVM, personal communication). 
Following CEF therapy, there was a reduction in total bacteria number and an 
increase in the number and proportion of CEF resistant E. coli. Following these initial 
changes, bacterial populations returned to pre-treatment levels by 14 days. This pattern was 
consistent with previous studies following CEF therapy (Jiang et al., 2006; Tragesser et al., 
2006; Lowrance et al., 2007; Singer et al., 2008). To our knowledge, no one has 
investigated the impact of clinical mastitis on shedding patterns of CEF resistant bacteria. 
It appears from the current study that the pattern following clinical disease is not different 
than previous studies, despite the fact that the TRT group was numerically higher in CEF 
resistant cfu counts early in the observation period. Therefore, the hypothesis for this trial 
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was not proven. It is possible that this study did not have sufficient power to discern a true 
difference in resistant bacterial between the TRT and PC group.  
All of the resistant CEF isolates were also resistant to ceftriaxone and ampicillin. 
However, there were eight isolates that were susceptible to CEF and resistant to ceftriaxone 
indicating different mechanisms may be present which drive ceftriaxone resistance 
compared to CEF.  
It should be noted that the breakpoints utilized for determining susceptibility to 
fecal isolates were based on NARMS guidelines (US FDA, 2016b), which are primarily 
dictated by human antimicrobial susceptibility testing methodologies (CLSI, 2017). 
Therefore, susceptibility patterns determined in this study may not be relevant to bovine 
fecal isolates. Additionally, there are no antimicrobial susceptibility breakpoints 
established for bovine fecal E. coli isolates.  
In total, 37% of the fecal isolates that were CEF resistant were carrying the     
blaCTX-M gene. This is consistent with previous reports suggesting the blaCTX-M gene is 
among the most prevalent reason for extended spectrum ß-lactamase E. coli (Davis et al., 
2015). From the 48 isolates, 37 were present on separate cow days, with 10 each of the 37 
appearing on day 0 and day 3, respectively. By day 28, none of the fecal isolates were 
found to contain the gene. While there is no other research having reported this finding, it 
is prudent to not over-interpret the significance of this finding due to the relatively small 
population of bacterial isolates and the random nature in which isolates were originally 
selected for further analysis.  
More than half of the CEF resistant isolates had resistance determinants that were 
not determined by the PCR analysis used in this study. In examining the phenotypic 
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resistance patterns of the E. coli isolates from this study, it is likely that several other 
resistance mechanisms were present in this microbial population. According to the NCBI 
website, there are 34 ß-lactamase families currently recorded on three different websites 
(NCBI, 2017). In the future, it would be prudent to use a technique with higher resolution 
of the genome, such as whole genome sequencing. This approach would provide a more 
complete picture of the entire resistome of such a diverse bacterial population as the one 
studied here.  
Previous research has suggested that E. coli isolates harboring the blaCMY gene 
exhibited the ampicillin, chloramphenicol, streptomycin, sulfisoxazole, and tetracycline 
resistance phenotype (Tragessor et al., 2006; Lowrance et al., 2007). In the present work, 
none of the blaCMY harboring isolates were resistant to sulfisoxazole. In addition, only three 
showed resistance to chloramphenicol. While it is not evident as to why this difference 
occurred, it is likely that a gene mutation occurred resulting in a narrower resistance 
phenotype in the current study.   
A weakness of this study was not creating a NC group with no history of CEF usage 
at the individual animal level. That may have allowed for an assessment on the impact CEF 
therapy on resistance development. However, one of the goals was to mimic normal 
management of a commercial dairy farm in this trial. Additionally, the common use of CEF 
on the investigational farm and the potential for horizontal transmission likely limited the 
utility of such a control group (Boyer and Singer, 2012). 
In conclusion, there was a correlation between CEF resistance and that of 
ceftriaxone and ampicillin. Initiation of CEF therapy resulted in a transient increase in 
resistant isolates, which returned to pretreatment levels in approximately 14 days. 
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However, this work did not show a difference in bacterial numbers or changes over time 
between healthy and diseased animals. Commonly described ß-lactamase genes were 
prevalent in resistant isolates but apparently other resistance mechanisms are substantial 
contributors to the resistome. Future work is needed to more completely describe the full 
range of resistance mechanisms in order to better understand the complex interactions that 
occur amongst bacterial populations. In addition, these complex interactions limit the 
ability to discern the impacts to implementation of antimicrobial stewardship programs on 
the resistome without the use of higher resolution sequencing techniques.  
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Table 1. PCR primer sequences used for analysis of resistance genes. (Davis et al., 
2015). 
 
Gene Primer name Sequence (5’ to 3’) 
blaCTX-M CTX-M.F TTT GCG ATG TGC AGT ACC AGT AA 
 CTX-M.R CGA TAT CGT TGG TGG TGC CAT A 
blaCMY CMY-F GAC AGC CTC TTT CTC CAC A 
 CMY-R TGG AAC GAA GGC TAC GTA 
 
 
 
 
 
 
 
Table 2. Distribution of mean resistance (95% CI) of 129 (ALL) E. coli isolates that were 
resistant to CEF as tested with the National Antimicrobial Resistance Monitoring System 
(NARMS) gram-negative plate compared to the three comparison groups (TRT, n=46; 
PC, n=33; & NC, n=28) following CEF therapy. 
 
Antimicrobial All TRT PC NC 
Amoxicillin/ 
Clavulanic Acid 27.2 (19.3-34.9) 29.8 (17.7-42.1) 25.6 (11.3-40) 24.2 (8.8-39.7) 
Ampicillin 100 100 100 100 
Azithromycin 0 0 0 0 
Cefoxitin 27.9 (20-35.8) 31.6 (19.1-44) 25.6 (11.3-40) 24.2 (8.8-39.7) 
Ceftiofur 100 100 100 100 
Ceftriaxone 100 100 100 100 
Chloramphenicol 17.0 (10.5-23.6) 19.3 (8.7-29.9)  20.5 (7.2-33.8) 9.1 (-1.2-19.4) 
Ciprofloxacin 1.6 (-0.6-3.7) 0 2.6 (-2.6-7.7) 3 (-3.1-9.2) 
Gentamicin 1.6 (-0.6-3.7) 0 2.6 (-2.6-7.7) 3 (-3.1-9.2) 
Nalidixic Acid 1.6 (-0.6-3.7) 0 2.6 (-2.6-7.7) 3 (-3.1-9.2) 
Streptomycin 32.6 (24.4-40.8) 36.8 (23.9-49.8) 33.3 (17.8-48.8) 24.2 (8.8-39.7) 
Sulfisoxazole 0 0 0 0 
Tetracycline 64.3 (56-72.7) 54.4 (41-67.7) 71.8 (57-86.6) 72.7 (56.7-88.8) 
Trimethoprim/ 
Sulfamethoxazole 0 0 0 0 
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Figure 1. Log transformations of mean (± 1 SE) total fecal E. coli cfu with moderate or 
severe mastitis (TRT; n=10) and without disease (PC; n=10) following a single 
administration of ceftiofur crystalline free acid at 6.6 mg ceftiofur equivalents (CE)/kg of 
body weight versus healthy control cows (NC) that did not receive antimicrobial therapy 
(n=10). 
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Figure 2. Log transformations of mean (± 1 SE) ceftiofur resistant fecal E. coli cfu from 
cows with moderate or severe mastitis (TRT; n=10) and without disease (PC; n=10) 
following a single administration of ceftiofur crystalline free acid at 6.6 mg ceftiofur 
equivalents (CE)/kg of body weight versus healthy control cows (NC; n=10) that did not 
receive antimicrobial therapy.   
  
145 
 
 
 
Figure 3. Proportion of log transformed ceftiofur resistant fecal E. coli cfu (± 1 SE) of 
total non-type specific E. coli from cows with moderated or severe mastitis (TRT; n=10) 
and without disease (PC; n=10) following a single administration of ceftiofur crystalline 
free acid at 6.6 mg ceftiofur equivalents (CE)/kg of body weight versus healthy control 
cows (NC; n=10) that did not receive antimicrobial therapy. 
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Figure 4. Dendrogram demonstrating the phylogenetic tree of the blaCTX-M isolates.  
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Figure 5. Dendrogram demonstrating the phylogenetic tree of the blaCMY isolates.  
 
 
 
 
  
 
Figure 6. Frequency distribution of when blaCTX-M was isolated. 
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Figure 7. Frequency distribution of the number of antimicrobials that are resistant against. a) Isolates that were CEF susceptible; b) 
Isolates that were CEF resistant; c) Isolates determined to be carrying the blaCTX-M gene; d) Isolates determined to be carrying the 
blaCMY gene; and e) Isolates that were CEF resistant where neigher gene was found.  
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CHAPTER 6.  SUMMARY AND CONCLUSIONS 
 
 
 
Since its introduction into the veterinary industry, the various formulations of ceftiofur 
(CEF) have been widely used in dairy cattle. While national estimates of CEF use are not 
available down to the animal level, a recent study indicates it is used nearly twice as often as 
other competitive products (Schuler et al., 2017).  This is likely due its broad spectrum of 
activity and short duration of milk and meat withdrawals. However, despite its short 
withdrawal times, violative meat residues in cull dairy cattle are most commonly associated 
with CEF. Over the last ten years, CEF violative residues have gone from zero to the over 200 
per year, surpassing penicillin as the most common residue in 2012 (Chapter 1, Figure 2). The 
potential reasons for the increase in violative residues include: marketing of animals before the 
meat withdrawal periods have elapsed; errors in record keeping regarding treatment status; 
changes in the tolerance and consequently the meat withdrawal intervals over the years; and 
potentially differences in animal health status compared to the status of the animals used during 
the drug approval process. In the drug approval process, healthy animals are utilized, whereas 
the majority of these drugs are not intended for and are not administered to healthy animals in 
clinical dairy practice. As a result of disease, there are potentially differences in drug 
absorption, distribution, metabolism, and excretion. The first objective of this dissertation was 
to study CEF pharmacokinetics (PK) in healthy versus diseased cattle and to investigate CEF 
tissue depletion following induction of coliform mastitis. 
Two studies were conducted to investigate the PK of ill versus healthy animals. In the 
first study, CEF hydrochloride was administered over a five-day period to cows with naturally 
occurring coliform mastitis (Chapter 2) and in the second study, a single dose of CEF 
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crystalline free acid (CFA) was administered to cows with induced coliform mastitis (Chapter 
4). In both of these studies, we were able to prove that certain PK parameters were significantly 
altered compared to healthy control cows. In the first study (Chapter 2), diseased cows had 
higher volume of distribution per fraction of the dose absorbed (Vz/F) and clearance per 
fraction of the dose absorbed (CL/F) compared to the healthy herdmates. The diseased group 
also had significantly lower steady-state maximum concentration (Cmax ss) and area under the 
concentration curve in the interval between drug doses (AUCtau). Despite changes in Vz/F and 
CL/F, there was not a significant change in the elimination half-life (T1/2 last dose). In this study, 
the mean T1/2 last dose in the control group was 35.8 hours, while in the mastitic group it was 41.9 
hours. However, one of the cows had an elimination half-life of nearly two times the mean of 
the control group at 70.9 hours.  
In a separate study (Chapter 4), cows were inoculated with IMM E. coli to induce the 
disease process. As a result, it was possible to again demonstrate significantly higher Vz/F in 
the diseased group but no differences in CL/F. Additionally, the diseased group had a 
significantly higher elimination half-life (T1/2 !"). Again, the cow with the longest T1/2 !"	was 
nearly twice as long as the mean of the control group. An elimination half-life that is twice as 
long indicates that the time to reach a regulatory tolerance level will take twice as long, 
provided the drug is not bound within the organ of elimination like may be the case with 
aminoglycosides (Riviere et al., 1998). At the conclusion of this study, cows were sacrificed 
and kidney tissues were analyzed for CEF residue concentrations. While none of the cows had 
residue levels above the tolerance for desfuroylceftiofur, the target metabolite for CEF, the 
cow with the longest T1/2 !"	had a kidney tissue concentration slightly below the tolerance. 
While this work did not prove that violative residues could occur as a consequence of utilizing 
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CEF in diseased cows, it should be noted that the cows in this latter study were not as clinically 
ill as the first study. Future work should focus on assessing tissue residues in cattle that are 
more severely affected by clinical disease in order to rule out the potential for creating violative 
residues when marketing these animals.  
In the first study (Chapter 2), Cmax ss and AUCtau were significantly higher in the control 
group, leading to the question of whether a clinically effective concentration of CEF was 
reaching the bio-phase. Therefore, in the induced mastitis trial (Chapter 4), subcutaneous 
ultrafiltration probes were utilized to collect interstitial fluid and measure non-protein-bound 
CEF concentrations. In this study, there were no differences in ISF CEF PK between the two 
groups of cows. However, there also was no difference in plasma area under the curve 
extrapolated to infinity (AUC0-∞), even though there was a trend toward a higher Cmax and area 
under the curve in the first 24-hours after CEF dosing (AUC0-24) in the disease group. A lack 
of difference in plasma PK would not be expected to result in differences in ISF PK.  
In plasma, CEF is typically >90% protein-bound in the adult bovine (S. A. Brown et 
al., 1991). Drugs that are weak acids, like CEF, are primarily bound to albumin (Riviere, 
2009a). In disease, albumin concentrations typically decrease to compensate for the liver’s 
need to increase production of acute phase proteins (Ceciliani et al., 2012), which could lead 
to a higher unbound fraction of drugs that primarily bind to albumin. As CEF is a low extraction 
ratio drug, an increase in the unbound fraction will reduce the total concentration of the drug 
in the circulation, but not the free concentration (Toutain and Bousquet-Melou, 2002). This 
could have explained the lower AUCtau seen in the first study (Chapter 2); however, we did not 
measure plasma albumin concentrations or the degree of protein binding, nor did we collect 
interstitial fluid to determine drug concentrations in that matrix. This would suggest that the 
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bio-phase CEF concentration will be unaffected by disease, if passive diffusion is the only 
mechanism involved in moving drug into the bio-phase. However, there may be other factors 
contributing such as efflux pumps (Foster et al., 2015) and pathological processes associated 
with clinical disease (Walker et al., 1994; Clarke et al., 1996; Washburn et al., 2005) that may 
contribute to different bio-phase concentrations depending on location in the body. Future PK 
studies investing the clinical efficacy of drugs need to involve measurement of drug 
concentrations within the bio-phase.  
Ceftiofur sodium is reported to have nearly a 100% bioavailability (S. A. Brown et al., 
1991) and the kinetics between CEF sodium and CEF hydrochloride are similar (Pharmacia 
and Upjohn, 1998). Additionally, bioavailability of CEF CFA has been reported to be 100% 
following IM administration in the equine (Collard et al. 2011). Bioavailability of CEF CFA 
has not been reported in the bovine to date. An objective of Chapter 4 of this dissertation was 
to describe the bioavailability of CEF CFA in healthy cattle versus cattle with induced coliform 
mastitis. The absolute bioavailability was determined to be approximately 160% in both 
groups. A bioavailability value >100% is not theoretically physiologically, but when extended 
duration drugs, such as CEF CFA, are administered they often result in a difference in 
clearance as compared to IV administration. This increases the exposure of the drug following 
extravascular administration, which increases the AUC resulting in this phenomenon. 
Therefore, CL via both routes of administration were introduced into the equation to account 
for potential difference. As a result, the apparent bioavailability was determined to be 98% and 
110% for the DIS and CON groups. Plasma CEF Cmax was lower and Tmax was longer in this 
trial compared to the previous work (Chapters 2 and 3) due to flip-flop kinetics associated with 
CEF CFA when administered at the base of the ear per label compared to CEF hydrochloride.   
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Another potential change in clinical practice compared to the drug approval process is 
the co-administration of two or more drugs to alleviate the symptoms of clinical disease. In the 
drug approval process, drugs are administered singly (US FDA, 2006b). However, in clinical 
practice antimicrobials are often administered with other drugs, such as steroidal and non-
steroidal anti-inflammatories, fluids, electrolytes, and diuretics. A commonly administered 
drug combination is CEF and flunixin meglumine (Kissell et al., 2015; Schuler et al., 2017). 
Ceftiofur (S. A. Brown et al., 1991) and flunixin meglumine (Anderson et al., 1990; Odensvik 
et al., 1995) are both >90% protein-bound. Flunixin and CEF are weak acids for which protein-
binding is primarily associated with albumin (Riviere, 2009a). The objective of Chapter 3 was 
to compare plasma and ISF PK between CEF and flunixin administered individually versus 
co-administration of the two drugs. It was hypothesized that simultaneous administration 
would result in a drug interaction that would alter the plasma or ISF PK of one or both drugs. 
The results of this trial indicated that drug interactions between flunixin and CEF did not occur 
when the two drugs are administered simultaneously in healthy cattle. However, as albumin 
concentrations typically decrease to compensate for the body’s need to increase production of 
acute phase proteins in disease (Ceciliani et al., 2012), it would be enlightening to repeat this 
work in diseased cattle to discover if there are interactions that occur as albumin concentrations 
decrease.  
This work did not prove the hypothesis that disease would result in alterations in CEF 
PK necessitating implementation of an extended meat withdrawal time. However, the evidence 
uncovered suggests that it is theoretically possible. Therefore, tissue residue depletion studies 
should continue in animals that are more severely affected than those in the residue depletion 
trial (Chapter 4).  
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Internationally, there is concern that administration of veterinary drugs is resulting in 
dissemination of antimicrobial resistant (AMR) bacteria to humans. There is particular concern 
with the use of CEF, as it is a third generation cephalosporin closely related to the human 
antimicrobial, ceftriaxone. Antimicrobial resistance mechanisms that result in CEF resistance 
are highly correlated with resistance to ceftriaxone. This is particularly concerning since 
ceftriaxone is often used in human medicine for the treatment of invasive enteric salmonellosis 
in children (Whichard et al., 2005; Tragesser et al., 2006). Concerns regarding the future 
efficacy of 3rd generation cephalosporins has led the World Health Organization to classify 
them as the highest priority, critically important antimicrobials for the preservation of human 
health (WHO, 2017). Additionally, the US Food and Drug Administration has restricted the 
extra-label use of CEF in an attempt to limit the impacts on AMR development (US FDA, 
2012b).   
Resistance to ß-lactams is most commonly associated with the production of ß-
lactamase enzymes. Extended spectrum ß-lactamases are the primary cause of AMR in isolates 
of Enterobacteriaceae on a worldwide basis (Bonnet, 2004; Zhao and Hu, 2013). Prior to 2010, 
resistance determinants amongst Enterobacteriaceae for CEF in dairy cattle have primarily 
been related to the blaCMY-2 gene. However, recent data suggests the blaCTX-M is now the most 
prevalent cause of extended spectrum ß-lactamase derived resistance (Daniels et al., 2009; 
Davis et al., 2015). The final objective of this dissertation was to enumerate total and resistant 
E. coli from fecal samples CEF following administration of CEF CFA versus non treated 
control animals, compare phenotypic antimicrobial resistance and underlying genetic 
mechanisms from isolated bacteria, and determine if there was an impact of clinical disease on 
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the development of AMR. The hypothesis was that administration of CEF would result in 
altered AMR patterns in diseased animals compared to healthy animals.  
Following treatment with CEF, there was a decrease in total E. coli cfu count and an 
increase in CEF resistant E. coli. There was a significant effect of CEF treatment on resistant 
bacteria between the negative control and diseased group and a tendency for a difference 
between the healthy cows receiving CEF and diseased cows receiving CEF. Like prior studies 
have shown, changes in total and resistant E. coli populations were transient and returned to 
approximately pre-treatment levels by 14 days following therapy.  
One hundred twenty-nine E. coli isolates were found to be CEF resistant. All of these 
were also ampicillin and ceftriaxone resistant and 64.3% were tetracycline resistant. This is 
particularly troubling as CEF, ampicillin, and the tetracycline family drugs are amongst the 
most commonly used drugs in the dairy industry (Schuler et al., 2017).  
In total, 55 of 129 CEF resistant fecal isolates had at least one ß-lactamase resistance 
gene detected by PCR. Forty-eight harbored the blaCTX-M gene while nine harbored the blaCMY 
gene, with two of these isolates harboring both genes. All of the cows treated with CEF shed 
E. coli that were positive for the blaCTX-M gene at least one time during the first 21 days of the 
28-day trial. Interestingly, no E. coli isolate had the blaCTX-M gene on day 28 following 
treatment. Isolates that were blaCTX-M positive were resistant to 4.7 antimicrobials, while those 
with the blaCMY gene were resistant to 5.5 antimicrobials. Bacterial isolates that were resistant 
to CEF and did not contain either of the bla genes were resistant to 4.65 antimicrobials. In 
contrast, from the 93 isolates that were CEF susceptible there was a mean resistance to 1.1 
antimicrobials/isolate.  
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Going forward, the dairy industry must continue to improve management practices in 
order to minimize the need for antimicrobial use. Additionally, implementation of prudent 
treatments by veterinarians and the use of well-defined treatment protocols by lay personnel 
on farms is an essential goal to minimize drug use, especially since there are many conditions 
in which the use of antimicrobials is not indicated. Antimicrobials are essential for the 
treatment of many disease conditions in order to preserve animal welfare. However, if 
veterinarians do not take the lead on implementing prudent antimicrobial stewardship 
programs, the consuming public is going to demand dairy products that have been produced 
without the use of any antimicrobials.  
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APPENDIX A: A STUDY TO EXAMINE THE RELATIONSHIP BETWEEN METRITIS 
SEVERITY AND DEPLETION OF OXYTETRACYCLINE IN PLASMA AND MILK 
AFTER INTRAUTERINE INFUSION 
 
An abstract presented at the 2015 American Association of Bovine Practitioners 
Annual Conference and with full manuscript published in J. Dairy Sci. 2016, 99:8314–8322. 
 
Abstract 
Metritis is a frequent problem in post-partum dairy cows. Intrauterine therapy (IU) 
with the antimicrobial oxytetracycline (OTC) is often used, although efficacy data supporting 
this therapy has not been shown to be superior to systemic therapy. The objectives of this 
study were to (1) use high-pressure liquid chromatography coupled with mass spectrometry 
technology (LC-MS) to determine the plasma and milk concentrations of OTC following IU 
infusion in post-partum dairy cows with varying degrees of metritis severity, (2) determine 
the depletion time of OTC in an attempt to provide veterinarians withdrawal guidelines 
should they utilize this therapy, and (3) correlate metritis severity scores with OTC 
concentrations in plasma and milk. Our hypothesis was that cows with more severe metritis, 
as assessed by metritis scores, would have higher OTC concentrations in milk following IU 
therapy. Thirty-two cows were selected to participate in the study after farm personnel had 
determined the cows had metritis based on their evaluation of the character of vaginal 
discharge between 4 -14 days in milk, in accordance with the farm’s treatment protocols. 
Metritis scores (1 - 4) were assigned as follows based on a published scheme where; (1) 
represented a yellow to orange thick discharge or translucent mucus, no fetid smell; (2) 
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represented a blood tinged vaginal mucus, slightly watery, little or no fetid smell; (3) 
represented a red to red/brown watery discharge; moderate fetid smell and (4) represented a 
red to red/brown watery discharge containing pieces of placenta and an intense fetid smell.  
Trial cows received a single treatment of 4 grams of OTC (approximately 6.7 mg/kg) via IU 
infusion. Blood samples were collected over 96 h and milk samples were collected prior to 
IU therapy and three times a day for 4 days post-infusion. Following treatment, OTC rapidly 
diffused to plasma and subsequently to milk. Maximum OTC concentration in plasma and 
milk occurred within the first 24 h following IU infusion and 25 of the 32 cows had 
detectable OTC concentrations in milk at four days after IU infusion. Cows with metritis 
scores consistent with clinical metritis (score=3 or 4) at the initiation of treatment were 
significantly, and positively, correlated with higher milk OTC concentration at the second 
milking (T9 h) (R2 = 0.43), fourth (T25 h) (R2 = 0.42) and fifth following treatment (T33 h) 
(R2 = 0.38) milking following treatment compared to cows with normal vaginal discharge. 
There was also a positive correlation between an initial metritis score and milk maximum 
concentration (R2 = 0.36) and also milk area under the concentration curve (R2 = 0.36).  
Given that IU administration of OTC is considered to be an extra-label therapy, dairy 
producers should consult with their veterinarian to ensure that milk is being tested at or 
below the established tolerance for OTC. This will ensure that violative drug residues do not 
enter the human food supply. 
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APPENDIX B: COMPARISON OF MILK AND PLASMA PHARMACOKINETICS OF 
MELOXICAM IN POST-PARTUM VERSUS MID-LACTATION HOLSTEIN COWS 
 
An abstract presented at the 2017 American Association of Bovine Practitioners 
Annual Conference and with full manuscript submitted for publication in J. Vet. Pharmacol. 
Ther., 2017. 
 
Abstract 
Recently, researchers determined that treatment of post-partum dairy cows with 
meloxicam resulted in increased milk production throughout the entire lactation (Carpenter et 
al, 2016). However, according to the Animal Medicinal Drug Use Clarification Act 
(AMDUCA), this type of practice would not be allowed unless the practice was a therapeutic 
use (US FDA, 1996). The objective of this study reported here was determine if differences 
occurred in meloxicam pharmacokinetics between post-partum cows and mid-lactation cows. 
Three different groups were enrolled, each with 10 cows. The treatment group (TRT) was 
post-partum cows treated with meloxicam; 2) the negative control (NC) group was post-
partum that received a placebo; and 3) the positive control (PC) group was cows in mid-
lactation treated with meloxicam. Plasma and milk meloxicam concentrations between the 
TRT and PC group were compared. Significant differences in meloxicam concentration in 
plasma were determined at all time points from 8 h to 120 h post-treatment. In milk, there 
was a treatment (P=0.003), time (P<0.001), and treatment by time interaction (P<0.001). 
Significant differences in milk meloxicam concentration were determined at all time points 
from 8 h to 96 h post-treatment, except for the 16 h time point. The time needed for 
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meloxicam to no longer be detected in milk of the TRT group was longer compared to the PC 
group, indicating that a longer milk withdrawal is needed. These data suggest higher 
bioavailability as the underlying mechanism. Further research is needed to determine the 
mechanisms underlying differences this outcome. 
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APPENDIX C: SURVEY OF TREATMET PRACTICES ON MIDWEST DAIRY FARMS 
 
An abstract presented at the 2016 American Association of Bovine Practitioners 
Annual Conference and submitted for published in Bov. Pract. 2017, 51:190–199. 
 
Abstract 
The objective of this study was to assess current antimicrobial use practices and 
veterinarian involvement with these practices on upper Midwest dairy farms. Eighty-five 
dairy farms ranging in size from 105 to 5,400 lactating cows located in six states (SD, NE, 
IA, MN, WI, and IL) were visited by two veterinary students during the summer of 2015. 
Interns observed farm treatment practices, reviewed individual herd treatment protocols and 
records, and conducted a standardized survey with farm management assessing mastitis, 
metritis, lameness, pneumonia, heifer pneumonia, and heifer diarrhea. Results indicate the 
presence of written treatment protocols varied by disease type. Metritis was the most 
common disease for which a protocol was found on-farm (49%), followed by mastitis (46%), 
lameness (39%), adult cow pneumonia (34%), heifer pneumonia (21%), and heifer diarrhea 
(19%). Ceftiofur was the most common primary antimicrobial selected for the treatment of 
mastitis (61%), metritis (82%), lameness (54%), and pneumonia (72%). Thirty-nine percent 
of farms selected enrofloxacin as their primary antimicrobial for the treatment of calf 
diarrhea. This use of enrofloxacin was also the most common unapproved treatment observed 
in the study. Results of this study demonstrate an opportunity for veterinarians to educate 
producers about judicious antimicrobial use on dairy farms. 
 
